

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1	ascorbic acid	n/a	5/11/2009	Treatment of Charcot-Marie-Tooth disease type 1A.	Murigenetics SAS
2	budesonide	n/a	12/20/2006	Treatment of patients with eosinophilic esophagitis	Shire ViroPharma Incorporated
3	single chain urokinase plasminogen activator	n/a	9/11/2014	Treatment of empyema (pleural)	Lung Therapeutics, Inc.
4	(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester	n/a	10/12/2011	Treatment of Fragile X syndrome	Novartis Pharmaceuticals Corp.
5	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate	n/a	6/5/2013	Treatment of pancreatic cancer	EMD Serono
6	(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate	n/a	3/9/2012	Treatment of soft tissue sarcoma	Threshold Pharmaceuticals, Inc.
7	(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-	n/a	2/17/2009	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Pfizer, Inc.
8	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/10/2004	Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia	Mundipharma Research Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
9	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	8/13/2004	Treatment of acute lymphoblastic leukemia	Mundipharma Research Limited
10	(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride	n/a	1/29/2004	Treatment of T-cell non-Hodgkin's lymphoma	Mundipharma Research Limited
11	(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride	n/a	9/15/2010	Treatment of infantile spasms.	Catalyst Pharmaceutical Partners
12	(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1"S)-7,9-acrolein acetal-11(15-1)-abeotaxane	n/a	6/23/2014	Treatment of progressive supranuclear palsy	Cortice Biosciences, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
13	(2E, 4E, 6Z, 8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl) nona-2,4,6,8-tetraen-1-yl acetate	n/a	12/2/2010	Treatment of retinitis pigmentosa	QLT Inc.
14	(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenyl acetate 9-cis-retinyl acetate (API)	n/a	12/2/2010	Treatment of Leber congenital amaurosis (LCA) due to inherited mutations in RPE65 (encoding the protein retinal pigment epithelial protein 65) or LRAT (encoding the enzyme lecithin:retinol acyltransferase)genes.	QLT, Inc.
15	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of primary biliary cirrhosis	Albireo AB
16	(2S)-2-[[[(2R)-2-[[[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]butanoic acid	n/a	10/31/2012	Treatment of progressive familial intrahepatic cholestatis	Albireo AB

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
17	(2Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-hepten-6-ynamide	Fk778	1/10/2005	Prevention of acute rejection following kidney, heart, and liver transplantation	Fujisawa Healthcare, Inc.
18	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of pancreatic cancer	NATCO Pharma Limited
19	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-yl amino) phenyl] benzamide	n/a	3/18/2011	Treatment of chronic myelogenous leukemia.	NATCO Pharma Limited
20	(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-yl amino) phenyl] benzamide NRC-AN-019	n/a	3/18/2011	Treatment of Glioma	NATCO Pharma Limited
21	(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-one	n/a	4/30/2014	Treatment of multiple myeloma	VivoLux AB
22	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl} carbamate	n/a	9/11/2014	Treatment of Gaucher disease	Genzyme
23	(3S)-1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl} carbamate	n/a	8/26/2014	Treatment of Fabry's disease	Genzyme Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
24	(3S)-3-(4-trifluoromethoxybenzyloxy)-6-nitro-2H-3,4-dihydroimidazo[2,1-b]oxazine	n/a	7/5/2007	Treatment of tuberculosis	Global Alliance for TB Drug Development
25	(3S)-3-[(2S)-2-({N-[2-tert-butyl]phenyl}carbonyl)carboxylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanocic acid	n/a	8/19/2003	Treatment of patients undergoing solid organ transplantation.	Pfizer Global Research and Development
26	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-1-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of alagille syndrome	Shire Human Genetic Therapies, Inc.
27	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-1-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary biliary cirrhosis	Shire Human Genetic Therapies, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
28	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of primary sclerosing cholangitis	Shire Human Genetic Therapies, Inc.
29	(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy)methyl]phenyl)methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride	n/a	9/4/2013	Treatment of progressive familial intrahepatic cholestasis	Shire Human Genetic Therapies, Inc.
30	(5R)-5-(4-{[2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride	n/a	7/24/2013	Treatment of trigeminal neuralgia	Convergence Pharmaceuticals Ltd.
31	(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoyl]glycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)	n/a	2/21/2014	Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics	DARA BioSciences, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
32	(6-maleimidocaproyl)hydrazone of doxorubicin	n/a	6/29/2011	Treatment of soft tissue sarcoma	CytRx Corporation
33	(6R,S)5,10-methylene-tetrahydrofolic acid	Cofactor	8/13/2004	For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer	Adventrx Pharmaceuticals, Inc.
34	(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid	n/a	12/8/2004	Prevention of post-operative complications of aortic aneurysm surgical repair	Inotek Pharmaceuticals Corporation
35	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	6/1/2012	Prevention of acute radiation toxicity, also known as Acute Radiation Syndrome (ARS)	Onconova Therapeutics, Inc.
36	(E)-4-carboxystyryl-4-chlorobenzyl-sulfone, sodium salt	Ex-Rad(R)	9/4/2012	Treatment of acute radiation syndrome	Onconova Therapeutics, Inc.
37	(N-[2,6-bis(1-methylethyl)-pheyl-N'-[[1-4-dimethyl-amino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	3/9/2012	Treatment of adrenocortical carcinoma	Atterocor, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
38	(R)-1-(2,2-difluorobenzo [d][1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide	n/a	4/24/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
39	(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt	n/a	4/15/2011	Treatment of idiopathic pulmonary fibrosis	Bristol-Myers Squibb Company
40	(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)pipe ridin-1-yl]phenoxyethyl}-2,3-dihydroimidazo[2,1-b]oxazole	n/a	7/12/2007	Treatment of pulmonary tuberculosis.	Otsuka Pharmaceutical Company, Ltd
41	(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride	n/a	12/19/2007	Treatment of small cell lung cancer.	AbbVie, Inc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
42	(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	n/a	7/3/2003	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc.
43	(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	n/a	10/3/2001	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc.
44	(RS)-baclofen, naltrexone and D-sorbitol	n/a	3/17/2014	Treatment of Charcot-Marie-Tooth disease type 1A	Pharnext SAS
45	(S)-10-[[dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2",4",5",7"-tetranitro-9"-fluorenylideneaminoxy)propionyl]-1H-pyrano[3',4',6',7',]indolizino [1,2-B]-quinoline-3,14-(4H, 12H)-dione, hydrochloride	Lipotecan	10/6/2010	Treatment of hepatocellular carcinoma	TLC Biopharmaceuticals, Inc.
46	(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile	n/a	1/26/2015	Treatment of pemphigus vulgaris	Almirall S.A.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
47	(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium	n/a	11/17/2014	Treatment of pulmonary arterial hypertension	Pulmokine, Inc.
48	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	4/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Infinity Pharmaceuticals
49	(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	n/a	8/1/2013	Treatment of follicular lymphoma	Infinity Pharmaceuticals, Inc.
50	(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid	n/a	2/4/2009	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Ferrokin BioSciences, Inc.
51	(S)-4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-1H-pyrrole-2-carboxamide hydrochloride	n/a	6/24/2013	Treatment of Stage IIb through Stage IV BRAF mutant melanoma	BioMed Valley Discoveries, Inc.
52	(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride	n/a	11/17/2014	Treatment of inherited mitochondrial respiratory chain diseases	Khondrion BV

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
53	(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	n/a	4/29/2015	Treatment of Hodgkin lymphoma	Incyte Corporation
54	(S)-perillyl alcohol temozolomide	n/a	11/14/2014	Treatment of glioma	NeOnc Technologies, Inc.
55	(UDU-stereoisomer of c-UUUun UNU-terminal UUnhibitor)	n/a	3/28/2006	Treatment of acute sensorineural hearing loss	Auris Medical, Inc.
56	(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of diffuse large B-cell lymphoma	Karyopharm Therapeutics, Inc.
57	(monomethoxypolyethylene glycol) recombinant adenosine deaminase	n/a	3/19/2015	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency	Sigma-Tau Pharmaceuticals, Inc.
58	1 8-(p[131I]-iodophenyl)octadecyl phosphocholine	n/a	12/3/2014	Treatment of multiple myeloma	Collectar Biosciences, Inc.
59	1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one	n/a	11/19/2012	Treatment of erythromelalgia	Teva Pharmaceuticals
60	1,2:5,6-Dianhdrogallactitol, NSC-132313	n/a	1/31/2012	Treatment of malignant gliomas	DelMar Pharmaceuticals (BC), Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
61	1,5-(Butylimino)-1,5 dideoxy,D-glucitol	n/a	5/12/1998	Treatment of Fabry's disease.	Oxford GlycoSciences
62	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of myelodysplastic syndrome	Cyclacel Limited
63	1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine	Sapacitabine	6/24/2010	Treatment of acute myelogenous leukemia	Cyclacel Limited
64	1-(3-chloro-5-{{4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl}carbamoyl}-2-pyridyl) piperidine-4-carboxylic acid Monomaleate	n/a	9/1/2011	Treatment of idiopathic thrombocytopenic purpura	Eisai, Inc.
65	1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid	n/a	3/31/2015	Treatment of systemic sclerosis	Inventiva Pharma
66	1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzimidazol-2-yl)-1H-pyrazol-4-yl]-urea	n/a	11/12/2009	Treatment of acute myeloid leukemia	Astex Therapeutics Ltd
67	1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene	n/a	1/9/2012	Treatment of poliovirus infection.	ViroDefense, Inc.
68	10 synthetic peptides targeting 5 tumor associated antigens	n/a	1/23/2013	Treatment of non-small cell lung cancer in patients expressing HLA-A2	Orphan Synergy Europe Pharma (OSE Pharma)

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
69	111Indium pentetreotide	Somatother	6/10/1999	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation
70	12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21)	n/a	6/7/2011	Treatment of pancreatic cancer	Targovax AS
71	17 amino acid peptide	n/a	1/29/2010	Prevention of ischemia reperfusion injury in the lung during lung transplantation	Apeptico
72	17-allylamino-17-demethoxygeldanamycin (17-AGG)	n/a	9/3/2004	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
73	177-LU-DOTA-GlyGlyNle-CycMSHhex	n/a	4/16/2015	Treatment of Stage IIB through IV malignant melanoma	SolaranRx, Inc.
74	177Lu-tetraxetan-tetulumab	Betalutin	5/14/2014	Treatment of Follicular Lymphoma	Nordic Nanovector AS
75	18-(p-[124I]-iodophenyl)octadecyl phosphocholine	n/a	4/30/2014	Diagnostic for the management of glioma	Cellectar Biosciences, Inc.
76	18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropine	n/a	1/26/2015	Diagnostic to be used in the management of multiple system atrophy (MSA)	Advanced Imaging Projects, LLC
77	2 dimethylbutyrate	n/a	6/18/2008	Treatment of beta thalassemia	HemaQuest Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
78	2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3'	n/a	10/31/2012	Treatment of amyotrophic lateral sclerosis	LifeSplice Pharma LLC
79	2'-deoxycytidine	n/a	9/9/1996	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D.
80	2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)	n/a	3/9/2012	Treatment of systemic light chain (AL) amyloidosis.	Millennium Pharmaceuticals, Inc.
81	2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-	n/a	1/15/2015	Treatment of congenital adrenal hyperplasia (CAH)	Neurocrine Biosciences, Inc.
82	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione	n/a	9/21/2010	Treatment of idiopathic pulmonary fibrosis.	GenKyoTex S.A.
83	2-(2-phenylvinyl)-4-[-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	1/29/2010	Treatment of acute myeloid leukemia.	EntreMed, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
84	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	7/1/2014	Treatment of hepatocellular carcinoma	CASI Pharmaceuticals, Inc.
85	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	12/22/2008	Treatment of multiple myeloma.	EntreMed, Inc.
86	2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt	n/a	3/18/2009	Treatment of ovarian carcinoma	EntreMed, Inc.
87	2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate	n/a	1/26/2015	Treatment of pancreatic cancer	Incyte Corporation
88	2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5]decane dimaleate	Atiprimod	9/18/2006	Treatment of carcinoid tumors	Callisto Pharmaceuticals, Inc.
89	2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate	Atiprimod	12/2/2003	Treatment of mulitple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
90	2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	n/a	8/15/2003	Treatment of cystic fibrosis	Inologic, Inc.
91	2-0-desulfated heparin	Aeropin	9/17/1993	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
92	2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Can-Fite BioPharma Ltd.
93	2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate	n/a	4/9/2015	Treatment of anal cancer	Eli Lilly and Company
94	2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzimidazole	Prevonco (Tm)	8/27/2008	Treatment of hepatocellular carcinoma.	BioQuant, Inc.
95	2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate	n/a	7/16/2014	Treatment of acute myeloid leukemia	OncoEthix SA
96	2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide	n/a	12/18/2007	Treatment of malignant melanoma stages IIb through IV.	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
97	2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxy-methyl]-quinoline succinic acid	n/a	6/2/2014	Treatment of Huntington's disease.	Pfizer Inc.
98	2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indian-2-carboxylic acid	n/a	5/14/2013	Treatment of patients with systemic sclerosis	Sanofi U. S., Inc.
99	2-[4-[[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	4/15/2015	Treatment of patients with Frederickson Type I or V hyperlipoproteinemia	Cymabay Therapeutics, Inc.
100	2-[4-[[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate	n/a	3/18/2015	Treatment of homozygous familial hypercholesterolemia (HoFH)	CymaBay Therapeutics, Inc.
101	2-[[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl)(ethyl)amino]ethyl dihydrogen phosphate trihydrate	n/a	1/19/2010	Treatment of acute myeloid leukemia	AstraZeneca Pharmaceuticals LP
102	2-chloroethyl-3-sarcosinamide-1-nitrosourea	Sarmustine	11/15/2001	Treatment for malignant glioma	Pangene Corporation
103	2-chloroethyl-3-sarcosinamide-1-nitrosourea	n/a	8/3/2001	Treatment for malignant gliomas	Lawrence Panasci, MD

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
104	2-hydroxypropyl-B-cyclodextrin	Kleptose	2/18/2013	Treatment of Niemann Pick disease, type C.	Vtesse, Inc.
105	2-iminobiotin	n/a	2/24/2009	Treatment of perinatal asphyxia.	Neurophyxia B.V.
106	2-methoxyestradiol	Pulmolar	4/11/2005	Treatment of pulmonary arterial hypertension	PR Pharmaceuticals, Inc.
107	2-{{{(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoxy)methyl)cyclohexyl)methoxy} acetic acid	n/a	8/28/2014	Treatment of pulmonary arterial hypertension	Arena Pharmaceuticals, Inc.
108	20-mer complementary to Akt mRNA	n/a	12/10/2004	Treatment of stomach cancer	Rexahn Corporation
109	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of glioblastoma	Rexahn Corporation
110	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/8/2004	Treatment of pancreatic cancer	Rexahn Corporation
111	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of ovarian cancer	Rexahn Corporation
112	20-mer oligonucleotide complementary to Akt mRNA	n/a	12/1/2004	Treatment of renal cell carcinoma	Rexahn Corporation
113	225Ac-lintuzumab	n/a	11/25/2014	Treatment of acute myelogenous leukemia	Actinium Pharmaceuticals, Inc.
114	24,25 dihydroxycholecalciferol	n/a	2/27/1987	Treatment of uremic osteodystrophy.	Lemmon Company

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
115	2S,4R ketoconazole	n/a	3/9/2012	Treatment of endogenous Cushing's syndrome	Cortendo AB (HQ address)
116	3,4 diaminopyridine and choline bitartrate	n/a	4/30/2010	Treatment of Lambert-Eaton myasthenic syndrome	MS Therapeutics Limited
117	3,4-Diaminopyridine phosphate	n/a	11/12/2009	Treatment of Lambert-Eaton Myasthenic Syndrome	Catalyst Pharmaceutical Partners, Inc.
118	3,4-diaminopyridine	n/a	12/18/1990	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company
119	3,5,3'-triiodothyroacetate	n/a	9/20/2000	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D.
120	3,5-diiodothyropropionic acid	n/a	5/14/2013	Treatment of Allan-Herndon-Dudley syndrome	Zarion Pharmaceuticals P/L
121	3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	3/23/2000	Treatment of von Hippel-Lindau disease.	Sugen, Inc.
122	3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one	n/a	9/11/1998	Treatment of Kaposi's sarcoma.	Sugen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
123	3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid	n/a	3/2/2010	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
124	3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid	n/a	12/23/2014	Prevention of acute attacks of angioedema in individuals with hereditary angioedema	BioCryst Pharmaceuticals, Inc.
125	3-bromopyruvate	n/a	3/5/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
126	3-bromopyruvate	n/a	4/29/2014	Treatment of pancreatic cancer	PreScience Labs, LLC
127	3-chloro-4-fluorophenyl-[4-fluoro-4-[[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone	n/a	10/25/2013	Treatment of Rett syndrome	Neurolaxis, Inc.
128	3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethynyl)-pyridin-2-yl]-benzonitrile dihydrochloride	n/a	7/28/2008	Treatment of behavioral abnormalities associated with fragile X syndrome.	Seaside Therapeutics
129	3-pentylbenzenacetic acid sodium salt	n/a	2/11/2015	Treatment of idiopathic pulmonary fibrosis.	ProMetic Life Sciences, Inc.
130	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of diffuse large B-cell lymphoma	Kiadis Pharma Canada, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
131	4, 5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/30/2008	Treatment of follicular lymphoma	Kiadis Pharma Canada, Inc.
132	4,5 dibromorhodamine methyl ester	Theralux Photodynamic Therapy	10/23/2007	For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Canada, Inc.
133	4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium salt	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	Provectus Pharmaceuticals, Inc.
134	4-(2-fluorophenyl)-6-methyl-2-(1-piperziny)	n/a	10/11/2006	Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.	Dynogen Pharmaceuticals, Inc.
135	4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl	n/a	12/12/2005	Treatment of Huntington's disease.	Teva Branded Pharmaceutical Products R&D
136	4-(4-Methoxy-phenylamino)-6-methylcarbaryl-quinoline-3-carboxylic acid	n/a	3/24/2015	Prevention of scarring post ab externo glaucoma surgery	Clanotech AB

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
137	4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl]piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	AbbVie
138	4-(4-([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl]piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide	n/a	9/20/2012	Treatment of chronic lymphocytic leukemia	AbbVie, Inc.
139	4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride	n/a	4/15/2013	Treatment of fibrodysplasia ossificans progressiva	La Jolla Pharmaceutical Company, Inc.
140	4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one	n/a	5/4/2015	Treatment of congenital long QT syndrome	Gilead Sciences, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
141	4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone	n/a	8/22/2007	Treatment of hepatocellular carcinoma.	Ligand Pharmaceuticals, Inc.
142	4-Aminopyridine	n/a	12/14/2005	Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome	Acorda Therapeutics, Inc.
143	4-[131I]iodo-L-phenylalanine	n/a	1/4/2011	Treatment of glioma.	Therapeia GmbH & Co KG
144	4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide	n/a	7/30/2008	Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.	SuperGen, Inc.
145	4-[2-(3-Propyl-[1,2,4]Oxadiazol-5-yl)-vinyl]-benzene-1,2-diol	n/a	10/4/2011	Treatment of chronic myeloid leukemia	Piramal Enterprises Limited
146	4-[4-[[[3-(1,1-dimethylethyl)-1-(6-quinolinyl)-1H-pyrazol-5-yl]amino]carbonyl]-amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide, p-toluenesulfonate salt	n/a	9/3/2009	Treatment of Philadelphia chromosome positive chronic myeloid leukemia	Deciphera Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
147	4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol	n/a	9/23/2011	Treatment of idiopathic pulmonary fibrosis	Celgene Corporation
148	4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one	n/a	9/23/2014	Treatment of pancreatic cancer.	Rexahn Pharmaceuticals, Inc.
149	4-aminosalicylic acid	Pamisyl (P-D), Rezipas (Squibb)	12/13/1989	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D.
150	4-aminosalicylic acid	Paser Granules	4/26/2006	Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease	Jacobus Pharmaceutical Co., Inc.
151	4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride	n/a	7/20/2006	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev,
152	4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide	n/a	11/2/2010	Treatment of pancreatic cancer.	Apogee Biotechnology Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
153	4-[[[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid	n/a	5/19/2014	Treatment of Acute Myeloid Leukemia	Roche Genentech
154	40K PEGylated recombinant factor IX	n/a	3/18/2013	Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease).	Novo Nordisk, Inc.
155	5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+	n/a	3/31/2015	Treatment of diffuse large B-cell lymphoma.	Idera Pharmaceuticals, Inc.
156	5'-GCCATGGTTTTTCTCAGG-3'	n/a	10/31/2012	Prophylaxis for patients following documented or suspected exposure to ebolavirus	Sarepta Therapeutics, Inc.
157	5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin	n/a	6/15/2007	Treatment of osteosarcoma (bone cancer)	Dr. Reddy's Laboratories, Inc.
158	5,5',5"-[Phosphinothiolyldyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	n/a	8/20/2003	Treatment of pancreatic cancer	Now Pharm AG
159	5,6-dihydro-5-azacytidine	n/a	5/11/1992	Treatment of malignant mesothelioma.	ILEX Oncology, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
160	5,7-dichloro-2-methylaminomethyl-8-hydroxyquinolone hydrochloride	n/a	9/4/2014	Treatment of Huntington's disease	Prana Biotechnology Limited
161	5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one	n/a	6/18/2007	Prevention of acute radiation syndrome	Humanetics Corporation
162	5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride	n/a	4/18/2011	Treatment of progressive supranuclear palsy.	Mithridion, Inc.
163	5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide	n/a	1/15/2015	Treatment pulmonary arterial hypertension	Gilead Sciences, Inc.
164	5-(ethylsulfonyl)-2-(naphthalen-2-yl)benz[p[d]oxazole	n/a	11/22/2011	Treatment of Duchenne Muscular Dystrophy	Summit Corporation plc
165	5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol	Resveratrol	3/13/2008	Treatment of MELAS syndrome	Sirtris Pharmaceuticals, Inc.
166	5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine	n/a	8/25/2009	Treatment of spinal muscular atrophy	Pfizer Incorporated
167	5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine	n/a	2/10/2015	Treatment of malignant mesothelioma	Verastem, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
168	5-aminolevulinic acid	Gliolan	1/15/2013	Visualization of malignant tissue during surgery for malignant glioma (WHO grade III and IV)	NX Development Corporation
169	5-aza-2'-deoxycytidine	n/a	8/3/1987	Treatment of acute leukemia.	SuperGen, Inc.
170	5-hydroxymethyl-2-furfuraldehyde	n/a	5/26/2006	Treatment of sickle cell disease	AesRx, LLC
171	5-iodo-2-pyrimidinone-2'-deoxyribose	n/a	5/26/2006	Treatment of malignant glioma	Hana Biosciences, Inc.
172	5'-phosphoryl-3'-phosphoryl-2'-deoxy-5-iodo-2-pyrimidinone-2'-deoxyribose GAATATTAACAIACTGACAAGTC-3'-phosphoryl-5'-phosphoryl-2'-deoxy-5-iodo-2-pyrimidinone-2'-deoxyribose	n/a	10/31/2012	Prophylaxis following documented or suspected exposure to marburg virus	Sarepta Therapeutics, Inc.
173	6,8-bis-benzylsulfanyl-octanoic acid	n/a	9/26/2013	Treatment of myelodysplastic syndrome	Cornerstone Pharmaceuticals, Inc.
174	6,8-bis-benzylsulfanyl-octanoic acid	n/a	8/22/2011	Treatment of acute myeloid leukemia.	Cornerstone Pharmaceuticals, Inc.
175	6,8-bis-benzylsulfanyl-octanoic acid	n/a	2/6/2006	Treatment of pancreatic cancer	Cornerstone Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
176	6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydropyran-4-yl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one	n/a	9/4/2014	Treatment of sickle cell disease	Pfizer, Inc.
177	6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo-[1,2-alpha]pyrazin-8-amine bis-methanesulfonate	n/a	4/14/2014	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
178	6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine	n/a	6/12/2014	Treatment of multiple myeloma	DARA BioSciences, Inc.
179	6-alpha-ethylchenodeoxycholic acid	n/a	4/9/2008	Treatment of primary sclerosing cholangitis	Intercept Pharmaceuticals, Inc.
180	6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimidinecarboxamide	n/a	10/15/2013	Treatment of stage IIb-IV melanoma	Millennium Pharmaceuticals, Inc.
181	6-mercaptopurine oral liquid	n/a	12/7/2009	Treatment of acute lymphoblastic leukemia in the pediatric population	Orbona Pharma Ltd

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
182	68G-OPS202, small somatostatin analog labeled with 68Gallium	n/a	9/24/2014	Management of gastroenteropancreatic neuroendocrine tumors.	OctreoPharm Sciences GmbH
183	7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester	n/a	6/15/2011	Treatment of gliomas.	Intsel Chimos SA
184	8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one	n/a	1/21/2015	Treatment of glioblastoma multiforme	RestorGenex Corporation
185	8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride	n/a	9/3/2009	Treatment of ovarian cancer.	Merck Sharp & Dohme Corp.
186	8-methoxsalen	Uvadex	5/12/1994	For the prevention of acute rejection of cardiac allografts.	Therakos, Inc.
187	8-methoxsalen	Uvadex	6/22/1993	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc.
188	9-nitro-20-(S)-camptothecin	Camvirex	5/15/2001	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc.
189	9-nitro-20-(S)-camptothecin	n/a	9/16/1996	Treatment of pancreatic cancer.	SuperGen, Inc.
190	90Y-hPAMA4	Pan-Cide	1/29/2004	Treatment of pancreatic cancer	Immunomedics, Inc.
191	A-dmDT390-bisFv(UCHT1)	Resimmune	10/9/2014	Treatment of cutaneous T-cell lymphoma	Angimmune, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
192	A10 & AS2-1 Antineoplaston	n/a	9/3/2004	Treatment for patients with brain stem glioma	Burzynski Research Institute, Inc.
193	AAV-G6Pase vector	n/a	3/11/2013	Treatment of glycogen storage disease type Ia	GlyGenix Therapeutics, Inc.
194	ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides	n/a	9/28/2012	Treatment of renal cell carcinoma in HLA-A*2 positive patients	Immatics Biotechnologies GmbH
195	ADXS11-001	n/a	8/12/2013	Treatment of HPV-positive associated anal cancer	Advaxis, Inc.
196	AEZS-108 (LHRH-agonist linked to doxorubicin)	n/a	4/30/2010	Treatment of ovarian cancer	Aeterna Zentaris
197	ALX-0081 nanobody, directed towards the human A1 domain of von Willebrand factor	n/a	4/14/2009	Treatment of thrombotic thrombocytopenic purpura	Ablynx NV
198	AQ-13 (4-aminoquinoline analog)	n/a	9/12/2008	Treatment of malaria	Immtech Pharmaceuticals, Inc.
199	Abetimus	n/a	7/28/2000	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co.
200	Ac-Ile-Cys-Val-Trp(1-Me)-Gln-Asp-Trp-Gly-Ala-His-Arg-Cys-Thr-AEEA-Lys-PEG 40KDa-Lys-AEEA-Thr-Cys-Arg-His-ALa-Gly-Trp-Asp-Gln-(1-Me)Trp-Val-Cys-Ile-Ac	n/a	4/20/2014	Treatment of paroxysmal nocturnal hemoglobinuria	Apellis Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
201	Acetylcysteine	Mucomyst/Mucomyst 10 lv	8/13/1987	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company
202	ActRIIB-IgG1)	n/a	8/16/2010	Treatment of Duchenne muscular dystrophy	Acceleron Pharma, Inc.
203	Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus	n/a	3/17/2014	Treatment of ovarian cancer	Oncos Therapeutics Ltd
204	Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor	n/a	1/31/2012	Treatment of homozygous familial hypercholesterolemia	ReGenX Biosciences LLC
205	Adeno-associated vector expressing the human lipoprotein lipase protein	n/a	5/21/2007	Treatment of lipoprotein lipase deficiency	uniQure B.V.
206	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc.
207	Adeno-associated viral vector containing the gene for human coagulation factor IX	Coagulin-B	6/13/2001	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc.
208	Adeno-associated viral vector expressing human acid alpha glucosidase gene	n/a	3/20/2007	Treatment of Pompe disease	Applied Genetic Technologies Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
209	Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter	n/a	9/4/2014	For the treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)	Columbia University Medical Center
210	Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase	n/a	3/3/2011	Treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and myelofibrosis)	Eli Lilly and Company
211	Adenoviral vector expressing Herpes simplex virus thymidine kinase gene	n/a	6/17/2005	Treatment of malignant brain tumors	Advantagene, Inc.
212	Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)	n/a	9/4/2014	Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)	Etubics Corporation
213	Adenovirus-based vector Factor VIII complementary DNA to somatic cells	Miniadfviii	12/15/1999	Treatment of hemophilia A.	GenStar Therapeutics Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
214	Albendazole	Albenza	1/18/1996	Treatment of neurocysticercosis due to <i>Taenia solium</i> as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	Amedra Pharmaceuticals LLC
215	Albendazole	Albenza	1/17/1996	Treatment of hydatid disease (cystic echinococcosis due to <i>E. granulosus</i> larvae or alveolar echinococcosis due to <i>E. multilocularis</i> larvae).	Amedra Pharmaceuticals LLC
216	Albuterol	n/a	3/12/2002	Prevention of paralysis due to spinal cord injury	MotoGen, Inc.
217	Aldesleukin	Proleukin	3/22/1989	Treatment of primary immunodeficiency disease associated with T-cell defects.	Prometheus Laboratories, Inc.
218	Aldesleukin	Proleukin	9/14/1988	Treatment of metastatic renal cell carcinoma.	Chiron Corporation
219	Aldesleukin	Proleukin	9/10/1996	Treatment of metastatic melanoma.	Chiron Corporation
220	Aldesleukin	Proleukin	11/24/1998	For the treatment non-Hodgkin's lymphoma.	Prometheus Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
221	Alendronate disodium	Fosamax	2/13/2001	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D.
222	Alfentanil	n/a	7/8/2005	Management of postherpetic neuralgia	Cinergen, LLC
223	Alfentanil	n/a	8/9/2005	Treatment of painful HIV-associated neuropathy	Cinergen, LLC
224	Alglucerase injection	Ceredase	7/21/1995	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation
225	Alglucerase injection	Ceredase	3/11/1985	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation
226	Alitretinoin	Panretin	3/24/1998	Treatment of AIDS-related Kaposi's sarcoma.	Eisai, Inc
227	Alitretinoin	Panretin	4/10/1992	Treatment of acute promyelocytic leukemia	Ligand Pharmaceuticals, Inc.
228	Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro	n/a	1/28/2005	Immunotherapy for acceleration of T-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation	MolMed S.p.A.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
229	Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix	Vascugel (R)	4/3/2009	Prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis	Shire
230	Allogeneic motor neuron progenitor cells derived from human embryonic stem cells	Motorgraft (Tm)	1/17/2014	Treatment of Amyotrophic Lateral Sclerosis	California Stem Cell Inc.
231	Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture	Cytoimplant	6/13/1997	Treatment of pancreatic cancer	Applied Immunotherapeutics, LLC
232	Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	9/1/2004	Treatment of retinitis pigmentosa	Neurotech USA, Inc.
233	Allopurinol sodium	Aloprim For Injection	10/16/1992	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.	Catalytica Pharmaceuticals, Inc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
234	Alpha-galactosidase A	Replagal	6/22/1998	Long-term enzyme replacement therapy for the treatment of Fabry disease	Shire Human Genetic Therapies, Inc.
235	Alpha-galactosidase A	Cc-Galactosidase	6/17/1991	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	David Calhoun, Ph.D.
236	Alpha-galactosidase A	Fabrase	7/20/1990	Treatment of Fabry's disease.	Desnick, Robert J. M.D.
237	Alpha-melanocyte stimulating hormone	n/a	8/19/1997	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases
238	Alpha-tocopherol quinone	n/a	3/28/2006	Treatment of inherited mitochondrial respiratory chain diseases	Penwest Pharmaceuticals Company
239	Alpha1-Proteinase Inhibitor (Human)	n/a	12/22/2004	Inhalation therapy for the treatment of congenital deficiency of alpha1-proteinase inhibitor.	Kamada Ltd.
240	Alpha1-Proteinase Inhibitor (Human)	Arc-Api	9/1/2004	Treatment of cystic fibrosis	Kamada Ltd.
241	Alpha1-antitrypsin(human)	n/a	4/3/2008	Treatment of bronchiectasis	Kamada, Ltd.
242	Alpha1-proteinase inhibitor (human)	Prolastin	12/7/1984	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation
243	Altretamine	Hexalen	2/9/1984	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
244	Alvocidib	n/a	4/13/2007	Treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.	Tolero Pharmaceuticals, Inc.
245	Amantadine hydrochloride	Nurelin	4/9/2015	Treatment of levodopa-induced dyskinesia	Adamas Pharmaceuticals, Inc.
246	Amifostine	Ethyol	10/4/1999	Treatment of myelodysplastic syndromes.	Clinigen Group, plc
247	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Clinigen Group plc
248	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Clinigen Group plc
249	Amifostine	Ethyol	5/30/1990	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc.
250	Amifostine	Ethyol	11/24/1998	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Clinigen Group plc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
251	Amifostine	Ethyol	5/12/1998	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc.
252	Amikacin	Arikace	3/9/2006	Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients	Insmed, Inc.
253	Aminocaproic acid	Caprogel	1/6/1995	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School
254	Aminosalicilic acid	Paser Granules	2/19/1992	Treatment of tuberculosis infections	Jacobus Pharmaceutical Company
255	Aminosidine	Paromomycin	9/9/1994	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D.
256	Aminosidine	Gabbromicina	5/14/1993	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D.
257	Aminosidine	Gabbromicina	11/15/1993	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D.
258	Amiodarone	Amio-Aqueous	8/17/1993	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
259	Amiodarone HCl	Cordarone	3/16/1994	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories
260	Ammonium tetrathiomolybdate	Coprex	1/31/1994	Treatment of Wilson's disease.	Pipex Pharmaceuticals, Inc.
261	Amphotericin B inhalation powder	n/a	12/15/2005	Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies	Novartis Pharmaceuticals Corporation
262	Amphotericin B lipid complex	Abelcet	12/5/1991	Treatment of invasive fungal infections.	Liposome Company, Inc.
263	Amyl nitrite, sodium nitrite, sodium thiosulfate	Cyanide Antidote Kit	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.
264	Anagrelide	Agrylin	1/27/1988	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp.
265	Anagrelide	Agrylin	7/14/1986	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
266	Anagrelide	Agrylin	6/11/1985	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp.
267	Ananain, comosain	Vianain	1/21/1992	For the enzymatic debridement of severe burns.	Genzyme Corporation
268	Anatibant	n/a	4/15/2005	Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome	Xytis, Inc.
269	Ancrod	Viprinex	10/20/1989	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company
270	Angiotensin (1-7)	n/a	11/26/2013	Treatment of limb-girdle muscular dystrophy	US Biotest, Inc.
271	Angiotensin 1-7	n/a	2/16/2000	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals
272	Angiotensin 1-7	Marstem	8/3/2001	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation
273	Angiotensin-(1-7)	n/a	9/13/2011	Treatment of pulmonary arterial hypertension.	US Biotest, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
274	Anti-Beta1 integrin monoclonal antibody	n/a	8/7/2014	Treatment of glioblastoma	OncoSynergy, Inc.
275	Anti-T cell receptor murine monoclonal antibody	n/a	4/3/2009	Prophylaxis of acute rejection of solid organ transplantation	Tolera Therapeutics, Inc.
276	Anti-eTau Humanized IgG4 Monoclonal Antibody	n/a	5/13/2015	Treatment of Progressive Supranuclear Palsy	Britol-Myers Squibb Company
277	Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131	Neuradiab	10/4/2005	Treatment of primary malignant brain tumors	Bradmer Pharmaceuticals, Inc.
278	Anti-thymocyte serum	Nashville Rabbit Anti-Thymocyte Serum	6/2/1993	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research
279	Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E	n/a	7/29/2014	Treatment of ovarian cancer	Genentech, Inc.
280	Antiepilepsirine	n/a	3/23/1989	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital
281	Antihemophilic factor (human)	Alphanate	1/5/1996	Treatment of von Willebrand's disease	Grifols Biologicals Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
282	Antihemophilic factor (recombinant)	Kogenate	9/25/1989	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation
283	Antihemophilic factor (recombinant)	Refacto	2/8/1996	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Wyeth Pharmaceuticals, Inc.
284	Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized	Humate-P	10/16/1992	Treatment of patients with von Willebrand's disease	CSL Behring
285	Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA	n/a	4/15/2005	Treatment of acute myeloid leukemia	Lorus Therapeutics, Inc.
286	Antisense oligonucleotide directed against connexin43	Nexagon	4/27/2009	Treatment of persistent corneal epithelial defects	CoDa Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
287	Antithrombin III (human)	Atnativ	2/8/1985	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB
288	Antithrombin III (human)	Thrombate lii	11/26/1984	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation
289	Antithrombin III human	Antithrombin lii Human	1/2/1986	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.	American National Red Cross
290	Antivenin crotaline (pit-viper) equine immune F(ab)2	Antivipmyn	1/29/2004	Treatment of envenomation by Crotaline snakes	Instituto Bioclon, S.A de C.V.
291	Antivenin, crotalidae polyvalent immune Fab (ovine)	Crofab	1/12/1994	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
292	Antivenom (crotalidae) purified (avian)	n/a	2/12/1991	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc.
293	Apomorphine	n/a	7/17/1995	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc.
294	Apomorphine HCl	Apokyn	4/22/1993	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	US WorldMeds, LLC
295	Apomorphine hydrochloride	n/a	5/23/2006	For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous)	NeuroHealing Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
296				For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable.	
	Aprotinin	Trasylol	11/17/1993		Bayer Corporation
297	Arenegyr	n/a	8/22/2008	Treatment of malignant pleural mesothelioma	MolMed S.p.A.
298	Arginine butyrate	n/a	4/7/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D.
299	Arsenic trioxide	Trisenox	3/3/1998	Treatment of acute promyelocytic leukemia.	Cephalon
300	Arsenic trioxide	Trisenox	3/4/2005	Treatment of malignant glioma	Teva Branded Pharmaceutical Products R&D, Inc.
301	Arsenic trioxide	Trisenox	4/28/2000	Treatment of multiple myeloma.	TEVA Branded Pharmaceutical Products R & D, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
302	Arsenic trioxide	Trisenox	5/13/2003	Treatment of chronic lymphocytic leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
303	Artesunate	n/a	7/19/1999	Treatment of malaria.	World Health Organization
304	Artesunate	n/a	3/28/2006	Immediate treatment of malaria	US Army Medical Materiel Development Activity
305	Ascorbic acid	Ascor L 500	8/31/2007	Treatment of scurvy	McGuff Pharmaceuticals Inc.
306	Asfotase alfa	n/a	9/12/2008	Treatment of hypophosphatasia	Alexion Pharmaceuticals, Inc.
307	Atovaquone	Mepron	9/10/1990	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc.
308	Atovaquone	Mepron	8/14/1991	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
309	Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells	n/a	4/27/2007	Treatment of primary central nervous system malignancies	TVAX Biomedical, LLC
310	Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)	n/a	11/13/2014	Treatment of acute lymphoblastic leukemia (ALL)	Juno Therapeutics, Inc.
311	Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)	n/a	4/30/2010	Treatment of Wiskott Aldrich syndrome	GlaxoSmithKline Intellectual Property Development
312	Autologous DNP-conjugated tumor vaccine	M-Vax	2/23/1999	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc.
313	Autologous Engineered Skin Substitute	Permaderm	6/1/2012	Treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.	Lonza

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
314	Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	1/31/2014	For the treatment of Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals Corporation
315	Autologous cultured endothelial cells on a donor human corneal disk	n/a	6/1/2007	Treatment of Fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy	Cellular Bioengineering, Inc.
316	Autologous dendritic cells pulsed with autologous antigens from primary malignant brain tumor cells	Dcvax-Brain	11/29/2002	Treatment of primary brain malignant cancer	Northwest Biotherapeutics, Inc.
317	Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1-glutathione S transferase) coupled to oxidized polymannose	Cvac(Tm)	9/13/2010	Treatment of ovarian cancer.	Prima Biomed Ltd.
318	Autologous incubated macrophage	n/a	9/3/2004	Therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury	Proneuron Biotechnologies, Inc.
319	Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin	Biovaxid	10/18/2011	Treatment of Waldenstrom's macroglobulinemia	Biovest International, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
320	Autologous olfactory neural progenitors	Rhinocytes	2/1/2008	Treatment of spinal cord injury patients with ASIA Impairment grades A, B, or C	RhinoCyte, Inc.
321	Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane	n/a	7/14/2005	Treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency	TissueTech, Inc.
322	Autolymphocyte therapy	n/a	7/12/1994	Treatment of renal cell carcinoma.	Cytogen Corporation
323	Azacitidine	Vidaza	6/18/2008	Treatment of acute myeloid leukemia	Celgene Corporation
324	Azathioprine	Imuran	9/14/1999	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc.
325	BF2.649 (Pitolisant)	n/a	5/17/2010	Treatment of narcolepsy	Bioprojet Pharma
326	Bacillus Calmette-Guerin vaccine	n/a	8/9/2006	Treatment of stage IIb through IV metastatic melanoma	OncoVac Corporation
327	Bacitracin	Altracin	3/13/1984	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc.
328	Baclofen	Lioresal Intrathecal	9/26/1994	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
329	Balsalazide disodium	Colazal	8/12/2005	Treatment of pediatric patients with ulcerative colitis	Salix Pharmaceuticals, Inc.
330	Bardoxolone	n/a	8/6/2008	Treatment of pancreatic cancer	Reata Pharmaceuticals, Inc.
331	Basiliximab	Simulect	12/12/1997	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals Corporation
332	Beclomethasone dipropionate	n/a	3/27/1998	For oral administration in the treatment of intestinal graft-versus-host disease.	Soligenix, Inc.
333	Belinostat	Beleodaq	9/3/2009	Treatment of peripheral T-cell lymphoma (PTCL).	Spectrum Pharmaceuticals, Inc.
334	Bendamustine hydrochloride	Treanda	8/17/2007	Treatment of chronic lymphocytic leukemia	Cephalon, Inc.
335	Benzoate and phenylacetate	Ucephan	1/21/1986	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	ImmunexImmunex

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
336	Benzophenone-3, octylmethoxycinnamate, avobenzene, titanium dioxide, zinc oxide	Total Block VI Spf 75	8/13/2001	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd.
337	Benzydamine hydrochloride	Tantum	5/18/1998	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc.
338	Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid	Pre-Pen/Mdm	9/28/1987	Assessing the risk of administering penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	AllerQuest LLC
339	Beractant	Survanta Intratracheal Suspension	12/20/1993	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories
340	Beractant	Survanta Intratracheal Suspension	2/5/1986	Treatment of neonatal respiratory distress syndrome.	Ross Laboratories

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
341	Beractant	Survanta Intratracheal Suspension	2/5/1986	Prevention of neonatal respiratory distress syndrome.	Ross Laboratories
342	Beraprost	n/a	4/29/1999	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	LungRx, Inc.
343	Beta alethine	Betathine	3/24/1997	Treatment of multiple myeloma.	Dovetail Technologies, Inc.
344	Beta alethine	Betathine	3/24/1997	Treatment of metastatic melanoma.	Dovetail Technologies, Inc.
345	Betahistine dihydrochloride	n/a	11/8/2007	Treatment of obesity associated with Prader Willi syndrome	Floyd R. Sallee, M.D., Ph.D.
346	Betaine	Cystadane	5/16/1994	Treatment of homocystinuria.	Jazz Pharmaceuticals
347	Betulinic acid	n/a	8/9/2007	Topical treatment of metastatic melanoma	Advanced Life Sciences, Inc. (ALS)
348	Bexarotene	Targretin	6/18/1999	Treatment of cutaneous T-cell lymphoma.	Eisai, Inc.
349	Bindarit	n/a	2/3/1998	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
350	Bio-engineered oral mucosal tissue	n/a	4/27/2006	For use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency	TissueTech, Inc.
351	Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	n/a	2/11/2002	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc.
352	Bis(4-fluorophenyl)phenylacetamide	n/a	3/2/2000	Treatment of sickle cell disease.	ICAgen Inc.
353	Bleomycin	n/a	12/20/2010	Treatment of pancreatic cancer.	CIRJ Company Ltd.
354	Bleomycin	Blenoxane	2/9/1999	Treatment of pancreatic cancer.	Genetronics, Inc.
355	Bleomycin sulfate	Blenoxane	9/17/1993	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute
356	Blinatumomab	n/a	5/16/2008	Treatment of chronic lymphocytic leukemia	Amgen, Inc.
357	Bone marrow-derived mononuclear cells	n/a	5/17/2010	Treatment of thromboangiitis obliterans (Buerger's disease)	t2cure GmbH
358	Bosentan	Tracleer	10/6/2000	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
359	Botulinum toxin type A	Dysport	3/23/1989	Treatment of essential blepharospasm.	Porton International, Inc.
360	Botulinum toxin type A	n/a	9/15/1992	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc.
361	Botulinum toxin type A	Dysport	8/12/1998	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Biopharm Limited
362	Botulinum toxin type A	Dysport	10/20/1999	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited
363	Botulinum toxin type A	Botox	8/20/1986	Treatment of cervical dystonia.	Allergan, Inc.
364	Botulinum toxin type A	Botox	3/22/1984	Treatment of strabismus and blepharospasms	Allergan, Inc.
365	Botulinum toxin type A	Botox	12/6/1991	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc.
366	Botulinum toxin type B	Myobloc	1/16/1992	Treatment of cervical dystonia.	Soltice Neurosciences, LLC
367	Botulinum toxin type F	n/a	10/24/1991	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited
368	Botulism immune globulin	Babybig	1/31/1989	Treatment of infant botulism.	California Department of Health Services
369	Bovine colostrum	n/a	11/19/1990	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
370	Bovine immunoglobulin concentrate, Cryptosporidium parvum	Sporidin-G	3/1/1994	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc.
371	Bovine whey protein concentrate	Immuno-C	9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc.
372	Branched chain amino acids	n/a	12/23/1988	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center
373	Brilliant Blue G	Dorc Ilm-Blue	7/31/2012	To selectively stain the thickened internal limiting membrane, which has formed onto the inner side of the retina in vitreo-retinal disorders	Dutch Ophthalmic Research Center
374	Brimonidine	Alphagan	2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc.
375	Brivaracetam	n/a	10/5/2005	Treatment of symptomatic myoclonus	UCB Pharma, Inc.
376	Broxuridine	Broxine/Neomark	9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
377	Bruton's Tyrosine Kinase (Btk) Inhibitor	n/a	5/13/2015	Treatment of chronic lymphocytic leukemia (CLL).	Acerta Pharma BV
378	Buffered Ursodeoxycholic Acid	Ursocarb	9/3/2004	Treatment of pruritus in patients with Alagille Syndrome	Digestive Care, Inc.
379	Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma	Lukare Medical, LLC
380	Buprenorphine hydrochloride	Subutex	6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc.
381	Busulfan	Busulfex	7/28/1994	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Otsuka Pharmaceutical Company
382	Busulfan	Spartaject	7/7/1997	Treatment of primary brain malignancies.	SuperGen, Inc.
383	Busulfan	Spartaject	4/21/1994	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc.
384	Buthionine sulfoxamine	n/a	10/5/2005	For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
385	Buthionine sulfoxamine	n/a	10/5/2005	Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors	USC-CHLA Institute for Pediatric Clinical Research
386	Butyrylcholinesterase	n/a	9/30/1992	Treatment of post-surgical apnea.	Shire Laboratories Inc.
387	Butyrylcholinesterase	n/a	3/25/1992	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc.
388	C1 esterase inhibitor (human)	Cinryze(R)	7/16/2004	Treatment of angioedema	Shire
389	C1 esterase inhibitor (human)	n/a	8/21/1996	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation
390	C1-esterase inhibitor (recombinant)	Ruconest	2/23/1999	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Santarus, Inc.
391	C1-esterase-inhibitor, human, pasteurized	Berinert	10/16/1992	Prevention and/or treatment of acute attacks of hereditary angioedema.	CSL Behring LLC
392	C20-D3-retinyl acetate	n/a	9/16/2010	Treatment of Stargardt's disease	Alkeus pharmaceuticals, Inc.
393	C24H28N8O7S2	n/a	4/2/2015	Treatment of diffuse large B-cell lymphoma (DLBCL).	Curis, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
394	C66H100N6O27	n/a	3/11/2013	Treatment of of hepatocellular carcinoma	GenSpera, Inc.
395	CD40/CD80/CD86 modified autologous dendritic cell therapy	n/a	12/20/2013	Treatment Type 1 diabetes mellitus patients with residual beta cell function	DiaVacs, Inc.
396	CNDO-109-activated allogeneic natural killer cells	n/a	6/18/2012	Treatment of acute myeloid leukemia	Coronado Biosciences, Inc.
397	Caffeine	Cafcit	9/20/1988	Treatment of apnea of prematurity.	O.P.R. Development, L.P.
398	Calcitonin-human for injection	Cibacalcin	1/20/1987	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical Corporation
399	Calcium acetate	n/a	6/27/1989	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company
400	Calcium acetate	Phos-Lo	12/22/1988	Treatment of hyperphosphatemia in end stage renal failure.	Fresenius Medical Care North America
401	Calcium carbonate	R & D Calcium Carbonate/600	6/6/1990	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc.
402	Calcium gluconate	Calgonate	11/20/1997	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp.
403	Calcium gluconate gel	H-F Gel	5/21/1991	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Calgonate Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
404	Calcium gluconate gel 2.5%	n/a	9/10/1990	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc.
405	Calfactant	Infasurf	9/5/2000	Acute respiratory distress syndrome (ARDS)	ONY, Inc.
406	Capsaicin	n/a	8/3/2005	Treatment of postherpetic neuralgia.	TheraQuest Biosciences, LLC
407	Capsaicin	n/a	9/29/2006	Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis	Centrexion Corporation
408	Carmustine	n/a	7/3/2000	Treatment of intracranial malignancies.	Direct Therapeutics, Inc.
409	Cascara sagrada fluid extract	n/a	3/21/1989	Treatment of oral drug overdose to speed lower bowel evacuation.	Intramed Corporation
410	Catumaxomab	Removab	6/9/2006	Treatment of ovarian cancer	NeoviiBiotech North America, Inc.
411	Ceftriaxone sodium	Rocephin	3/28/2006	Treatment of amyotrophic lateral sclerosis	Mass General Hospital

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
412	Cells produced using the AastromReplicelle System and SC-I Therapy Kit	n/a	7/10/2002	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated
413	Centruroides immune F(ab)2	Anascorp	6/12/2000	Treatment of scorpion envenomations requiring medical attention.	Rare Disease Therapeutics, Inc.
414	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	1/19/1988	Treatment of Fabry's disease.	Genzyme Corporation
415	Chelating agent delivering Holmium-166	n/a	2/10/1999	Treatment of multiple myeloma.	NeoRx Corporation
416	Chenodeoxycholic acid	Chenofalk	1/29/2004	Treatment of cerebrotendinous xanthomatosis	Dr. Falk Pharma GmbH
417	Chimeric monoclonal antibodies, c-alphaStx2	n/a	10/4/2005	For treatment of shiga-toxin producing bacterial infection	Thallion Pharmaceuticals, Inc.
418	Chimeric monoclonal antibody to mesothelin	n/a	10/31/2006	Treatment of pancreatic cancer	Morphotek, Inc.
419	Chimeric, humanized monoclonal antibody to staphylococcus	n/a	8/3/2000	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
420	Chlorhexidine gluconate mouthrinse	Peridex	8/18/1986	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company
421	Chlorotoxin	n/a	12/18/2007	Treatment of malignant glioma	Morphotek, Inc.
422	Choline chloride	Intrachol	7/20/2006	Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition	QOL Therapeutics EU, Ltd
423	Choline chloride	Intrachol	2/10/1994	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	QOL Therapeutics EU Ltd
424	Chondrocyte-alginate gel suspension	n/a	12/1/1997	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc.
425	Ciliary neurotrophic factor	n/a	1/30/1992	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc
426	Cintredekin Besudotox	n/a	4/30/2010	Treatment of idiopathic pulmonary fibrosis	Insys Therapeutics, Inc.
427	Cisplatin in liposomal formulation	Slit Cisplatin For Inhalation	3/20/2007	Treatment of osteosarcoma	Eleison Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
428	Cisplatin/epinephrine	Intradose	9/7/2000	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc.
429	Cisplatin/epinephrine	Intradose	4/3/2000	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc.
430	Citric acid, glucono-delta-lactone and magnesium carbonate	Renacidin Irrigation	8/28/1989	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc.
431	Cladribine	Mylinax	4/19/1994	Treatment of the chronic progressive form of multiple sclerosis.	Johnson & Johnson Pharmaceutical R & D, LLC
432	Cladribine	Leustatin Injection	11/15/1990	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute
433	Clazosentan	Erajel	2/16/2006	Treatment of cerebral vasospasm following subarachnoid hemorrhage	Actelion Pharmaceuticals Ltd.
434	Clindamycin	Cleocin	10/28/1988	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn
435	Clindamycin	Cleocin	10/28/1988	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc.
436	Clindamycin hydrochloride	n/a	8/9/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
437	Clofazimine	Lamprene	6/11/1984	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation
438	Clonazepam	Klonopin	8/4/1994	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc.
439	Clonazepam Intranasal Spray	n/a	12/19/2007	Treatment of recurrent acute repetitive seizures	Jazz Pharmaceuticals, Inc.
440	Clonidine	Duraclon	1/24/1989	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc.
441	Clotrimazole	n/a	4/24/1995	Treatment of sickle cell disease.	Brugnara, Carlo M.D.
442	Clotrimazole	n/a	3/13/2006	Treatment of Huntington's disease	EnVivo Pharmaceuticals, Inc.
443	Clotrimazole	n/a	6/14/2005	Topical treatment of children and adults with pouchitis	AesRx, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
444	Coagulation Factor IX (human)	Alphanine	7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation
445	Coagulation Factor IX (recombinant)	Benefix	10/3/1994	Treatment of hemophilia B.	Genetics Institute, Inc.
446	Coagulation Factor VIIa (Recombinant)	Novoseven	7/16/2004	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
447	Coagulation factor IX	Mononine	6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company
448	Coagulation factor IX (recombinant), Fc fusion protein	Alprolix	10/30/2008	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Biogen Idec Inc.
449	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors	Novo Nordisk, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
450	Coagulation factor VIIa (recombinant)	Novoseven	7/21/2004	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Novo Nordisk, Inc.
451	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Novo Nordisk, Inc.
452	Coagulation factor VIIa (recombinant)	Novoseven	9/10/2004	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Novo Nordisk, Inc.
453	Coagulation factor VIIa (recombinant)	Novoseven	6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk, Inc.
454	Coagulation factor VIIa (recombinant)	Novoseven	6/18/2004	Prevention of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk, Inc.
455	Coenzyme Q10	n/a	3/5/2001	Treatment of Huntington's disease	Integrative Therapeutics, Inc.
456	Colchicine	n/a	9/25/2007	Treatment of Behcet's Syndrome	AR Scientific, Inc.
457	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.	Glaxo Wellcome Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
458	Colfosceril palmitate, cetyl alcohol, tyloxapol	Exosurf Neonatal For Intratracheal Suspension	10/20/1989	Treatment of established hyaline membrane disease at all gestational ages.	Glaxo Wellcome Inc.
459	Combination of nivolumab and ipilimumab	n/a	10/9/2014	Treatment of Stage IIb to Stage IV melanoma	Bristol-Myers Squibb Company
460	Combretastatin A4 Phosphate	n/a	7/23/2003	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc
461	Combretastatin A4 phosphate	n/a	5/8/2006	Treatment of ovarian cancer	OXiGENE, Inc.
462	Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer	n/a	8/6/2013	Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)	NanoViricides Incorporated
463	Contulakin-G	n/a	7/7/2005	Intrathecal treatment of neuropathic pain associated with spinal cord injury	Cognetix, Inc.
464	Cordycepin	n/a	7/5/2007	Treatment of TdT-positive acute lymphocytic leukemia	OncoVista, Inc.
465	Corticotropin-releasing factor, human	Acthrel	11/24/1989	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.	Ferring Laboratories, Inc.
466	Corticotropin-releasing factor, human	Xerecept	4/6/1998	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
467	Coumarin	Onkolox	12/22/1994	Treatment of renal cell carcinoma.	Drossapharm LTD
468	Coxsackievirus A21	Cavatak	12/15/2005	Treatment of stage II (T4), stage III, and stage IV melanoma	Viralytics Limited
469	Creatine	Creapure	10/11/2005	Treatment of Huntington's disease	Marathon Pharmaceuticals, LLC
470	Cromolyn sodium	Gastrocrom	3/8/1984	Treatment of mastocytosis.	Fisons Corporation
471	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	7/24/1985	Treatment of vernal keratoconjunctivitis.	Fisons Corporation
472	Cryptosporidium hyperimmune bovine colostrum IgG concentrate	n/a	12/30/1991	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation
473	Cyclo {(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}	n/a	12/20/2006	Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis	Lux Biosciences, Inc.
474	Cyclosporin A	Mitogard	10/29/2004	Treatment of amyotrophic lateral sclerosis and its variants	Maas Biolab, LLC
475	Cyclosporine	Pluminiq	11/25/2003	Treatment of acute rejection in patients requiring allogeneic lung transplants	APT Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
476	Cyclosporine	n/a	11/25/2003	Prophylaxis of organ rejection in patients receiving allogeneic lung transplant	APT Pharmaceuticals, Inc.
477	Cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	Treatment of patients at high risk of graft rejection following penetrating keratoplasty	Allergan, Inc.
478	Cyclosporine A	n/a	5/4/2007	Treatment of vernal keratoconjunctivitis	Santen SAS
479	Cyclosporine in combination with omega-3 polyunsaturated fatty acids	n/a	12/6/2000	Prevention of solid organ graft rejection.	RTP Pharma Corporation
480	Cyclosporine ophthalmic	Optimmune	11/9/1988	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia
481	Cys-His-Ala-Val-Cys	n/a	2/14/2008	For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV	Adherex Technologies, Inc.
482	Cysteamine	n/a	5/1/1986	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D.
483	Cysteamine	Cystagon	1/25/1991	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc.
484	Cysteamine	Lynovex	9/11/2014	Treatment of cystic fibrosis	NovaBiotics Ltd.
485	Cysteamine hydrochloride	Cystaran	8/19/1997	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
486	Cystic fibrosis Tr gene therapy (recombinant adenovirus)	Adgvcftr.10	3/9/1995	Treatment of cystic fibrosis.	GenVec, Inc.
487	Cystic fibrosis transmembrane conductance regulator gene	n/a	1/8/1993	Treatment of cystic fibrosis.	Genetic Therapy, Inc.
488	Cytarabine liposomal	Depocyt	6/2/1993	Treatment of neoplastic meningitis.	Pacira Pharmaceuticals, Inc.
489	Cytarabine:daunorubicin liposome injection	n/a	8/22/2008	Treatment of acute myeloid leukemia	Celator Pharmaceuticals, Inc.
490	Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride	n/a	9/23/2006	For use in prevention of clinically significant CMV viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations	Vical Inc.
491	Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes	n/a	6/3/2005	Prevention of clinically significant cytomegalovirus (CMV) viremia, CMV disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations	Astellas Pharma Global Development, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
492	Cytomegalovirus immune globulin (human)	Cytogam	8/3/1987	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	CSL Behring LLC
493	Cytomegalovirus immune globulin intravenous (human)	n/a	1/28/1991	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation
494	D-mannitol and L-proline	Prodarsan	4/20/2009	Treatment of Cockayne syndrome	DNage B.V.
495	D-peptide	Nerofe	2/4/2011	Treatment of acute myelogenous leukemia	Immune System Key, Ltd
496	D-peptide of the sequence AKRHHGYKRKFH - NH2	Pulmadex	10/23/2002	Treatment of cystic fibrosis	Demegen, Inc.
497	DCVAC OvCa	n/a	5/14/2013	Treatment of ovarian cancer	SOTIOS a.s.
498	DEAE-rebeccamycin	n/a	3/1/2004	Treatment of bile duct tumors	Helsinn Healthcare SA
499	DHA-paclitaxel	Taxoprexin	5/1/2003	Treatment of adenocarcinoma of the stomach or lower esophagus	Luitpold Pharmaceuticals, Inc.
500	DHA-paclitaxel	Taxoprexin	9/25/2001	Treatment of pancreatic cancer	Luitpold Pharmaceuticals, Inc..
501	DHA-paclitaxel	Taxoprexin	10/10/2002	Treatment of metastatic malignant melanoma	Luitpold Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
502	DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19	n/a	8/20/2009	Treatment of ovarian cancer	BioCancell Therapeutics Ltd.
503	DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor	n/a	2/6/2014	Treatment of amyotrophic lateral sclerosis	ViroMed Co., Ltd.
504	DNA plasmid vector expressing eIF5Ak50	n/a	12/13/2010	Treatment of multiple myeloma.	Senesco Technologies, Inc.
505	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of diffuse large B cell lymphoma	Senesco Technologies, Inc.
506	DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)	n/a	7/24/2012	Treatment of mantle cell lymphoma	Senesco Technologies, Inc.
507	DNA plasmid vector expressing human IL-12 gene	n/a	4/4/2005	Treatment of ovarian cancer.	Expression Genetics, Inc.
508	DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Leuvectin	4/28/2000	Treatment of renal cell carcinoma.	Vical Incorporated

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
509	DNP-Modified autologous tumor vaccine	O-Vax	9/21/2000	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc.
510	DOXO-EMCH	n/a	4/18/2011	Treatment of adenocarcinoma of the pancreas.	CytRx Corporation
511	Daclizumab	Zenapax	3/5/1993	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc.
512	Dapsone	n/a	11/7/1994	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc.
513	Dapsone USP	Dapsone	12/24/1991	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company
514	Dapsone USP	Dapsone	1/8/1992	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company
515	Darinaparsin	n/a	9/13/2010	Treatment of peripheral T-cell lymphoma.	Solasia Pharma K.K.
516	Dasatinib	Sprycel	11/28/2005	Treatment of chronic myelogenous leukemia	Bristol-Myers Squibb Company
517	Dasatinib	Sprycel	11/18/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Bristol-Myers Squibb Company
518	Daunorubicin citrate liposome injection	Daunoxome	5/14/1993	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
519	Daunorubicin liposomal	n/a	9/5/2008	Treatment of acute myeloid leukemia	Diatos USA, LLC
520	Deferasirox	Exjade	11/21/2002	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals Corporation
521	Defibrotide	n/a	7/5/1985	Treatment of thrombotic thrombocytopenic purpura.	Crinos International
522	Dehydroepiandrosterone (DHEA)	Fidelin	8/19/2003	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc.
523	Dehydroepiandrosterone sulfate sodium	n/a	1/29/1997	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc.
524	Dehydroepiandrosterone sulfate sodium	n/a	1/28/1997	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc.
525	Dermagraft	n/a	12/13/2010	Treatment of epidermolysis bullosa	Shire Regenerative Medicine, Inc.
526	Deslorelin	Somagard	11/5/1987		Roberts Pharmaceutical Corp.
527	Desmoglein 3 synthetic peptide (PI-0824)	n/a	10/26/2004	Treatment of pemphigus vulgaris	Peptimmune, Inc.
528	Desmopressin acetate	n/a	1/22/1991	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
529	Dexrazoxane	Zinecard	12/17/1991	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn
530	Dextran 70	Dehydrex	3/5/1990	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc.
531	Dextran and deferoxamine	Bio-Rescue	3/8/1991	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc.
532	Dextran sulfate (inhaled, aerosolized)	Uendex	10/5/1990	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
533	Dextran sulfate sodium	n/a	11/19/1987	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd.
534	Dianeal peritoneal dialysis solution with 1.1% amino acids	Nutrineal (Peritoneal Dialysis Solution With 1.1% Amino Acid	6/11/1992	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation
535	Diazepam viscous solution for rectal administration	n/a	2/25/1992	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Valeant Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
536	Diethyldithiocarbamate	Imuthiol	4/3/1986	Treatment of AIDS.	Connaught Laboratories
537	Diethylenetriaminepentaacetic acid (DTPA)	n/a	4/28/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.	Hameln Pharmaceuticals gmbh
538	Digoxin immune FAB (Ovine)	Digibind	11/1/1984	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc.
539	Digoxin immune fab(ovine)	Digidote	3/11/1985	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp.
540	Dihydrotestosterone	Androgel -Dht	2/5/1996	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Besins Internaitonal, US Inc.
541	Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP)	n/a	11/24/1999	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Bellicum Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
542	Dimethyl sulfoxide	n/a	11/22/1994	Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.	Abela Pharmaceuticals, Inc.
543	Dimethylsulfoxide	n/a	4/15/1997	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc.
544	Dimethylsulfoxide	n/a	4/6/1998	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc.
545	Dipalmitoylphosphatidylcholine /phosphatidylglycerol	Alec	7/28/1988	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc.
546	Diphenylcyclopropenone gel	Samcyprone (Tm)	4/15/2015	Treatment of malignant melanoma stage IIB to IV	RXi Pharmaceuticals Corp.
547	Disaccharide tripeptide glycerol dipalmitoyl	Immther	3/1/1990	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc.
548	Disodium clodronate	n/a	6/16/1993	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc.
549	Disodium clodronate tetrahydrate	Bonefos	3/5/1990	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
550	Doripenem	n/a	7/16/2004	Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.	Shionogi, Inc.
551	Dornase alfa	Pulmozyme	1/16/1991	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc.
552	Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain	n/a	8/6/2010	Treatment of pancreatic cancer	BioCancell Therapeutics Israel Ltd.
553	Doxorubicin HCl with pluronic L-61 and pluronic F-127	n/a	10/7/2005	Treatment of esophageal carcinoma	Supratek Pharma Inc.
554	Doxorubicin liposome	Doxil	11/4/1998	Treatment of ovarian cancer.	Alza Corporation
555	Dronabinol	Marinol	1/15/1991	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc.
556	Duramycin	n/a	12/11/1997	Treatment of cystic fibrosis.	Lantibio, Inc.
557	Dynamine	n/a	10/16/1991	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation
558	Dynamine	n/a	2/5/1990	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
559	E-selectin antagonist	n/a	5/13/2015	Treatment of acute myeloid leukemia (AML)	GlycoMimetics, Inc.
560	Eculizumab	n/a	9/21/2000	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc.
561	Edaravone	n/a	5/12/2015	Treatment of amyotrophic lateral sclerosis	Mitsubishi Tanabe Pharma Corporation
562	Edotreotide	Onalta(Tm)	7/28/2005	Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors	ITG Isotope Technologies Garchig GmbH
563	Efdispo (tm)	Efdispo (Tm)	1/15/2013	Treatment of Ewings Sarcoma.	TDP Biotherapeutics, Inc.
564	Eflornithine	n/a	9/29/2006	Treatment of anaplastic glioma	Orbus Therapeutics, Inc.
565	Eflornithine HCl	Ornidyl	4/23/1986	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel
566	Elcatonin	n/a	9/25/1995	Intrathecal treatment of intractable pain.	Innapharma, Inc.
567	Elesclomol	n/a	12/18/2007	Treatment of metastatic melanoma in combination with paclitaxel	Synta Pharmaceuticals Corporation
568	Enadoline hydrochloride	n/a	1/28/1997	Treatment of severe head injury.	Warner-Lambert Company

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
569	Encapsulated porcine islet preparation	Betarx	7/5/1995	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx
570	Engineered variant of recombinant human fibroblast growth factor 19	n/a	2/6/2014	Treatment of primary biliary cirrhosis	NGM Biopharmaceuticals, Inc.
571	Enzastaurin	n/a	9/19/2005	Treatment of glioblastoma multiforme	Eli Lilly and Company
572	Epidermal growth factor (human)	n/a	10/5/1987	For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.	Chiron Vision
573	Epirubicin	Ellence	9/14/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company
574	Epitalon	n/a	9/2/2010	Treatment of retinitis pigmentosa	BioDiem Ltd
575	Epoetin alfa	n/a	12/20/1993	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev.,
576	Epoetin alfa	Epogen	4/10/1986	Treatment of anemia associated with end stage renal disease.	Amgen, Inc.
577	Epoetin alfa	Epogen	7/1/1991	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc.
578	Epoetin alpha	Procrit	3/7/1989	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
579	Epoetin alpha	Procrit	8/27/1987	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute
580	Epoetin beta	Marogen	10/22/1987	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc.
581	Epoprostenol	Flolan	9/25/1985	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc.
582	Eprodisate	Kiacta(Tm)	4/6/1999	Treatment of secondary amyloidosis	C. T. Development America, Inc.
583	Epstein-Barr virus-specific autologous cytotoxic T lymphocytes	n/a	6/12/2014	Treatment of Epstein-Barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma)	FFCanVac Pte Ltd
584	Erlotinib Hydrochloride	Tarceva	7/18/2003	Treatment of malignant gliomas	Genentech, Inc
585	Erwinia L-asparaginase	Erwinase	7/30/1986	Treatment of acute lymphocytic leukemia.	Jazz Pharmaceuticals, Inc.
586	Erythropoietin (recombinant human)	n/a	8/19/1987	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp
587	Ethanol gel	n/a	3/29/2006	Treatment of congenital venous malformations	Orfagen
588	Ethanol gel	n/a	3/13/2006	Treatment of congenital lymphatic malformations	Orfagen
589	Ethanolamine oleate	Ethamolin	3/22/1984	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	QOL Medical

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
590	Ethyl eicosapentaenoate	n/a	4/6/2000	Treatment of Huntington's disease.	Laxdale Ltd.
591	Etidronate disodium	Didronel	3/21/1986	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc.
592	Etiocholanedione	n/a	11/3/1995	Treatment of aplastic anemia.	SuperGen, Inc.
593	Etiocholanedione	n/a	5/7/1996	Treatment of Prader-Willi syndrome.	SuperGen, Inc.
594	Ex vivo cultured adult human mesenchymal stem cells	Prochymal(R)	12/14/2005	Treatment of acute graft versus host disease	Mesoblast, Inc.
595	Exemestane	Aromasin	9/19/1991	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn
596	Exisulind	n/a	2/14/1994	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	OSI Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
597	Exon 44 specific phosphorothioate oligonucleotide	n/a	11/5/2009	Treatment of Duchenne Muscular Dystrophy in patients who have a mutation correctable by skipping of exon 44 of the dystrophin gene.	Prosensa Therapeutics B.V.
598	Exon 45 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 45	Prosensa Therapeutics B V
599	Exon 51 specific phosphorothioate oligonucleotide	n/a	8/25/2009	Treatment of Duchenne Muscular Dystrophy.	Prosensa Therapeutics BV
600	Exon 52 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 52	Prosensa Therapeutics B V
601	Exon 55 specific phosphorothioate oligonucleotide	n/a	1/23/2013	Treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 55	Prosensa Therapeutics B.V.
602	Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass	n/a	5/14/2012	Treatment of multiple myeloma	Unicorn Pacific Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
603	FTV1+GDP-fucose	n/a	3/18/2011	To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.	America Stem Cell, Inc.
604	Facilitated DNA Plasmid Vaccine	n/a	3/8/1995	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics
605	Factor XIII [A2] homodimer, recombinant DNA origin	n/a	5/21/2003	Treatment of congenital FXIII deficiency	Novo Nordisk Pharmaceuticals, INC.
606	Fampridine	Neurelan	6/2/1997	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc.
607	Fast skeletal muscle troponin activator	n/a	3/2/2010	Treatment of amyotrophic lateral sclerosis (ALS)	Cytokinetics Inc.
608	Felbamate	Felbatol	1/24/1989	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories
609	Fenobam hydrochloride	n/a	11/20/2006	Treatment of fragile X syndrome	Neuropharm, Ltd.
610	Fenretinide	n/a	10/5/2005	Treatment of neuroblastoma	USC-CHLA Institute for Pediatric Clinical Research
611	Fenretinide	n/a	4/7/2010	Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients	McGill University

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
612	Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGpPTH1-34	n/a	2/1/2007	Treatment of solitary (unicameral) bone cysts	Kuros Biosurgery AG
613	Fibrinogen (human)	n/a	8/23/1995	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation
614	Fibronectin (human plasma derived)	n/a	9/5/1988	Treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.	Melville Biologics, Inc.
615	Fibronectin Peptide	n/a	6/29/2011	Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.	NeoMatrix Formulations, Inc.
616	Filgrastim	Neupogen	7/17/1995	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
617	Filgrastim	Neupogen	11/7/1990	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm ³).	Amgen, Inc.
618	Filgrastim	Neupogen	10/1/1990	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc.
619	Filgrastim	Neupogen	11/7/1996	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc.
620	FliC Flagellin Deletion Variant TLR5 Agonist	n/a	11/23/2010	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Cleveland BioLabs, Inc.
621	Floxuridine, FUDR	n/a	12/22/2004	Intraperitoneal treatment of gastric cancer.	Franco Muggia, M.D.
622	Fludarabine phosphate	Fludara	4/18/1989	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc.
623	Fludarabine phosphate	Fludara	4/18/1989	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc.
624	Fludarabine phosphate oral tablets	n/a	12/18/2007	Treatment of B-cell chronic lymphocytic leukemia	Sanofi-Aventis U.S., Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
625	Flunarizine	Sibelium	1/6/1986	Treatment of alternating hemiplegia.	Janssen Research Foundation
626	Fluocinolone	Retisert	7/31/2000	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, Inc.
627	Fluorouracil	n/a	6/29/2000	Treatment of glioblastoma multiforme.	Ethypharm SA
628	Fluorouracil	n/a	4/18/1990	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc.
629	Fluorouracil	n/a	10/27/1989	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.
630	Fluoxetine	Prozac	4/14/2004	Treatment of body dysmorphic disorder in children and adolescents	Hollander, Eric MD
631	Fluoxetine	Prozac	4/30/1999	Treatment of autism.	Neuropharm, Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
632				For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	
	Follitropin alfa, recombinant	Gonal-F	12/21/1998		EMD Serono, Inc.
633	Fomepizole	Antizole	12/22/1988	Treatment of methanol or ethylene glycol poisoning.	Jazz Pharmaceuticals
634	Fosphenytoin	Cerebyx	6/4/1991	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company
635	Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
636	Fully human anti-interferon gamma monoclonal antibody	Ni-0501	3/26/2010	Treatment of hemophagocytic lymphohistiocytosis	NovImmune S.A.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
637	Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1	n/a	1/11/2006	Treatment of X-linked hypohidrotic ectodermal dysplasia	Edimer Pharmaceuticals, Inc.
638	G17DT Immunogen	Gastrimmune(Tm)	7/10/2002	Treatment of adenocarcinoma of the pancreas	Cancer Advances, Inc.
639	G17DT Immunogen	Gastrimmune(Tm)	7/18/2002	Treatment of gastric cancer	Cancer Advances, Inc.
640	GNE Lipoplex	n/a	11/13/2008	Treatment of hereditary inclusion body myopathy-2	Gradalis, Inc.
641	GNE plasmid(H001)	n/a	3/26/2010	Treatment of hereditary inclusion body myopathy type 2	HIBM Research Group
642	GVAX melanoma	n/a	12/23/2010	Treatment of stage IIb to IV melanoma	Aduro BioTech, Inc.
643	Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide	n/a	12/31/2013	Diagnostic for the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumors	Advanced Accelerator Applications
644	Gallium-68 (DOTA0-Phel-Tyr3)octreotide	n/a	10/23/2013	The management of neuroendocrine tumors	University of Iowa Hospital & Clinics

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
645	Gamma hydroxybutyrate	n/a	12/3/1987	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.	Biocraft Laboratories, Inc.
646	Gammalinolenic acid	n/a	7/27/1994	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D.
647	Ganaxolone	n/a	5/25/1994	Treatment of infantile spasms.	Marinus Pharmaceuticals, Inc.
648	Ganciclovir intravitreal implant	Vitrasert Implant	6/7/1995	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products
649	Gastrin 17C Diphtheria Toxoid Immunogen	n/a	7/7/2009	Treatment of pancreatic cancer	Astrimmune Ltd.
650	Gemtuzumab zogamicin	Mylotarg	11/24/1999	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories
651	Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha	n/a	12/11/1997	Treatment of Crohn's disease.	Celltech Chiroscience Limited
652	Geneticin	n/a	6/6/2005	Treatment of amoebiasis.	ProcesScience, Inc (PSI)
653	Gentamicin impregnated PMMA beads on surgical wire	Septopal	1/31/1991	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
654	Gentamicin liposome injection	Maitec	7/10/1990	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc.
655	Glatiramer acetate	Copaxone	11/9/1987	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA
656	Glatiramer acetate for injection	Copaxone	6/5/2001	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA
657	Glutamine	Nutrestore	3/6/1995	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Emmaus Medical, Inc.
658	Glutathione pegylated liposomal doxorubicin hydrochloride	n/a	8/16/2010	Treatment of glioma	to-BBB technologies BV
659	Glyceryl tri (4-phenylbutyrate)	n/a	5/24/2005	Treatment of spinal muscular atrophy	Ucyclyd Pharma, Inc
660	Glyceryl trioleate and glyceryl trierucate	n/a	2/14/1995	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D.
661	Glyeraldehyde-3-phosphate dehydrogenase	Proenzy	4/30/2010	Treatment of pediatric multiple sclerosis	BPT Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
662	Gonadorelin acetate	Lutrepulse	4/22/1987	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc.
663	Gossypol	n/a	10/22/1990	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D.
664	Gp100 adenoviral gene therapy	n/a	3/25/1997	Treatment of metastatic melanoma.	Genzyme Corporation
665	Growth hormone releasing factor	n/a	8/7/1989	For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Valeant Pharmaceuticals North America
666	H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt	n/a	12/22/2011	For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma	CanBas Company, Ltd.
667	H-Leu-Pro-Pro-Ser-Arg-OH	n/a	9/20/2012	Treatment of Kaposi sarcoma	Immuno Tech, Inc.
668	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH	n/a	4/11/2014	Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset	NoNO, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
669	H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Arg-Arg-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH	n/a	5/14/2013	Treatment of subarachnoid hemorrhage	NoNO, Inc.
670	HIRMAb-IDS	n/a	5/15/2013	Treatment of mucopolysaccharidosis Type II (Hunter Syndrome)	ArmaGen Technologies, Inc.
671	HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex	Allovectin-7	9/30/1999	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated
672	HPV-16 cancer therapeutic trojan peptide vaccine	n/a	1/12/2009	Treatment of HPV-16 expressing head and neck squamous cell carcinoma.	Gliknik, Inc.
673	HPV16 E6/E7 synthetic long peptides vaccine	n/a	9/1/2011	Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.	ISA Therapeutics BV
674	Halofantrine	Halfan	11/4/1991	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham Pharmaceuticals
675	Halofuginone	Stenorol	2/7/2000	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd.
676	Hanferon	Hanferon	3/9/2012	Treatment of Behcet's disease	HanAll BioPharma Co., Ltd.
677	Hantaan virus and Puumala virus DNA vaccines	n/a	11/13/2012	Prevention of hemorrhagic fever with renal syndrome caused by Hantaan virus and Puumala virus.	Surgeon General of the U. S. Army

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
678	Heat Shock Protein (hsp60) antigen	Diapep277	5/21/2012	For use in type 1 diabetic mellitus patients with residual beta-cell function	Andromeda Biotech, LTD
679	Heat Shock Protein 70	n/a	3/18/2011	Treatment of amyotrophic lateral sclerosis	ALS Biopharma, LLC
680	Heme arginate	Normosang	3/10/1988	Treatment of symptomatic stage of acute porphyria.	Orphan Europe SARL
681	Heme arginate	Normosang	3/1/1994	Treatment of myelodysplastic syndromes.	Orphan Europe
682	Hemin	Panhematin	3/16/1984	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.	Abbott Laboratories
683	Hemin and zinc mesoporphyrin	Hemex	12/20/1993	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D.
684	Hemoximer (pyridoxalated hemoglobin polyoxyethylene)	n/a	12/18/2007	Treatment of cardiogenic shock	Apex Bioscience, Inc.
685	Heparin sodium	n/a	6/29/2006	Treatment of cystic fibrosis	Ockham Biotech Limited
686	Heparin-binding epidermal growth factor-like growth factor	n/a	9/18/2006	Prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants with birth weight less than 1,500 grams	Trillium Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
687	Hepatitis B immune globulin intravenous (human)	Nabi-Hb	3/8/1995	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	Biotest Pharmaceuticals Corporation
688	Hepatitis C virus immune globulin (human)	Civacir(Tm)	11/14/2002	Prophylaxis of hepatitis C infection in liver transplant recipients.	Biotest Pharmaceuticals Corporation
689	Heptadecasodium salt of an 18-base residue phosphorothioate oligonucleotide	n/a	4/18/2011	Treatment of spinal muscular atrophy	Isis Pharmaceuticals, Inc.
690	Herpes simplex virus gene	n/a	10/16/1992	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc.
691	His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr	n/a	3/11/2013	Treatment of retinal detachment	ONL Therapeutics, Inc
692	Histamine	Maxamine	2/1/2000	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	EpiCept Corporation
693	Histamine	Ceplene	12/15/1999	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	EpiCept Corporation
694	Histrelin	n/a	5/3/1991	Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.	Anderson, Karl E., M.D.
695	Histrelin	Supprelin La	11/18/2005	Treatment of central precocious puberty	Endo Pharmaceuticals Solutions, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
696	Histrelin acetate	Supprelin Injection	8/10/1988	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp.
697	Hu1D10, humanized monoclonal antibody	Remitogen	11/28/2001	For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma	PDL BioPharma, Inc.
698	Human Hemin	n/a	8/6/2013	Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation	Borders Technology Management Ltd
699	Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F	n/a	5/29/2014	Treatment of glioblastoma multiforme	AbbVie, Inc.
700	Human T-lymphotropic virus type III Gp160 antigens	Vaxsyn Hiv-1	11/20/1989	Treatment of AIDS.	MicroGeneSys, Inc.
701	Human alpha 2,6 sialyltransferase adenoviral gene therapy	n/a	4/4/2005	Treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.	Falk Center for Molecular Therapeutics
702	Human anti-CD30 monoclonal antibody	n/a	9/27/2004	Treatment of Hodgkin's disease	Bristol-Myers Squibb, Inc.
703	Human autologous bone-forming cell derived from bone marrow stem cells	n/a	3/24/2008	Treatment of osteonecrosis	Bone Therapeutics S.A.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
704	Human cytomegalovirus immunoglobulin	n/a	12/20/2006	Prevention of congenital cytomegalovirus (CMV) infection following primary CMV infection in pregnant women	Biotest Pharmaceuticals Corporation
705	Human factor X	n/a	11/8/2007	Treatment of hereditary factor X deficiency	Bio Products Laboratory
706	Human immune globulin	Flebogamma(R) 5% Dif	3/29/2006	Treatment of post-polio syndrome	Instituto Grifols, S.A.
707	Human immunoglobulin anti-CD30 monoclonal antibody	n/a	1/10/2006	Treatment of CD30+ T-cell lymphoma	Bristol-Myers Squibb
708	Human monoclonal antibody against platelet-derived growth factor D	n/a	11/2/2004	To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease.	CuraGen Corporation
709	Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa	Aerumab 11	9/18/2006	Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa	Kenta Biotech Limited
710	Human monoclonal antibody inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2)	n/a	12/16/2013	Prevention (inhibition) of complement-mediated thrombotic microangiopathy	Omeros Corporation
711	Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)	n/a	4/30/2010	Treatment of ovarian cancer	Ortho Biotech

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
712	Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	4/18/2007	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Octapharma USA, Inc.
713	Human plasma derived conagulation protein-Factor XI	n/a	4/30/2014	For the treatment of congenital Factor XI deficiency	Cambryn Biologics
714	Human prothrombin complex concentrate	Octaplex	2/1/2008	Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures	Octapharma USA, Inc.
715	Human telomerase reverse transcriptase peptide vaccine	n/a	7/20/2006	Treatment of pancreatic cancer	GemVax A/S
716	Humanized 3F8-IgG1 monoclonal antibody	n/a	6/24/2013	Treatment of neuroblastoma	Memorial Sloan-Kettering Cancer Center
717	Humanized IgG monoclonal antibody hRS7 conjugated to topoisomerase I inhibitor	n/a	5/29/2014	Treatment of pancreatic cancer.	Immunomedics, Inc.
718	Humanized anti-CD3 monoclonal antibody	n/a	9/29/2006	Treatment of recent-onset Type I diabetes	MacroGenics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
719	Humanized anti-tac	Zenapax	3/5/1993	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc.
720	Humanized monoclonal antibody to TumorEndothelial Marker-1	n/a	4/29/2011	Treatment of soft tissue sarcoma	Morphotek
721	Hydralazine	n/a	4/9/2004	Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy	Bioniche Pharma USA LLC
722	Hydroxocobalamin	n/a	9/22/2000	Treatment of acute cyanide poisoning	Jazz Pharmaceuticals
723	Hydroxocobalamin	Cyanokit	11/25/2003	Treatment of acute cyanide poisoning	Merck Sante, s.a.a.
724	Hydroxy-Propyl-Beta-Cyclodextrin	Trappsol	5/17/2010	Treatment of Niemann Pick Disease, Type C	Childrens Hospital & Research Center Oakland
725	Hydroxyurea	Droxia	10/1/1990	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute
726	Hypericin	n/a	8/3/2000	Treatment of glioblastoma multiforme.	HyBiopharma, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
727	Hypericin	n/a	2/7/2000	Treatment of cutaneous T-cell lymphoma.	Soligenix, Inc.
728	Hypothiocyanite and lactoferrin	Meveol	11/5/2009	Treatment of cystic fibrosis	Alaxia Biotechnologies Sante
729	I(131)-TM-601 (chlorotoxin)	n/a	2/14/2002	Treatment of malignant glioma	Morphotek, Inc.
730	IDUA-HIRMAb fusion protein	Agt-181	1/10/2008	Treatment of mucopolysaccharidosis Type 1 (MPS)	ArmaGen Technologies, Inc.
731	IL-12 secreting dendritic cells loaded with autologous tumor lysate	n/a	6/24/2013	Treatment of malignant glioma	Activartis Biotech GmbH
732	IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	n/a	4/6/2000	Treatment of astrocytic glioma.	Medicenna Therapeutics, Inc.
733	IL13-PE38QQR	n/a	11/2/2001	Treatment of malignant glioma	Insys Therapeutics, Inc.
734	Ibuprofen i.v. solution	Salprofen	10/29/1996	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC
735	Ibuprofen lysine	Neoprofen	10/29/1996	Treatment of patent ductus arteriosus	Lundbeck, Inc.
736	Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	7/18/1997	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
737	Idarubicin HCl for injection	Idamycin	7/25/1988	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc.
738	Idoxuridine	n/a	4/8/1996	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc.
739	Ifosfamide	Ifex	8/7/1985	Treatment of bone sarcomas	Bristol-Myers Squibb Company
740	Ifosfamide	Ifex	8/7/1985	Treatment of soft tissue sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute
741	Ifosfamide	Ifex	1/20/1987	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute
742	IgG1 chimeric monoclonal antibody	n/a	6/22/2011	Treatment of multiple myeloma.	Immune System Therapeutics Ltd
743	Iloprost inhalation solution	Ventavis	8/17/2004	Treatment of pulmonary arterial hypertension	CoTherix, Inc.
744	Imatinib	Gleevec	1/31/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals Corporation
745	Imatinib mesylate	Gleevec	9/9/2005	Treatment of systemic mastocytosis without the D816V c-kit mutation	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
746	Imatinib mesylate	Gleevec	8/25/2005	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Novartis Pharmaceuticals Corporation
747	Imatinib mesylate	Gleevec	10/5/2005	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Novartis Pharmaceuticals Corporation
748	Imciromab pentetate	Myoscint	1/25/1989	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc.
749	Imexon	n/a	11/8/1996	Treatment of multiple myeloma.	AmpliMed Corporation
750	Imiglucerase	Cerezyme	11/5/1991	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation
751	Imiquimod	n/a	12/3/2014	Treatment of carcinoma in situ (CIS) of the urinary bladder	Telormedix SA
752	Immortalized human liver cells found in the extracorporeal liver assist device	Elad	7/16/2004	Treatment of fulminant hepatic failure (acute liver failure)	Vital Therapies, Inc.
753	Immune Globulin (Human)	Gamunex(R)-C	7/27/2004	Treatment of chronic inflammatory demyelinating polyneuropathy	Grifols Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
754	Immune Globulin (Human) containing high titers of West Nile virus antibodies	Omr-Igg-Am (Tm) 5% (Wnv)	3/17/2004	Treatment of the West Nile virus infection	OMRIX Biopharmaceuticals, Ltd.
755	Immune Globulin Intravenous (human)	Carimune Nf	5/4/2004	Treatment for Guillain Barre Syndrome	ZLB Bioplasma AG
756	Immune Globulin Subcutaneous (Human), 20% Liquid	Hizentra	8/18/2014	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	CSL Behring
757	Immune globulin intravenous, human	Gamimune N	2/18/1993	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation
758	Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val	n/a	3/16/1994	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation
759	Imported fire ant venom, allergenic extract	n/a	5/12/1992	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc.
760	Inalimarev and falimarev	n/a	1/10/2006	Treatment of adenocarcinoma of the pancreas	Therion Biologics Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
761	Indium-111 pentetreotide	Neuroendomedix	6/16/2006	Treatment of neuroendocrine tumors	Radiolotope Therapy of America (RITA) Foundation
762	Inecalcitol	n/a	5/14/2014	Treatment of chronic lymphocytic leukemia	Hybrigenics, S.A.
763	Infliximab	Remicade	5/21/2003	Treatment of chronic sarcoidosis	Centocor, Inc.
764	Infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc.
765	Inhibitor of Tissue Factor Pathway Inhibitor (TFPI)	n/a	1/29/2010	Treatment of hemophilia A and hemophilia B.	Baxter Healthcare Corporation, Baxter BioScience
766	Inhibitor of primary and secondary KIT and PDGFR alpha kinase mutants found in GIST	n/a	10/2/2014	Treatment of gastrointestinal stromal tumors (GIST)	Deciphera Pharmaceuticals, LLC
767	Inosine pranobex	Isoprinosine	9/20/1988	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals
768	Interferon alfa-2a	Roferon A	6/6/1989	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc.
769	Interferon alfa-2a (recombinant)	Roferon-A	10/27/1989	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
770	Interferon alfa-2a (recombinant)	Roferon-A	5/2/1990	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
771	Interferon alfa-2a (recombinant)	Roferon-A	4/18/1988	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc.
772	Interferon alfa-2a (recombinant)	Roferon-A	5/11/1990	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc.
773	Interferon alfa-2a (recombinant)	Roferon-A	12/14/1987	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc.
774	Interferon alfa-2a (recombinant)	Roferon-A	5/14/1990	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc.
775	Interferon alfa-2b (recombinant)	Intron A	6/24/1987	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation
776	Interferon beta-1a	Avonex	12/16/1991	Treatment of multiple sclerosis.	Biogen, Inc.
777	Interferon beta-1a	Rebif	3/11/1996	Treatment of patients with secondary progressive multiple sclerosis.	EMD Serono, Inc.
778	Interferon beta-1a (recombinant human)	n/a	7/24/1992	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
779	Interferon beta-1a (recombinant)	Rebif	12/2/1992	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	EMD Serono, Inc.
780	Interferon beta-1b	Betaseron	11/17/1988	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories
781	Interferon gamma	n/a	10/11/2007	Treatment of idiopathic pulmonary fibrosis	mondoBIOTECH Laboratories AG
782	Interferon gamma 1-b	Actimmune	9/30/1988	Treatment of chronic granulomatous disease.	Horizon Pharma Ireland Limited
783	Interferon gamma-1b	Actimmune	12/4/1995	Treatment of renal cell carcinoma.	Horizon Pharma Ireland Limited
784	Interferon gamma-1b	Actimmune	9/30/1996	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	Horizon Pharma Ireland Limited
785	Interferon-alfa-1b	n/a	4/17/2001	Treatment of multiple myeloma	Ernest C.Borden
786	Interleukin-1 Trap	n/a	4/4/2005	Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease	Regeneron Pharmaceuticals, Inc.
787	Interleukin-1 receptor antagonist, human recombinant	Antril	10/16/1992	Prevention and treatment of graft versus host disease in transplant recipients.	Swedish Orphan Biovitrum AB (publ) (SOBI)
788	Interleukin-1 receptor antagonist, human recombinant	Antril	9/23/1991	Treatment of juvenile rheumatoid arthritis.	Swedish Orphan Biovitrum AB (publ) (SOBI)

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
789	Interleukin-2	Teleleukin	2/6/1990	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
790	Interleukin-2	Tecleukin	2/5/1990	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
791	Interleukin-2	Tecleukin	5/3/1990	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc.
792	Interleukin-2	Tecleukin	5/11/1990	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc.
793	Intraoral fluoride releasing system	lfrs	7/31/2001	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc.
794	Intravenous immune globulin	Vitigam	7/26/2007	Treatment of Stage IIB to IV malignant melanoma	GammaCan Ltd.
795	Intravenous immune globulin (human) 10%	Octagam(R)	7/31/2008	Treatment of stiff-person syndrome	Octapharma USA, Inc.
796	Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of pheochromocytomas	GE Healthcare, Inc.
797	Iobenguane I 123	Adreview	12/1/2006	For the diagnosis of neuroblastomas	GE Healthcare, Inc.
798	Iobenguane I 131	Azedra Ultratrace	1/18/2006	Treatment of neuroendocrine tumors	Molecular Insight Pharmaceuticals
799	Iobenguane Sulfate I-123	Omaclear	10/17/2005	For scintigraphic detection, localization and staging of neuroblastoma.	Brogan Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
800	Iodine 131 6B-iodomethyl-19-norcholesterol	n/a	8/1/1984	For use in adrenal cortical imaging.	David E. Kuhl, M.D.
801	Iodine I 123 murine monoclonal antibody to hCG	n/a	11/7/1988	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc.
802	Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody	Pentacea	2/22/2000	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C.
803	Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B)	131ichtnt-1	2/12/1999	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc.
804	Ipatasertib	n/a	4/30/2014	For the treatment of gastric cancer including cancer of the gastro-esophageal junction.	Genentech, Inc.
805	Isobutyramide	n/a	5/25/1994	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation
806	Isobutyramide	Isobutyramide Oral Solution	12/18/1992	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D.
807	Itraconazole suspension	n/a	10/30/2008	Topical treatment of fungal otitis externa (otomycosis)	Fairfield Clinical Trials, LLC
808	Japanese encephalitis vaccine (live, attenuated)	n/a	5/19/1999	Prevention of Japanese encephalitis.	Glovax Co., Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
809	Japanese encephalitis vaccine, inactivated, adsorbed	Ixiaro	9/25/2012	Prevention of Japanese encephalitis virus in pediatric patients.	Intercell AG
810	Kre-Celazine	n/a	4/1/2013	Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population	All American Pharmaceutical & Natural Foods Corpor
811	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	7/30/1996	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc.
812	L-2-oxothiazolidine-4-carboxylic acid	Procysteine	6/14/1994	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc.
813	L-5 Hydroxytryptophan	n/a	11/1/1984	Treatment of postanoxic intention myoclonus.	Watson Laboratories, Inc.
814	L-5-hydroxytryptophan	n/a	1/20/1999	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc.
815	L-amino acids, vitamins and minerals combined with omega-3 fatty acids	n/a	1/12/2011	Treatment of patients with pediatric Crohn's disease	Immunopath Profile, Inc.
816	L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal	n/a	1/18/2006	Treatment of Duchenne and Becker muscular dystrophy	CepTor Corporation
817	L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide	n/a	9/11/2013	Treatment of acute radiation syndrome	Soligenix, Inc.
818	L-asparaginase	n/a	3/27/2014	Treatment of acute myeloid leukemia	ERYTECH Pharma S.A.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
819	L-asparaginase encapsulated in red blood cells	Graspa	7/6/2012	Treatment of pancreatic cancer.	ERYTECH Pharma
820	L-asparaginase encapsulated in red blood cells	Graspa	1/6/2010	Treatment of acute lymphoblastic leukemia	Erytech Pharma
821	L-baclofen	Neuralgon	12/17/1991	Treatment of spasticity associated with spinal cord injury or multiple sclerosis.	Osmotica Pharmaceutical Corp.
822	L-baclofen	Neuralgon	1/30/1992	Treatment of intractable spasticity in children with cerebral palsy.	Osmotica Pharmaceutical Corp.
823	L-baclofen	n/a	7/13/1990	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D.
824	L-baclofen	n/a	1/6/1998	Treatment of trigeminal neuralgia	Osmotica Pharmaceutical Corp.
825	L-cycloserine	n/a	8/1/1989	Treatment of Gaucher's disease.	Lev, Meir M.D.
826	L-cysteine	n/a	5/16/1994	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Brigham and Women's Hospital
827	L-glutamine	n/a	8/1/2001	Treatment of sickle cell disease	Emmaus Medical, Inc.
828	L-glutamyl-L-tryptophan	n/a	10/20/1999	Treatment of AIDS-related Kaposi's sarcoma.	Implicit Bioscience Pty Ltd

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
829	L-ornithine phenylacetate	n/a	4/7/2010	Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disease	Ocera Therapeutics, Inc.
830	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/13/2011	Treatment of neuropathic pain in patients with sarcoidosis.	Araim Pharmaceuticals, Inc.
831	L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser	n/a	9/18/2009	Prevention of delayed graft function following renal transplant	Araim Pharmaceuticals, Inc.
832	L-threonyl-L-prolyl-L-prolyl-L-threonine	n/a	4/26/2005	Treatment of neuropathic pain associated with spinal cord injury	Nyxis Neurotherapies, Inc.
833	L-tyrosine-L-serine-L-leucine	Cms-024	9/10/2004	Treatment of hepatocellular carcinoma.	CMS Peptides Patent Holding Company Limited
834	L. reuteri	n/a	8/1/2013	Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams	Infant Bacterial Therapeutics

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
835	LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL	n/a	5/4/2015	Treatment of pancreatic cancer	Lokon Pharma AB
836	Lactic acid	Aphthaid	6/29/1999	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc.
837	Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis	n/a	3/24/2015	Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams	Sigma-Tau Pharmaceuticals, Inc.
838	Lamotrigine	Lamictal	8/23/1995	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development
839	Lanreotide	Somatuline Depot	9/11/2000	Treatment for acromegly	IPSEN, Inc.
840	Laromustine	Cloretazine	3/27/2014	Treatment of acute myelogenous leukemia	Nanotherapeutics, Inc.
841	Latrodectus immune F(ab)2	Analatro	6/18/2001	Treatment of black widow spider envenomations	Instituto Bioclon, S.A. de C.V.
842	Leflunomide	n/a	10/18/1996	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
843	Lentiviral vector containing the human ABCA4 gene	Stargen (Tm)	4/30/2010	Treatment of Stargardt disease	Sanofi US Services, Inc.
844	Lentiviral vector containing the human MYO7A gene	Ushstat(Tm)	5/17/2010	Treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.	Sanofi US Services, Inc.
845	Lentiviral vector encoded with a human beta-globin gene plasmid	Thalagen	1/11/2006	Treatment of beta-thalassemia major and beta-thalassemia intermedia	Memorial Sloan-Kettering Cancer Center
846	Lepirudin	Refluden	2/13/1997	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel
847	Lestaurtinib	n/a	3/24/2006	Treatment of acute myeloid leukemia	Teva Branded Pharmaceutical Products R&D, Inc.
848	Leucovorin	Leucovorin Calcium	12/8/1986	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation
849	Leucovorin	Leucovorin Calcium	8/17/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation
850	Leupeptin	n/a	9/18/1990	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc.
851	Leuprolide acetate	Lupron Injection	7/25/1988	Treatment of central precocious puberty	Tap Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
852	Levocarnitine	Carnitor	7/26/1984	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc.
853	Levocarnitine	Carnitor	2/28/1984	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc.
854	Levocarnitine	Carnitor	9/6/1988	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc.
855	Levocarnitine	Carnitor	11/15/1989	For the treatment of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.
856	Levocarnitine	Carnitor	4/7/1997	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc.
857	Levocarnitine	Carnitor	11/15/1989	For the prevention of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc.
858	Levocarnitine	Carnitor	11/22/1993	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc.
859	Levodopa and carbidopa	Duodopa	1/18/2000	Treatment of late stage Parkinson's disease	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
860	Levofloxacin	n/a	2/27/2008	Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients	Forest Research Institute, Inc.
861	Levoleucovorin	Fusilev	8/1/1991	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Spectrum Pharmaceuticals, Inc.
862	Levomethadyl acetate hydrochloride	Orlaam	1/24/1985	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation
863	Lidocaine patch 5%	Lidoderm Patch	10/24/1995	For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.	Teikoku Pharma USA, Inc.
864	Liothyronine sodium injection	Triostat	7/30/1990	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals
865	Liposomal Glutathione	n/a	4/30/2010	Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG)	Your Energy Systems, LLC
866	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolipalmitoyl	Immther	6/10/1998	Treatment of osteosarcoma.	Endorex Corp.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
867	Liposomal N-Acetylglucosminyl-N-Acetylmuramyl-L-Ala-D-isoGln-L-Ala - glycerolipalmitoyl	Immther	6/10/1998	Treatment of Ewing's sarcoma.	Endorex Corp.
868	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of histoplasmosis.	Fujisawa USA, Inc.
869	Liposomal amphotericin B	Ambisome	12/10/1996	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc.
870	Liposomal amphotericin B	Ambisome	12/6/1996	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc.
871	Liposomal annamycin	n/a	6/17/2005	Treatment of acute myeloid leukemia	Callisto Pharmaceuticals, Inc.
872	Liposomal annamycin	n/a	6/17/2005	Treatment of acute lymphoblastic leukemia	Callisto Pharmaceuticals, Inc.
873	Liposomal ciprofloxacin for inhalation	n/a	4/19/2006	Management of cystic fibrosis	Aradigm Corporation
874	Liposomal ciprofloxacin for inhalation	n/a	12/27/2006	Management of bronchiectasis	Aradigm Corporation
875	Liposomal cisplatin	Lipova-Pt	5/23/2006	Treatment of ovarian cancer	Eleison Pharmaceuticals, LLC
876	Liposomal cyclosporin A	Cyclospire	4/30/1998	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
877	Liposomal doxorubicin hydrochloride	Sarcodoxome	12/27/2006	Treatment of soft tissue sarcomas	GP-Pharm SA
878	Liposomal nystatin	Nyotran	6/13/2000	Treatment of invasive fungal infections.	The University of Texas
879	Liposome encapsulated recombinant interleukin-2	n/a	6/20/1994	Treatment of cancers of the kidney and renal pelvis	Oncothyreon Canada, Inc.
880	Liposome encapsulated recombinant interleukin-2	n/a	11/25/1991	Treatment of brain and CNS tumors.	Oncothyreon Canada, Inc.
881	Lisofylline	n/a	6/10/1999	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc.
882	Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38	Not Determined	3/24/2015	Treatment of mesothelioma.	Aduro Biotech, Inc.
883	Lodoxamide tromethamine	Alomide Ophthalmic Solution	10/16/1991	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc.
884	Lonafarnib	n/a	11/19/2013	Treatment of Hepatitis Delta Virus (HDV)infection	Eiger Biopharmaceuticals, Inc.
885	Lucinactant	Surfaxin	7/17/1995	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc.
886	Lucinactant	Surfaxin	10/21/2005	Treatment of bronchopulmonary dysplasia in premature infants.	Discovery Laboratories, Inc.
887	Lucinactant	Surfaxin(R), Aerosurf(R)	10/21/2010	Treatment of cystic fibrosis.	Discovery Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
888	Lucinactant	Surfaxin	5/23/2006	Prevention of bronchopulmonary dysplasia in premature infants	Discovery Laboratories, Inc
889	Lucinactant	Surfaxin	10/18/1995	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc.
890	MA09-hRPE cells	n/a	2/2/2010	Treatment of Stargardt's macular dystrophy.	Advanced Cell Technology, Inc.
891	MAGE-A3 cancer therapeutic Trojan peptide vaccine	n/a	11/24/2008	Treatment of MAGE-A3 expressing head and neck squamous cell carcinoma	Gliknik, Inc.
892	MCMV5322A/MCMV3068A	n/a	11/22/2011	Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy	Genentech
893	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of acute myelogenous leukemia.	Millennium Pharmaceuticals
894	MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)	n/a	2/4/2011	Treatment of Myelodysplastic syndrome	Millennium Pharmaceuticals, Inc.
895	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	9/18/1998	Treatment of small cell lung cancer	Immunomedics, Inc.
896	MN14 monoclonal antibody to carcinoembryonic antigen	Cea-Cide	11/24/1998	Treatment of pancreatic cancer.	Immunomedics, Inc.
897	MOD-423 hGH analogue	n/a	9/29/2010	Treatment of growth hormone deficiency	OPKO Biologics Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
898	MTC-DOX for Injection	n/a	1/3/2001	Treatment of hepatocellular carcinoma	FeRx Incorporated
899	MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin	n/a	9/23/2014	Treatment of Neuroblastoma	MabVax Therapeutics, Inc.
900	Mafenide acetate solution	Sulfamylon Solution	7/18/1990	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc.
901	Mafofosamide	n/a	1/21/2003	Treatment of neoplastic meningitis	Baxter Healthcare Corporation
902	Manganese superoxide dismutase mimetic	n/a	2/27/2008	Prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients	Galera Therapeutics, LLC
903	Mannitol	Bronchitol	2/11/2005	For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis	Pharmaxis Ltd.
904	Marijuana	n/a	5/25/1999	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
905	Marizomib	n/a	12/13/2013	Treatment of multiple myeloma	Triphase Research and Development I Corp.
906	Matrix metalloproteinase inhibitor	Galardin	12/5/1991	Treatment of corneal ulcers.	Glycomed, Inc
907	MaxAdFVIII	n/a	3/3/2003	Treatment of Hemophilia A	GenStar Therapeutics Corporation
908	Mazindol	Sanorex	12/8/1986	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D.
909	Mecamylamine	Inversine	10/14/1998	Treatment of Tourette's syndrome.	Targacept, Inc.
910	Mecasermin	Increlex	12/12/1995	Treatment of growth hormone insensitivity syndrome.	Ipsen Biopharmaceuticals, Inc.
911	Medroxyprogesterone acetate	Hematrol	2/22/2001	Treatment of immune thrombocytopenic purpura.	ZaBeCor Pharmaceutical Company, LLC
912	Mefloquine HCl	Mephaquin	7/22/1987	Prevention of chloroquine-resistant Falciparum malaria.	Mepha AG
913	Mefloquine HCl	Mephaquin	7/22/1987	Treatment of chloroquine-resistant Falciparummalaria.	Mepha AG
914	Megestrol acetate	Megace	4/13/1988	Treatment of patients with anorexia, cachexia, or significant weight loss (= \geq 10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
915	Melanoma autologous dendritic cell vaccine	n/a	9/6/2006	Treatment of stage IIIb through IV metastatic melanoma	NeoStem, Inc.
916	Melanoma cell vaccine	Canvaxin	10/13/1994	Treatment of invasive melanoma.	CancerVax Corporation
917	Melanoma peptide vaccine	n/a	3/29/2005	Treatment of HLA-A2+ patients with stage IIB, IIC, III, and IV malignant melanoma	Bristol-Myers Squibb Research Inst
918	Melanoma vaccine	Melacine	12/20/1989	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc.
919	Melatonin	n/a	11/15/1993	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D.
920	Melatonin	Circadin	7/9/2004	Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception	Neurim Pharmaceuticals, Ltd.
921	Melphalan	Alkeran For Injection	2/24/1992	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc.
922	Menadione Sodium Bisulfite	n/a	5/14/2014	For the treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
923	Mesna	Mesnex	11/14/1985	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
924	Methionine/L-methionine	n/a	8/21/1996	Treatment of AIDS myelopathy.	Genopia USA, Inc.
925	Methotrexate	Amethopterin	8/28/2014	Treatment of Myasthenia Gravis	The Universtiy of Kanasa Medical Center
926	Methotrexate sodium	Methotrexate	10/21/1985	Treatment of osteogenic sarcoma.	Lederle Laboratories
927	Methotrexate with laurocapram	Methotrexate/Azone	10/15/1990	Topical treatment of mycosis fungoides.	Echo Therapeutics, Ltd.
928	Methoxsalen	Uvadex	10/14/1998	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc.
929	Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-Asparaginyl-4-aminobutanoyl]-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[n/a	4/18/2011	Prevention of ischemia reperfusion injury associated with solid organ transplantation	Endotis Pharma
930	Metronidazole	Metrogel	10/24/1991	Treatment of perioral dermatitis.	Galderma Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
931	Metronidazole (topical)	Metrogel	10/22/1987	Treatment of acne rosacea.	Galderma Laboratories, Inc.
932	Metronidazole 10% ointment	n/a	11/8/2007	Topical treatment of active perianal Crohn's disease	SLA Pharma (UK) Ltd
933	Microbubble contrast agent	Filmix Neurosonographic Contrast Agent	11/16/1990	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc.
934	Microvesiculated modified glycosylated tissue factor	n/a	1/25/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients	Thrombotargets Corp.
935	Microvesiculated modified glycosylated tissue factor	n/a	10/11/2007	Treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von Willebrand disease.	Thrombotargets Corp.
936	Midodrine HCl	Amatine	6/21/1985	Treatment of patients with symptomatic orthostatic hypotension.	Shire
937	Midostaurin	n/a	7/7/2009	Treatment of acute myeloid leukemia	Novartis Pharmaceuticals Corporation
938	Midostaurin	Rydapt	4/30/2010	Treatment of mastocytosis	Novartis Oncology
939	Mifepristone	n/a	2/7/2005	Treatment of Cushing's syndrome secondary to ectopic ACTH secretion	HRA Pharma

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
940	Minnelide	Minnelide (Tm)	2/18/2013	Treatment of pancreatic cancer	Minneamrita Therapeutics, LLC
941	Minocycline hydrochloride	n/a	3/28/2006	Treatment of sarcoidosis	Autoimmunity Research Foundation
942	Mitoguazone	Apep	3/18/1994	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc.
943	Mitolactol	n/a	7/12/1995	As adjuvant therapy in the treatment of primary brain tumors.	Targent, Inc.
944	Mitolactol	n/a	1/23/1989	Treatment of invasive carcinoma of the uterine cervix	Targent, Inc..
945	Mitomycin-C	n/a	8/20/1993	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc.
946	Mitoxantrone	Novantrone	8/13/1999	Treatment of secondary-progressive multiple sclerosis.	Serono, Inc.
947	Mitoxantrone	Novantrone	8/21/1996	Treatment of hormone refractory prostate cancer.	Serono
948	Mitoxantrone	Novantrone	8/13/1999	Treatment of progressive-relapsing multiple sclerosis.	Serono, Inc.
949	Mitoxantrone HCl	Novantrone	7/13/1987	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
950	Mocetinostat	n/a	6/12/2014	Treatment of myelodysplastic syndrome	Mirati Therapeutics, Inc.
951	Modafinil	Provigil	3/15/1993	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc.
952	Monoclonal antibody for immunization against lupus nephritis	n/a	1/7/1993	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc.
953	Monoclonal antibody-B43.13	Ovarex Mab-B43.13	11/25/1996	Treatment of epithelial ovarian cancer.	Quest PharmaTech, Inc.
954	Monolaurin	Glylorin	4/29/1993	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc.
955	Monooctanoin	Moctanin	5/30/1984	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc.
956	Morphine sulfate concentrate (preservative free)	Infumorph	7/12/1990	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc.
957	Multi-ligand somatostatin analog	n/a	7/27/2004	Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.	Novartis Pharmaceuticals Corporation
958	Multi-peptide cancer vaccine	n/a	6/23/2013	Treatment of multiple myeloma	OncoPep, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
959	Multi-vitamin infusion (neonatal formula)	n/a	12/12/1989	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P.
960	Multistem(r)	n/a	9/15/2010	Prophylaxis of graft vs host disease	Athersys, Inc.
961	Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	Oncolym	11/27/1998	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc.
962	Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	Theragyn	3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc
963	Mx-dnG1	Rexin-G	6/24/2008	Treatment of osteosarcoma.	Epeius Biotechnologies Corporation
964	Mx-dnG1	Rexin-G(R)	6/24/2008	Treatment of soft tissue sarcoma	Epeius Biotechnologies Corporation
965	Mx-dnG1 or Rexin-G retroviral vector	Rexin-G	8/15/2003	Treatment of pancreatic cancer	Epeius Biotechnologies Corporation
966	Mycobacterium avium sensitin RS-10	n/a	10/11/1995	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
967	N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)	n/a	4/6/2012	Treatment of mercury toxicity	CTI Science Limited
968	N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide	n/a	11/17/2014	Treatment of Duchenne muscular dystrophy	Catabasis Pharmaceuticals, Inc.
969	N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxopyrrolidin-1-yl)propyl]-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide	n/a	11/17/2014	Treatment of optic neuritis	Bionure Farma SL
970	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	2/1/2008	Treatment of acute myeloid leukemia	Mirati Therapeutics, Inc.
971	N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide	n/a	8/8/2007	Treatment of Hodgkin's lymphoma	Mirati Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
972	N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl}prop-2-enamide mesylate salt	n/a	9/4/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	AstraZeneca Pharmaceuticals LP
973	N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide	n/a	10/15/2014	Treatment of AL Amyloidosis	ProteoTech, Inc.
974	N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate	n/a	11/26/2013	Treatment of gliomas	Kinex Pharmaceuticals, Inc.
975	N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-(naphthyl-alanyl)-L-cysteiny-L-tyrosyl-L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-trosyl-L-arginyl-L-citrullinyl-L-cysteiny-L-arginine amide, cyclic (4-13)-disulfide	n/a	7/6/2012	For use in combination with G-CSF to mobilize HSCs from the marrow to peripheral blood for collection for autologous or allogeneic transplantation	BioLineRx, Ltd.
976	N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl}oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate	n/a	10/21/2014	Treatment of ovarian cancer	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
977	N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt	n/a	3/18/2009	Treatment of acute myeloid leukemia	Ambit Biosciences Corporation
978	N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride	n/a	11/17/2014	Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)	Unither Virology, LLC
979	N-(cyanomethyl)-4-(2-([4-(morpholin-4-yl(phenyl)amino}pyrimidin-4-yl)benzamide	n/a	8/5/2010	Treatment of myelofibrosis	Gilead Sciences, Inc.
980	N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate	n/a	10/17/2005	Treatment of multiple myeloma.	AB Science
981	N-Acetylmannosamine (ManNAc)	n/a	4/5/2010	Treatment of hereditary inclusion body myopathy type 2	New Zealand Pharmaceuticals Ltd
982	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/2012	Treatment of meningioma	Arno Therapeutics, Inc.
983	N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide	n/a	1/13/2012	Treatment of Schwannoma of the central nervous system	Arno Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
984	N-Methanocarbathymidine	n/a	10/15/2014	Treatment of neonatal herpes	N & N Pharmaceuticals, Inc.
985	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/29/2010	Treatment of pancreatic cancer	EMD Serono, Inc.
986	N-[(2S)-2,3-dihydroxypropyl]-3-[[2-fluoro-4-iodophenyl]amino]isonicotinamide hydrochloride	n/a	1/12/2011	Treatment of acute myeloid leukemia (AML).	EMD Serono, Inc.
987	N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt	n/a	1/7/2015	For the treatment of Cushing's Syndrome	Atterocor, Inc.
988	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide	n/a	9/30/2004	Treatment of neuroblastoma	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
989	N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{{(3S)-3-(dimethylamino)pyrrolidin-1-yl)methyl}-3-(trifluoromethyl)benzamide	n/a	12/27/2006	Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia.	CytRx Corporation
990	N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide	n/a	5/25/1995	Treatment of malignant glioma.	Sugen, Inc.
991	N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide	n/a	3/12/1996	Treatment of ovarian cancer.	Sugen, Inc.
992	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/3/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer	Ignyta, Inc.
993	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	12/22/2014	Treatment of neuroblastoma	Ignyta, Inc.
994	N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide	n/a	2/12/2015	Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer	Ignyta, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
995	N-acetyl cysteine amide	n/a	12/31/2013	Treatment of retinitis pigmentosa	Brighton Biotech, Inc.
996	N-acetyl-glucosamine thiazoline	n/a	2/6/2006	Treatment of adult Tay-Sachs disease	ExSAR Corporation
997	N-acetyl-procainamide	n/a	12/10/1996	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas
998	N-acetylcysteinate Lysine	Nacystelyn Dry Powder Inhaler	12/27/2000	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc.
999	N-acetylcysteine	n/a	7/19/2012	Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers	Edward A. Neuwelt, MD
1000	N-acetylcysteine	n/a	9/9/2002	Treatment of acute liver failure	Cumberland Pharmaceuticals, Inc.
1001	N-acetylgalactosamine-4-sulfatase, recombinant human	Naglazyme	2/17/1999	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc.
1002	N-adamantanyl-N'-Geranyl-ethylenediamine	n/a	10/16/2007	Treatment of tuberculosis.	Sequella, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1003	N-methyl-4-({4-[(3-methyl(methylsulfonyl)amino)pyrazin-2-yl)methyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide hydrochloride	n/a	7/18/2013	Treatment of mesothelioma	Verastem, Inc.
1004	N-t-butylhydroxylamine	n/a	5/12/2015	Treatment of infantile neuronal ceroid lipofuscinosis.	Andrew Lim
1005	N-tert-butyl-3-[(5-methyl-2-{4-(2-pyrrolidin-1-ylethoxy)phenyl}amino)pyrimidin-4-yl)amino]benzenesulfonamide dihydrochloride monohydrate	n/a	3/21/2013	Treatment of polycythemia vera	sanofi-aventis U.S. LLC
1006	N-tert-butyl-3-[5-methyl-2-{4-(2-pyrrolidin-1-ylethoxy)phenyl}amino]pyrimidin-4-yl-amino]benzenesulfonamide dihydrochloride monohydrate	n/a	5/18/2009	Treatment of secondary and primary myelofibrosis	Sanofi-Aventis US, LLC a Sanofi company
1007	N-{3-[(2-{4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl}amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino]phenyl}prop-2-enamide	n/a	5/14/2013	Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor	Clovis Oncology, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1008	N-[[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide	n/a	2/4/2011	Treatment of tuberculosis.	Sequella, Inc.
1009	N1,N14,-diethyl-3,12,-dihydroxyhomospermine	n/a	8/7/2014	Treatment of pancreatic cancer	Sun BioPharma, Inc.
1010	N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody	n/a	2/27/2008	Treatment of multiple myeloma	Biotest Pharmaceuticals Corporation
1011	N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody	n/a	12/7/2000	For pancreatic cancer	SmithKline Beecham Pharmaceuticals
1012	NDX-peptides	n/a	12/14/2010	Treatment of amyotrophic lateral sclerosis	NeoDiagnostic Research Ltd
1013	Nafarelin acetate	Synarel Nasal Solution	7/20/1988	Treatment of central precocious puberty.	Syntex (USA), Inc.
1014	Naltrexone HCl	Trexan	3/11/1985	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1015	NanoDTPA(tm)	n/a	6/17/2011	Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium	Nanotherapeutics, Inc.
1016	Natural human lymphoblastoid interferon-alpha	n/a	1/18/2000	Treatment of Behcet's disease	Amarillo Biosciences, Inc.
1017	Natural human lymphoblastoid interferon-alpha	n/a	8/10/2000	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Amarillo Biosciences, Inc.
1018	Nebacumab	Centoxin	10/1/1986	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc.
1019	Neurotrophin-1	n/a	9/13/1994	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D.
1020	Neutrophil-endothelial interaction inhibitor	Cylexin	12/22/1993	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation
1021	Nifedipine	n/a	6/13/1991	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D.
1022	Nikkomycin Z	n/a	2/14/2006	Treatment of coccidioidomycosis	Valley Fever Center for Excellence (1-111 INF)

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1023	Nimotuzumab	n/a	11/17/2004	Treatment of glioma	InnoKeys PTE Ltd.
1024	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of acute myelogenous leukemia	The Vaccine Company
1025	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of chronic myelogenous leukemia.	The Vaccine Company
1026	Nine amino acid polypeptide derived from proteinase 3	n/a	9/3/2004	Treatment of myelodysplastic syndromes requiring therapy	The Vaccine Company
1027	Nitazoxanide	Alinia	12/12/1996	Treatment of cryptosporidiosis.	Romark Laboratories, L.C.
1028	Nitisinone	Orfadin	10/19/2001	Treatment of alkaptonuria	Swedish Orphan AB
1029	Nitisinone	Orfadin	5/16/1995	Treatment of tyrosinemia type 1.	Swedish Orphan Biovitrum AB (PUBL)
1030	Nitric oxide	Inomax	9/27/2004	To reduce the risk of chronic lung disease in premature neonates	INO Therapeutics
1031	Nitric oxide	n/a	2/16/2005	Diagnosis of sarcoidosis	SensorMedics Corporation
1032	Nitric oxide	n/a	9/11/2013	Treatment of cystic fibrosis	Novoteris, LLC
1033	Nitric oxide	n/a	7/10/1995	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc.
1034	Nitric oxide	Inomax	6/22/1993	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1035	Nitroprusside	n/a	2/21/2001	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan
1036	NorLeu3-Angiotensin(1-7)) [NorLeu3-A(1-7)]	n/a	12/31/2013	Treatment of leakage from the surgical site following penetrating keratoplasty	US Biotest, Inc.
1037	NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)]	n/a	1/31/2014	Treatment of dermal injury due to nuclear/radiation incident	US Biotest, Inc.
1038	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	9/10/2009	Treatment of acute myeloid leukemia	Antisoma, Inc.
1039	Nucleic acid aptamer binding to tumor cell nucleolin	n/a	8/17/2004	Treatment of pancreatic cancer	Antisoma Research Ltd.
1040	Nucleic acid aptamer binding to tumor cell nucleon	n/a	7/28/2005	Treatment of renal cell carcinoma	Antisoma Inc.
1041	O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride	n/a	1/15/2013	Treatment of Duchenne Muscular Dystrophy	N-Gene Research Laboratories, Inc.
1042	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diolate	n/a	3/16/2012	Treatment of acute myeloid leukemia	JSK Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1043	O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate	n/a	12/13/2013	Treatment of multiple myeloma	JSK Therapeutics, Inc.
1044	OTL38; conjugate of pteroi acid and S0456 near infrared dye	n/a	12/23/2014	Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer)	On Target Laboratories, LLC
1045	Octreotide	Sandostatin Lar	8/24/1998	Treatment of acromegaly.	Novartis Pharmaceuticals Corporation
1046	Octreotide	Sandostatin Lar	8/24/1998	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals Corporation
1047	Octreotide	Sandostatin Lar	8/24/1998	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals Corporation
1048	Ofloxacin	Ocuflox Ophthalmic Solution	4/18/1991	Treatment of bacterial corneal ulcers.	Allergan, Inc.
1049	Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	n/a	11/22/1995	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals
1050	Omega-3 (n-3) polyunsaturated fatty acids	Omacor	5/4/2000	Treatment of IgA nephropathy.	Pronova Biocare, AS

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1051	Omegaven emulsion	Omegaven	2/27/2008	Treatment of parenteral nutrition associated liver disease	Fresenius Kabi Deutschland GmbH
1052	Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102)	n/a	12/22/2014	Treatment of malignant mesothelioma	Oncos Therapeutics, Ltd.
1053	Oprelvekin	Neumega	12/17/1996	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc.
1054	Oxaliplatin	n/a	10/6/1992	Treatment of ovarian cancer.	Debio Pharm S.A.
1055	Oxalobacter formigenes	n/a	3/29/2006	Treatment of primary hyperoxaluria	OxThera, Inc.
1056	Oxandrolone	Oxandrin	4/22/1997	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Savient Pharmaceuticals, Inc.
1057	Oxandrolone	Oxandrin	9/6/1991	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp.
1058	Oxymorphone	Numorphan H.P.	3/19/1985	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company
1059	Oxypurinol	n/a	11/9/1998	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp.
1060	P140K MGMT transduced human CD34 cells	n/a	1/9/2013	For bone marrow protection in the treatment of glioblastoma multiforme	Lentigen Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1061	PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)	n/a	4/2/2015	Treatment of angiosarcoma	Co-D Therapeutics, Inc.
1062	PEG-glucocerebrosidase	Lysodase	12/9/1992	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, NIH
1063	PEG-interleukin-2	n/a	2/1/1990	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation
1064	PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody	n/a	10/25/2013	Treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	KaloBios Pharmaceuticals, Inc.
1065	PEGylated recombinant human hyaluronidase PH20	n/a	10/1/2014	Treatment of pancreatic cancer	Halozyme Therapeutics, Inc.
1066	PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus)	n/a	7/5/2012	Treatment of idiopathic thrombocytopenic purpura	PhytoHealth Corporation
1067	PGC-C12E-terlipressin	n/a	12/27/2012	Treatment of refractory ascites due to all etiologies except for cancer	PharmaIN Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1068	Paclitaxel	Taxol	3/25/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute
1069	Paclitaxel	Paxene	4/15/1997	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc.
1070	Paclitaxel protein-bound particles for injection suspension	Abraxane	10/1/2009	Treatment of stage IIb to IV melanoma	Abraxis BioScience, LLC
1071	Pafuramidine maleate	n/a	5/14/2007	Treatment of malaria	Immtech Pharmaceuticals, Inc.
1072	Pafuramidine maleate	n/a	8/31/2007	Treatment of human African trypanosomiasis (sleeping sickness)	Immtech Pharmaceuticals, Inc.
1073	Palifosfamide	n/a	5/5/2008	Treatment of soft tissue sarcomas	ZIOPHARM Oncology, Inc.
1074	Papain, trypsin, and chymotrypsin	Wobe-Mugos	12/21/1998	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc.
1075	Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine	Medi-491	5/7/1999	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc.
1076	Pegademase bovine	Adagen	5/29/1984	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Sigma-tau Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1077	Pegaspargase	Oncaspar	10/20/1989	Treatment of acute lymphocytic leukemia.	Sigma-tau Pharmaceuticals, Inc.
1078	Pegfilgrastim	Neulasta	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
1079	Peginterferon alfa-2a	Pegasys	7/13/1998	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc.
1080	Peginterferon alfa-2a	Pegasys	9/30/1999	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc.
1081	Pegvisomant	Somavert	6/24/1997	Treatment of acromegaly.	Sensus Corporation
1082	Pegylated arginine deiminase	Melanocid	4/12/1999	Treatment of invasive malignant melanoma.	Polaris Pharmaceuticals, Inc.
1083	Peldesine	n/a	10/5/1993	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc.
1084	Pentamidine isethionate	Pentam 300	2/28/1984	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc.
1085	Pentamidine isethionate	Nebupent	1/12/1988	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc.
1086	Pentamidine isethionate	n/a	10/29/1984	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1087	Pentamidine isethionate (inhalation)	Pneumopent	10/5/1987	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fisons Corporation
1088	Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit	Cylexin	7/18/1997	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation
1089	Pentastarch	Pentaspan	8/28/1985	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Du Pont Pharmaceuticals
1090	Pentosan polysulfate sodium	Elmiron	8/7/1985	Treatment of interstitial cystitis.	Alza Corporation
1091	Pentostatin	Nipent	1/29/1991	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc.
1092	Pentostatin	Nipent	3/27/1998	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc.
1093	Pentostatin	Nipent	11/24/1999	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc.
1094	Pentostatin for injection	Nipent	9/10/1987	Treatment of hairy cell leukemia.	SuperGen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1095	Peptide 144 TGF beta-1 inhibitor	n/a	4/27/2006	Treatment of systemic sclerosis	Digna Biotech, S.L.
1096	Peptide 144 TGF beta-1-inhibitor	n/a	4/26/2006	Treatment of localized scleroderma	Digna Biotech, S.L.
1097	Peptide that inhibits mechanosensitive ion channel (MSC) activity	n/a	9/15/2010	Treatment of Duchenne Muscular Dystrophy (DMD.)	Rose Pharmaceuticals
1098	Peptidomimetic analog of hexarelin	n/a	5/14/2007	Diagnosis of growth hormone deficiency	Aeterna Zentaris GmbH
1099	Perflubron	Liquivent(Tm)	4/26/2001	Treatment of acute respiratory distress disease (ARDS) in adults	PFC Development/New Alliance Pharmaceutical
1100	Phenylacetate	n/a	3/6/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1101	Phenylalanine ammonia-lyase	Phenylase. Ravpal-Peg	3/8/1995	Treatment of hyperphenylalaninemia	BioMarin Pharmaceutical
1102	Phenylbutyrate	n/a	1/19/2000	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc.
1103	Phosphatidylinositol 3-Kinase "PI3K" Inhibitor	n/a	11/2/2010	Treatment of chronic lymphocytic leukemia (CLL)	Semafore Pharmaceuticals
1104	Picoplatin	n/a	11/2/2005	Treatment of small cell lung cancer	Poniard Pharmaceuticals
1105	Pilocarpine	Salagen	9/24/1990	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1106	Pilocarpine HCl	Salagen	2/28/1992	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc.
1107	Plasmid DNA vector expressing cystic fibrosis transmembrane gene	n/a	3/29/2005	Treatment of cystic fibrosis	Copernicus Therapeutics, Inc.
1108	Plitidepsin	Aplidin	9/30/2004	Treatment of multiple myeloma	PharmaMar USA, Inc.
1109	Poloxamer 188	Florcor	2/22/1990	Treatment of severe burns requiring hospitalization.	CytRx Corporation
1110	Poloxamer 188	n/a	8/5/1997	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation
1111	Poloxamer 331	Protox	3/21/1991	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation
1112	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc.
1113	Poly I: poly C12U	Ampligen	12/9/1993	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc.
1114	Poly I: poly C12U	Ampligen	5/20/1991	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc.
1115	Poly-ICLC	Hiltonol	3/17/1997	Treatment of primary brain tumors.	Oncovir

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1116	Polyethylene glycol-modified uricase	n/a	6/6/2005	Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated	EnzymeRx, LLC
1117	Polyethylene glycol-modified uricase	Zurase	12/21/1998	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	EnzymeRx, LLC
1118	Polyethylene glycol-modified uricase	Zurase	9/14/1999	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	EnzymeRx, LLC
1119	Polymeric oxygen	n/a	3/25/1992	Treatment of sickle cell anemia.	Capmed USA
1120	Polyribonucleotide; Polyribo- inosinic/-cyclidylic/-uridylic acid	Ampligen	7/19/1988	Treatment of AIDS.	Hemispherx Biopharma, Inc.
1121	Polyvalent, shed-antigen melanoma vaccine	n/a	6/9/2006	Treatment of stage IIb to stage IV melanoma	Polynoma LLC
1122	Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue	N-Graft	6/24/1997	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1123	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
1124	Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.	Neurocell-Pd	12/17/1996	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC
1125	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1126	Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.	Neurocell-Hd	12/10/1996	Treatment of Huntington's disease.	Diacrin/Genzyme LLC
1127	Porfimer sodium	Photofrin	6/6/1989	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1128	Porfimer sodium	Photofrin	11/15/1989	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc.
1129	Porfimer sodium	Photofrin	11/18/2004	Treatment of cholangiocarcinoma	Concordia Laboratories, Inc.
1130	Porfiromycin	Promycin	3/13/1997	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1131	Porfiromycin	Promycin	9/19/1995	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc.
1132	Posaconazole	Posoril	7/16/2004	Treatment of zygomycosis	Schering-Plough Corporation
1133	Potassium Iodide Oral Solution	Thyroshield	11/17/2004	For use as a thyroid blocking agent in pediatric patients exposed to radioactive iodine	Fleming & Company, Pharmaceuticals
1134	Potassium citrate	Urocit-K	11/1/1984	For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas
1135	Potassium citrate	Urocit-K	11/1/1984	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas
1136	Potassium citrate	Urocit-K	11/1/1984	Prevention of calcium renal stones in patients with hypocitraturia.	University of Texas Health Science Center at Dallas

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1137	Primaquine phosphate	n/a	7/23/1993	For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.	Sanofi Winthrop, Inc.
1138	Procarbazine HCl	Matulane	8/8/2006	Treatment of malignant glioma	Sigma-Tau Pharmaceuticals, Inc.
1139	Prostaglandin E1 enol ester (AS-013)	Circulase	6/12/1998	Treatment of Fontaine Stage IV chronic critical limb ischemia.	LTT Baio-Pharma Co., Ltd
1140	Protaxel	n/a	5/21/2003	Treatment of ovarian cancer	Biophysica, Inc.
1141	Protein C concentrate	Ceprothin	6/23/1992	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxter Healthcare Corporation
1142	Protein C concentrate	Protein C Concentrate (Human) Vapor Heated, Immuno	6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1143	Pulmonary surfactant replacement, porcine	Curosurf	8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Chiesi USA, Inc.
1144	Purified extract of Pseudomonas aeruginosa	Immudyn	9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	Able Laboratories, Inc.
1145	Purified type II collagen	Colloral	2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc.
1146	PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCA TT 3'	lmt504	11/24/2014	Treatment of rabies virus infections	Mid-Atlantic BioTherapeutics, Inc.
1147	Pyruvate	n/a	2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc
1148	R-(-)-gossypol	n/a	10/24/2006	Treatment of chronic lymphocytic leukemia.	Ascenta Therapeutics, Inc.
1149	R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H -1,4-benzodiazepine -3-yl]-3-(3-methylaminophenyl)urea	n/a	9/10/2009	Treatment of gastric carcinoids	Trio Medicines Ltd.
1150	R-4-amino-3-(4-chlorophenyl)butanoic acid	n/a	11/28/2008	Treatment of the behavioral abnormalities associated with fragile X syndrome	Seaside Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1151	REMUNE HIV 1	n/a	2/14/2014	Treatment of pediatric HIV/AIDS (age through 16 years)	Immune Response BioPharma, Inc.
1152	R11 retinamide	n/a	5/6/1993	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc.
1153	Rabbit anti-human thymocyte globulin (rATG)	Thymoglobulin	9/26/2006	Induction treatment to prevent rejection and to minimize maintenance immunosuppression in pediatric liver transplant recipients	Children's Hospital of Pittsburgh
1154	Rapamycin	n/a	3/20/2007	Treatment of tuberous sclerosis complex	OncolImmune, Inc.
1155	Re188 P2045 somatostatin analog	n/a	2/6/2014	Treatment of small cell lung cancer	Andarix Pharmaceuticals
1156	Re188 P2045 somatostatin peptide analogue	n/a	6/19/2014	Treatment of pancreatic cancer.	Andarix Pharmaceuticals, Inc.
1157	Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase	n/a	4/30/2014	Mucopolysaccharidosis III-B (Sanfilippo Syndrome Type B)	Abeona Therapeutics LLC
1158	Recombinant Epstein-Barr virus gp350 glycoprotein vaccine	n/a	8/18/2005	Prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation	Henogen S.A.
1159	Recombinant Fusion Protein	n/a	7/24/2012	Treatment of Myelodysplastic Syndrome	Apogenix GmbH

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1160	Recombinant Human Alpha-Fetoprotein (rhAFP)	n/a	2/22/2001	Treatment of myasthenia gravis	Merrimack Pharmaceuticals, Inc.
1161	Recombinant Human Factor VIIa Variant	n/a	11/30/2012	Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors	Pfizer, Inc.
1162	Recombinant Human Interleukin-21 (rIL-21)	n/a	10/4/2005	Treatment of stage II (T4), III or IV malignant melanoma.	Zymo Genetics, Inc
1163	Recombinant Human soluble Fc-gamma Receptor IIb	n/a	3/22/2010	Treatment of idiopathic thrombocytopenic purpura	SuppreMol GmbH
1164	Recombinant P-Selectin glycoprotein ligand	n/a	3/29/2006	Prevention of delayed graft function in renal transplant patients	Y's Therapeutics, Inc.
1165	Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig	n/a	7/26/2007	Prevention of ischemia reperfusion injury in all solid organ transplants	Y's Therapeutics, Inc.
1166	Recombinant T-cell receptor ligand	n/a	5/2/2003	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55	Artielle ImmunoTherapeutics, Inc.
1167	Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65	n/a	5/11/2009	Treatment of Leber's congenital amaurosis	AmpliPhi Biosciences Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1168	Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2	n/a	6/24/2008	Treatment of Leber congenital amaurosis due to RPE65 mutations.	Spark Therapeutics, Inc.
1169	Recombinant antibody construct against human CD30 and CD16A	n/a	8/20/2009	Treatment of Hodgkin lymphoma	Affimed Therapeutics AG
1170	Recombinant coagulation factor VIIa	n/a	4/26/2006	Treatment of diffuse alveolar hemorrhage	PharmaOrigin ApS
1171	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Prevention of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic and secondary forms.	Baxter Healthcare Corporation
1172	Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs	n/a	7/29/2008	Treatment of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic, and secondary forms.	Baxter Healthcare Corporation
1173	Recombinant fully human monoclonal antibody to anthrax protective antigen	Valortim	2/16/2006	Treatment of anthrax infection	PharmAthene, Inc.
1174	Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7	n/a	3/19/2001	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. is now Nventa
1175	Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1	n/a	10/13/2009	Treatment of glioblastoma multiforme	Apogenix GmbH

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1176	Recombinant human C1 inhibitor	n/a	6/9/2006	Prevention and/or treatment of delayed graft function after solid organ transplantation	Pharming Group N.V.
1177	Recombinant human C1 inhibitor	n/a	6/9/2006	Treatment of capillary leakage syndrome	Pharming Technologies B.V.
1178	Recombinant human C1-esterase inhibitor	n/a	2/23/1999	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming Group N.V.
1179	Recombinant human CD4 immunoglobulin G	n/a	8/30/1990	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc.
1180	Recombinant human Clara Cell 10kDa protein	n/a	7/13/1998	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Clarassance, Inc.
1181	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	8/19/1997	Treatment of glycogen storage disease type II.	Genzyme Corporation
1182	Recombinant human alpha 1-antitrypsin	n/a	4/28/2005	Prevention of bronchopulmonary dysplasia	Arriva Pharmaceuticals, Inc.
1183	Recombinant human alpha-mannosidase	n/a	2/2/2006	Treatment of alpha-mannosidosis	Zymenex A/S
1184	Recombinant human antithrombin III	n/a	4/6/2000	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1185	Recombinant human endostatin protein	n/a	8/13/2001	Treatment of neuroendocrine tumors	EntreMed, Inc.
1186	Recombinant human fibrinogen	n/a	10/4/2007	Treatment of bleeding in patients deficient in fibrinogen	Pharming Technologies B.V.
1187	Recombinant human gelsolin	n/a	3/6/1995	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	BioAgeis, Therapeutics, Inc.
1188	Recombinant human gelsolin	n/a	1/12/1994	Treatment of the respiratory symptoms of cystic fibrosis.	BioAegis Therapeutics, Inc.
1189	Recombinant human glutamic acid decarboxylase 65KDa isoform	n/a	3/22/2010	Treatment of Type I diabetes with residual beta cell function	Diamyd Therapeutics AB
1190	Recombinant human granulocyte colony stimulating factor	n/a	7/24/2006	Prevention of implantation failure and unexplained recurrent miscarriage	Nora Therapeutics, Inc.
1191	Recombinant human highly phosphorylated acid alpha-glucosidase	Tbd	9/20/2000	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc.
1192	Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA)	n/a	4/11/2001	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1193	Recombinant human insulin-like growth factor-I	Pv802	2/16/2000	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd.
1194	Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	n/a	6/15/1999	Treatment of major burns that require hospitalization.	Insmed, Inc.
1195	Recombinant human interleukin-12	n/a	10/20/1997	Treatment of renal cell carcinoma.	Genetics Institute, Inc.
1196	Recombinant human keratinocyte growth factor	n/a	12/20/1999	Reducing the incidence and severity of radiation-induced xerostomia.	Swedish Orphan Biovitrum AB (publ) (SOBI)
1197	Recombinant human luteinizing hormone	Luveris	10/7/1994	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	EMD Serono, Inc.
1198	Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase	Cholestrase	7/14/2005	Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease	Lysosomal Acid Lipase, LLC
1199	Recombinant human microplasmin	n/a	1/23/2006	Treatment of peripheral arterial occlusion	ThromboGenics Ltd

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1200	Recombinant human nerve growth factor	n/a	4/16/1999	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc.
1201	Recombinant human platelet derived growth factor BB	n/a	2/1/2007	Treatment of osteonecrosis of the jaws	Luitpold Pharmaceuticals, Inc.
1202	Recombinant human thrombopoietin	n/a	9/29/1997	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc.
1203	Recombinant humanized MAb 5c8	n/a	10/14/1998	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc.
1204	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc.
1205	Recombinant humanized MAb 5c8	n/a	3/22/1999	Prevention of rejection of solid organ transplants.	Biogen, Inc.
1206	Recombinant humanized anti-LOXL2 monoclonal antibody	n/a	4/18/2011	Treatment of idiopathic pulmonary fibrosis	Gilead Sciences, Inc.
1207	Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)	n/a	6/1/2011	Treatment of myelofibrosis.	Gilead Sciences, Inc.
1208	Recombinant humanized monoclonal antibody 5c8	n/a	2/3/1998	Treatment of immune thrombocytopenic purpura.	Biogen, Inc.
1209	Recombinant humanized monoclonal antibody 5c8	n/a	2/18/1998	Treatment of systemic lupus erythematosus.	Biogen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1210	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of epithelial ovarian cancer	National Institutes of Health
1211	Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin	n/a	2/11/2002	Treatment of malignant mesothelioma	National Institutes of Health
1212	Recombinant methionyl brain-derived neurotrophic factor	n/a	11/28/1994	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc.
1213	Recombinant replication deficient adenovirus vector carrying human p53 gene	n/a	4/12/1999	Treatment of primary ovarian cancer.	Schering Corporation
1214	Recombinant retroviral vector - glucocerebrosidase	n/a	11/15/1993	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc.
1215	Recombinant secretory leucocyte protease inhibitor	n/a	3/29/1991	Treatment of cystic fibrosis.	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1216	Recombinant soluble human CD4 (rCD4)	n/a	3/23/1989	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc.
1217	Recombinant truncated SPINT2 protease inhibitor	n/a	6/24/2005	Treatment of cystic fibrosis	Aerovance, Inc.
1218	Recombinant urate oxidase	n/a	10/11/2000	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
1219	Reduced L-glutathione	Cachexon	2/14/1994	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation
1220	Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region	Advexin	1/27/2003	Treatment of head and neck cancer	Introgen Therapeutics, Inc.
1221	Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines	Gvax Acute Myeloid Leukemia	3/2/2010	Treatment of acute myeloid leukemia	Aduro BioTech, Inc.
1222	Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines	Gvax Chronic Myeloid Leukemia	4/30/2010	Treatment of chronic myeloid leukemia	Aduro BioTech, Inc.
1223	Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines	Gvax Pancreas	3/1/2010	Treatment of pancreatic cancer.	Aduro BioTech, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1224	Respiratory Syncytial Virus Immune Globulin (human)	Hyperimmune Rsv	9/27/1990	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc.
1225	Respiratory syncytial virus immune globulin (Human)	Respigam	9/27/1990	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachusetts Public Health Biologics Labs.
1226	Reversal agent linked to chloroquine-like moiety	n/a	3/26/2010	Treatment of malaria	DesignMedix
1227	Revimmune	n/a	2/18/2011	Treatment of autoimmune hemolytic anemia.	Accentia Biopharmaceuticals
1228	Reviparin sodium	Clivarine	6/18/2001	Long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients	Abbott
1229	Reviparin sodium	Clivarine	6/18/2001	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Abbott
1230	Rho (D) immune globulin intravenous (human)	Winrho Sd	11/9/1993	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc.
1231	Rifabutin	n/a	12/18/1989	Treatment of disseminated Mycobacterium avium complex disease.	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1232	Rifabutin	Mycobutin	12/18/1989	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc.
1233	Rifalazil	n/a	4/13/1999	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation
1234	Rifampin	Rifadin I.V.	12/9/1985	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel
1235	Rifampin, isoniazid, pyrazinamide	Rifater	9/12/1985	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel
1236	Rifapentine	Priftin	6/9/1995	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel
1237	Rifapentine	Priftin	6/9/1995	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc.
1238	Rifapentine	Priftin	3/12/1996	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc.
1239	Rilonacept	Arcalyst	12/20/2004	Treatment of CIAS1-Associated Periodic Syndromes	Regeneron Pharmaceuticals, Inc.
1240	Riluzole	Rilutek	10/15/1996	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1241	Riluzole	Rilutek	3/16/1993	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1242	Rose Bengal Disodium	n/a	12/20/2006	Treatment of metastatic melanoma	Provectus Pharmaceuticals, Inc.
1243	Roseburia hominis	Rosburix	8/4/2014	Treatment of ulcerative colitis in pediatric patients age 0 through 16 years	GT Biologics Ltd
1244	S(-)-3-[3-amino-phthalimido]-glutaramide	n/a	3/14/2002	Treatment of multiple myeloma	EntreMed Incorporated
1245	S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light	Intercept Blood System For	2/14/2011	Treatment of thrombotic thrombocytopenic purpura	Cerus Corporation
1246	S-[2,3-bisphalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDENISFKEK	n/a	10/20/2009	Treatment of pancreatic cancer	MBiotec GmbH
1247	S-adenosylmethionine	n/a	4/30/1998	Treatment of AIDS-myelopathy.	Genopia USA, Inc.
1248	S-nitrosoglutathione	n/a	5/12/2009	Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function	N30 PHARMaceuticals, LLC
1249	S-nitrosoglutathione	n/a	12/28/2012	Treatment of severe preeclampsia	Salupont Consulting Ltd

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1250	S3,S13-cyclo(D-tyrosyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminy-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)	n/a	10/9/2014	Treatment of paroxysmal nocturnal hemoglobinuria (PNH)	Amyndas Pharmaceuticals
1251	SC-1 monoclonal antibody	n/a	11/12/2003	Treatment of patients with CD55 (sc-1) positive gastric tumors	Patrys Limited
1252	SDF-1 (108) Lysine Dimer	n/a	7/7/2005	Treatment of osteogenic sarcoma	Chemokine Therapeutics Corporation
1253	Sacrosidase	Sucraid	12/10/1993	Treatment of congenital sucrase-isomaltase deficiency	QOL Medical, LLC
1254	Sar9, Met(O2)11-Substance P	Homspera	3/16/2011	Treatment of idiopathic pulmonary fibrosis	ImmuneRegen BioSciences, Inc.
1255	Sargramostim	Leukine	3/6/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1256	Sargramostim	Leukine	5/3/1990	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation
1257	Satumomab pendetide	Oncoscint Cr/Ov	9/25/1989	Detection of ovarian carcinoma.	Cytogen Corporation
1258	Secalciferol	Osteo-D	7/26/1993	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA
1259	Secretory leukocyte protease inhibitor	n/a	6/30/1992	Treatment of bronchopulmonary dysplasia.	Synergen, Inc.
1260	Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase	n/a	6/4/1996	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company
1261	Selegiline HCl	Eldepryl	11/7/1984	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc.
1262	Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide	n/a	5/14/2014	Treatment of acute myeloid leukemia	Karyopharm Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1263	Seneca Valley virus	n/a	8/22/2008	Treatment of neuroendocrine tumors	Neotropix, Inc.
1264	Sermorelin acetate	Geref	9/14/1988	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
1265	Serratia marcescens extract (polyribosomes)	Imuvert	9/7/1988	Treatment of primary brain malignancies.	Cell Technology, Inc.
1266	Short chain fatty acid enema	Colomed	8/19/1997	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D.
1267	Short chain fatty acid solution	Colomed	5/29/1990	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer
1268	Silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon Sil	2/17/2012	Prevention of recurrent hepatitis C in liver transplant patients	Rottapharm S.p.A.
1269	Silver sulfadiazine and cerium nitrate	Flammacerium	11/17/1999	Treatment of patients with severe dermal burns	Sinclair Pharmaceuticals Ltd
1270	Siponimod	n/a	11/26/2013	Treatment of polymyositis	Novartis Pharmaceuticals Corporation
1271	Sitaxsentan Sodium	n/a	11/2/2004	For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.	Pfizer Global Research and Development

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1272	Sodium Monomercaptoundecahydro-closo-dodecaborate	Borocell	4/15/1992	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner
1273	Sodium Thiosulfate	n/a	2/16/2012	Treatment of uremic and non-uremic calciphylaxis	Luitpold Pharmaceuticals, Inc.
1274	Sodium aluminosilicate	n/a	3/4/2005	Treatment of chronic hepatic encephalopathy	Framework Therapeutics, LLC
1275	Sodium ascorbate and menadione sodium bisulfite	Apatone	7/31/2007	Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer)	IC-MedTech Corporation
1276	Sodium dichloroacetate	n/a	6/11/1990	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D.
1277	Sodium dichloroacetate	n/a	11/10/1994	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D.
1278	Sodium dichloroacetate	n/a	6/11/1990	Treatment of congenital lactic acidosis	Stacpoole, Peter W. M.D., Ph.D.
1279	Sodium nitrite	n/a	1/17/2007	Prevention of vasospasm associated with subarachnoid hemorrhage	Hope Pharmaceuticals
1280	Sodium nitrite	n/a	4/18/2007	Treatment of cyanide poisoning	Hope Pharmaceuticals
1281	Sodium nitrite	n/a	4/2/2007	Treatment of vaso-occlusive crisis associated with sickle cell disease	Hope Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1282	Sodium nitrite/sodium thiosulfate	Cyanide Antidote Package	3/23/2007	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
1283	Sodium phenylacetate/sodium benzoate 10%/10% Injection	Ammonul(R)	6/3/2005	Treatment of grade III and IV hepatic encephalopathy	Ucyclyd Pharma, Inc.
1284	Sodium phenylbutyrate	n/a	3/20/2007	Treatment of spinal muscular atrophy	Tikvah Therapeutics, Inc.
1285	Sodium phenylbutyrate	Buphenyl	1/25/2007	Treatment of spinal muscular atrophy	OrphaMed, Inc.
1286	Sodium phenylbutyrate	n/a	4/24/1998	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.	Elan Drug Delivery, Inc.
1287	Sodium pyruvate	n/a	3/31/2003	Treatment of cystic fibrosis	Cellular Sciences, Inc.
1288	Sodium stibogluconate	n/a	6/16/2006	Treatment of cutaneous leishmaniasis	VioQuest Pharmaceuticals, Inc.
1289	Sodium tetradecyl sulfate	Sotradecol	6/10/1986	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc.
1290	Sodium thiosulfate	n/a	3/17/2004	Prevention of platinum-induced ototoxicity in pediatric patients	Adherex Technologies, Inc.
1291	Sodium thiosulfate and sodium nitrite	n/a	12/18/2006	Treatment of cyanide poisoning	Akorn, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1292	Sodium thiosulfate, sodium nitrite, amyl nitrite	Cyanide Antidote Package	6/16/2006	Treatment of cyanide poisoning	Keystone Pharmaceuticals, Inc.
1293	Solasonine and solamargine	Coramsine	2/6/2006	Treatment of high risk stage II, stage III and stage IV melanoma	Solbec Pharmaceuticals Limited
1294	Solasonine and solamargine	Coramsine	11/2/2005	Treatment of renal cell carcinoma	Solbec Pharmaceuticals Limited
1295	Soluble complement receptor type 1	n/a	3/6/2000	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, Inc.
1296	Soluble recombinant human complement receptor type 1	n/a	11/21/1994	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc.
1297	Somatostatin	Zecnil	6/20/1988	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc.
1298	Somatostatin	n/a	12/22/1994	Treatment of bleeding esophageal varices.	Eumedita Pharmaceuticals A.G. (Schweiz)

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1299	Somatrem for injection	Protropin	12/9/1985	For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1300	Somatrem for injection	Protropin	12/9/1985	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
1301	Somatropin	Norditropin	8/9/2006	Treatment of short stature in patients with Noonan syndrome	Novo Nordisk Inc.
1302	Somatropin	Nutropin	3/6/1987	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1303	Somatropin	Serostim	3/16/2004	Treatment of patients with HIV-associated adipose redistribution syndrome	EMD Serono, Inc.
1304	Somatropin	Genotropin	9/6/1994	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn
1305	Somatropin	Humatrope	5/8/1990	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company
1306	Somatropin	Humatrope	12/15/2005	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Eli Lilly and Company

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1307	Somatropin (rDNA)	Saizen	5/3/1989	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	EMD Serono, Inc.
1308	Somatropin (r-DNA)	Zorbtive	3/6/1995	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	EMD Serono, Inc.
1309	Somatropin (r-DNA) for injection	Serostim	3/26/1996	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	EMD Serono, Inc.
1310	Somatropin (rDNA origin)	Saizen	3/6/1987	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	EMD Serono, Inc.
1311	Somatropin (rDNA origin)	Nutropin Depot	10/28/1999	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc.
1312	Somatropin (rDNA origin) injection	Norditropin	7/10/1987	Treatment of growth failure in children due to inadequate growth hormone secretion.	Novo Nordisk Pharmaceuticals
1313	Somatropin [rDNA]	Genotropin	7/6/1999	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1314	Somatropin for injection	Nutropin	8/4/1989	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc.
1315	Somatropin for injection	Serostim	11/15/1991	Treatment of AIDS-associated catabolism/weight loss.	EMD Serono, Inc.
1316	Somatropin for injection	Humatrope	6/12/1986	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company
1317	Somatropin for injection	Nutropin	11/18/1996	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Genentech, Inc.
1318	Somatropin for injection	Nutropin	3/23/1989	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc.
1319	Sorafenib	Nexavar	10/8/2004	Treatment of renal cell carcinoma.	Bayer Pharmaceutical Corporation
1320	Sorafenib	Nexavar	4/20/2006	Treatment of hepatocellular carcinoma	Bayer Pharmaceuticals Corporation
1321	Sotalol HCl	Betapace	9/23/1988	Treatment of life-threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1322	Staphylococcus aureus Immune Globulin (Human)	Altastaph	1/29/2004	Prophylaxis against Staphylococcus aureus infections in low birth weight neonates	Biotest Pharmaceuticals Corporation
1323	Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemodialysis Solution	Accusol	5/29/2009	For use as a replacement solution in adults and children during Continous Renal Replacement Therapy	Baxter Healthcare Corporation
1324	Sterile talc	Steritalc	12/8/1997	Treatment of pneumothorax.	Novatech SA
1325	Sterile talc	Steritalc	12/8/1997	Treatment of malignant pleural effusion.	Novatech SA
1326	Sterile talc powder	Sclerosol Intrapleural Aerosol	9/18/1995	Treatment of malignant pleural effusion.	Bryan Corporation
1327	Succimer	Chemet	11/5/1990	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc.
1328	Succimer	Chemet	3/22/1991	Treatment of mercury intoxication.	Sanofi Winthrop, Inc.
1329	Succimer	Chemet Capsules	5/9/1984	Treatment of lead poisoning in children.	Bock Pharmacal Company
1330	Sucralfate suspension	n/a	3/12/1990	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc.
1331	Sucralfate suspension	n/a	3/4/1991	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1332	Sulfadiazine	n/a	3/14/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Eon Labs Manufacturing, Inc.
1333	Sulfapyridine	n/a	9/10/1990	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company
1334	Superoxide dismutase (human)	n/a	3/6/1985	For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.	Pharmacia-Chiron Partnership
1335	Suramin	Metaret	5/6/1997	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company
1336	Surface active extract of saline lavage of bovine lungs	Infasurf	6/7/1985	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc.
1337	Synsorb Pk	n/a	7/17/1995	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1338	Synthetic 47 amino acid-long N-terminally myristoylated, HBV-L-protein derived lipopeptide	n/a	3/31/2015	Treatment of hepatitis D virus infection.	MYR GmbH
1339	Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid	Drepanol	10/24/1991	Prophylactic treatment of sickle cell disease.	Omex International, Inc.
1340	Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA	n/a	9/25/2012	Treatment of ischemic optic neuropathy	Quark Pharmaceuticals, Inc.
1341	Synthetic human secretin	n/a	9/18/2006	For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion	Innovate Biopharmaceuticals, Inc.
1342	Synthetic human secretin	n/a	6/16/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
1343	Synthetic human secretin	Chirostim	6/16/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
1344	Synthetic human secretin	n/a	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1345	Synthetic human secretin	n/a	6/16/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
1346	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc.
1347	Synthetic porcine secretin	n/a	6/18/1999	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc.
1348	Synthetic porcine secretin	Secreflo	6/18/1999	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc.
1349	Synthetic porcine secretin	Secreflo	3/7/2000	For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc.
1350	T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine	Neurovax	2/6/2014	Treatment of Pediatric Multiple Sclerosis	Immune Response BioPharma, Inc.
1351	T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	n/a	11/1/2001	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1352	T4 endonuclease V, liposome encapsulated	n/a	6/27/1989	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics
1353	TD-K6a.513a.12	Reveker	6/15/2006	Treatment of pachyonychia congenita	TransDerm, Inc.
1354	TXA127	n/a	10/25/2013	Treatment of acute radiation syndrome	US Biotest, Inc.
1355	Tacrolimus	Prograf	4/6/1998	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc.
1356	Tacrolimus	Prograf	6/6/2005	Prophylaxis of organ rejection in patients receiving heart transplants.	Astellas Pharma US, Inc.
1357	Tacrolimus	n/a	12/20/2013	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Veloxis Pharmaceuticals, Inc.
1358	Taliglucerase alfa	Elelyso For Injection	9/3/2009	Treatment of Gaucher's disease	Pfizer, Inc.
1359	Tamibarotene	n/a	10/11/2007	Treatment of acute promyelocytic leukemia (APL).	CytRx Corporation
1360	Tanespimycin	n/a	9/9/2004	Treatment of multiple myeloma	Bristol-Myers Squibb
1361	Targeted Gastrin 17 Complexed Peptide	n/a	5/14/2014	Treatment of pancreatic cancer	Tyg Oncology Ltd

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1362	Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell	Lymphoscan	4/7/1992	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic leukemia.	Immunomedics, Inc.
1363	Technetium Tc99m rh-Annexin V	Apomate	11/3/2000	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation
1364	Technetium Tc99m sulfur colloid injection, lyophilized	Technetium Tc99m Sulfur Colloi	3/17/2009	For localization of sentinel lymph nodes in patients with melanoma.	Pharmalucence, Inc.
1365	Tegafur/gimeracil/oteracil	n/a	7/20/2006	Treatment of gastric cancer	Taiho Pharma USA, Inc.
1366	Temoporfin	Foscan	10/28/1999	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Biolitec Pharma Ireland Ltd.
1367	Temozolomide	Temodal	10/14/1998	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute
1368	Temozolomide	Temodal	10/18/2004	Treatment of newly diagnosed high grade glioma	Schering-Plough Research Institute

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1369	Temsirolimus	Torisel	12/16/2004	Treatment of renal cell carcinoma	Wyeth Pharmaceuticals, Inc.
1370	Teniposide	Vumon For Injection	11/1/1984	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute
1371	Teriparatide	Parathar	1/9/1987	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc.
1372	Teriparatide	Parathar	10/28/1999	Treatment of idiopathic osteoporosis.	Biomedure, Inc.
1373	Terlipressin	Glypressin	3/6/1986	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc.
1374	Testosterone	Theraderm Testosterone Transdermal System	9/22/1997	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories
1375	Testosterone propionate ointment 2%	n/a	7/31/1991	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc.
1376	Tetrabenazine	Xenazine	12/11/1997	Treatment of Huntington's disease	Prestwick Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1377	Tetrabenazine	n/a	5/12/1998	Treatment of moderate/severe tardive dyskinesia.	Prestwick Pharmaceuticals, Inc.
1378	Tetraiodothyroacetic acid	n/a	5/1/2000	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot
1379	Tezacitabine	n/a	1/27/2003	Treatment of adenocarcinoma of the esophagus and stomach	Sanofi-Aventis US, Inc.
1380	Thalidomide	n/a	7/29/1998	Treatment of Kaposi's sarcoma.	Celgene Corporation
1381	Thalidomide	Thalomid	10/14/1998	Treatment of multiple myeloma	Celgene Corporation
1382	Thalidomide	Thalomid	4/6/1999	Treatment of Crohn's disease.	Celgene Corporation
1383	Thalidomide	n/a	3/5/1990	Prevention of graft versus host disease.	Andrulis Research Corporation
1384	Thalidomide	n/a	3/5/1990	Treatment of graft versus host disease.	Andrulis Research Corporation
1385	Thalidomide	n/a	1/12/1993	Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1386	Thalidomide	n/a	5/1/1995	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation
1387	Thalidomide	n/a	9/19/1988	Treatment of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
1388	Thalidomide	n/a	9/19/1988	Prevention of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc.
1389	Thalidomide	n/a	11/15/1988	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc.
1390	Thalidomide	n/a	5/15/1995	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulic Research Corporation
1391	Thalidomide	Thalomid	7/26/1995	Treatment of erythema nodosum leprosum.	Celgene Corporation
1392	Thalidomide	Synovir	3/11/1996	Treatment of HIV-associated wasting syndrome.	Celgene Corporation
1393	Thalidomide	n/a	2/27/1998	Treatment of primary brain malignancies.	Celgene Corporation
1394	Thalidomide	Thalomid	9/27/2004	Treatment of myelodysplastic syndrome	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1395	Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase	n/a	10/23/2008	To improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (IMD) undergoing umbilical cord blood transplantation.	Aldagen, Inc.
1396	Theranost 68 Ga RGD	n/a	10/1/2014	A Diagnostic for the management of Moyamoya disease (MMD)	Advanced Imaging Projects, LLC (AIP)
1397	Theranost 68Ga RGD	n/a	1/26/2015	Diagnostic for the clinical management of patients with tuberculosis	Advanced Imaging Projects, LLC
1398	Thiotepa	Tepadina	4/2/2007	Conditioning treatment prior to hematopoietic stem cell transplantation	Adienne S.A.
1399	Thymalfasin	Zadaxin	1/8/1998	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc.
1400	Thymalfasin	Zadaxin	3/13/2006	Treatment of stage IIb through Stage IV malignant melanoma	SciClone Pharmaceuticals, Inc.
1401	Thymalfasin	Zadaxin	5/3/1991	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc.
1402	Thymalfasin	Zadaxin	3/6/2000	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1403	Thymosin beta 4	n/a	5/28/2004	Treatment of epidermolysis bullosa.	RegeneRx Biopharmaceuticals, Inc.
1404	Thyrotropin alfa	Thyrogen	8/3/2001	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation
1405	Thyrotropin alpha	Thyrogen	2/24/1992	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation
1406	Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide)	n/a	12/27/2000	Chronic myelogenous leukemia (CML)	Valeant Pharmaceuticals North America
1407	Tilarginine acetate	n/a	4/11/2005	Treatment of cardiogenic shock	Arginox Pharmceuticals, Inc.
1408	Tinidazole	Tindamax	8/20/2003	Treatment of amebiasis	Presutti Laboratories, Inc.
1409	Tiopronin	Thiola	1/17/1986	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D.
1410	Tiotropium bromide	Spiriva	1/8/2008	To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc.
1411	Tipifarnib	Zarnestra	7/6/2004	Treatment of acute myeloid leukemia	Johnson & Johnson Pharmaceutical Research & Dev.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1412	Tiratricol	Triacana	8/13/1991	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires
1413	Tissue Plasminogen activator	n/a	4/18/2011	Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.	Catherine Amlié-Lefond, MD
1414	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	1/25/2007	Treatment of dilated cardiomyopathy	Vericel Corporation.
1415	Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system	n/a	3/13/2006	Treatment of osteonecrosis.	Aastrom Biosciences, Inc.
1416	Tizanidine HCl	Zanaflex	1/31/1994	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc.
1417	Tobramycin	Tobi	6/18/1999	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1418	Tobramycin for inhalation	Tobi	10/13/1994	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Novartis Pharmaceuticals Corp
1419	Tolcapone	n/a	12/24/2013	Treatment of transthyretin amyloidosis	SOM Innovation Biotech SL (SOM Biotech)
1420	Topiramate	Topamax	11/25/1992	Treatment of Lennox-Gastaut syndrome.	Johnson & Johnson Pharmaceutical R & D, LLC
1421	Toremifene	Fareston	9/19/1991	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation
1422	Toremifene	n/a	8/17/1993	Treatment of desmoid tumors.	Orion Corporation
1423	Tosedostat	n/a	12/10/2008	Treatment of acute myeloid leukemia	CTI BioPharma Corporation
1424	Tositumomab and iodine I 131 tositumomab	Bexxar	5/16/1994	Treatment of non-Hodgkin's B-cell lymphoma.	GlaxoSmithKline LLC
1425	Tramadol hydrochloride	n/a	1/28/2005	Treatment of painful HIV-associated neuropathy	TheraQuest Biosciences, LLC
1426	Tramadol hydrochloride	n/a	4/26/2005	Management of postherpetic neuralgia	TheraQuest Biosciences, LLC
1427	Tranilast	Rizaben	12/2/2003	For the treatment of malignant glioma	Angiogen Pharmaceuticals, Pty. Ltd.
1428	Transforming growth factor-beta 2	n/a	12/18/1992	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1429	Transgenic human alpha 1 antitrypsin	n/a	5/19/1999	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited
1430	Treosulfan	Ovastat	5/16/1994	Treatment of ovarian cancer.	Medac GmbH
1431	Tretinoin	Atra-lv	4/11/2003	Treatment of T-cell non-Hodgkin's lymphoma	Antigenics, Inc.
1432	Tretinoin	n/a	4/15/1985	Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.	Hannan Ophthalmic Marketing Services, Inc
1433	Tretinoin	Vesanoid	10/24/1990	Treatment of acute promyelocytic leukemia.	Hoffmann-La Roche, Inc.
1434	Tretinoin	Atra-lv	1/14/1993	Treatment of acute and chronic leukemia.	Antigenics, Inc.
1435	Trientine HCl	Syprine	12/24/1984	Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.	Merck Sharp & Dohme Research
1436	Triheptanoin	Triheptanoim-Sasol Special Oil	5/26/2006	Treatment of fatty acid disorders	Baylor Research Institute
1437	Triheptanoin	Triheptanoin-Sasol Special Oil	2/1/2008	Treatment of glycogen storage disorder II (Pompe disease)	Baylor Research Institute
1438	Trimetrexate glucuronate	Neutrexin	5/15/1986	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Medimmune Oncology, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1439	Trisaccharides A and B	Biosynject	4/15/1988	Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.	Chembiomed, Ltd.
1440	Trisaccharides A and B	Biosynject	4/20/1987	For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.	Chembiomed, Ltd.
1441	Trisaccharides A and B	Biosynject	4/12/1987	Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.	Chembiomed, Ltd.
1442	Trisodium citrate concentration	Hemocitrate	6/15/1995	For use in leukapheresis procedures.	Hemotec Medical Products, Inc.
1443	Trisodium zinc Diethylenetriaminepentaacetate	n/a	2/27/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.	CustomCare Pharmacy
1444	Trypan blue	Membraneblue	8/2/2006	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Dutch Ophthalmic Research Center Int'l BV

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1445	Tumor necrosis factor-binding protein 1	n/a	1/6/1993	Treatment of symptomatic patients with AIDS including all patients with CD4 counts less than 200 cells per mm ³ .	EMD Serono, Inc.
1446	Tumor necrosis factor-binding protein II	n/a	1/6/1993	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm ³ .	EMD Serono, Inc.
1447	Tyloxapol	Supervent	3/8/1995	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s
1448	Type 1 native bovine skin collagen	n/a	2/1/2008	Treatment of diffuse systemic sclerosis	arGentis Pharmaceuticals, LLC
1449	Ubiquinol, coenzyme Q10, ubiquinone	Ubi-Q-Nol	4/12/2004	Treatment of pediatric congestive heart failure	Gel-Tec, Division of TISHCON Corporation
1450	Ubiquinone	Ubi-Q-Gel	12/14/1999	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp.
1451	Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	n/a	3/22/2001	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH
1452	Urea for intravitreal injection	Neurosolve	12/14/2005	Treatment of retinitis pigmentosa	Vitreo Retinal Technologies, Inc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1453	Urofollitropin	Metrodin	11/25/1987	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	EMD Serono, Inc.
1454	Urogastrone	n/a	11/1/1984	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision
1455	Ursodiol	Urso 250	6/20/1991	Treatment of patients with primary biliary cirrhosis	Aptalis Pharma US, Inc.
1456	Vaccinia Immune Globulin (Human) Intravenous	n/a	6/18/2004	Treatment of severe complications from the smallpox vaccine	DynPort Vaccine Company LLC
1457	Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	6/18/2004	Treatment of complications of vaccinia vaccination	Cangene Corporation
1458	Valine, isoleucine and leucine	Vil	1/5/1996	Treatment of hyperphenylalaninemia	Leas Research Products
1459	Valproate	n/a	5/5/2008	Treatment of fragile X syndrome	Neuropharm Ltd,
1460	Valrubicin	Valstar	5/23/1994	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc.
1461	Vapreotide	Sanvar	4/6/2004	Treatment of symptomatic carcinoid tumors	H3 Pharma, Inc.
1462	Varbulin	Azixa	11/5/2009	Treatment of glioblastoma multiforme.	Myrexix, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1463	Varicella Zoster Immune Globulin (Human)	Varizig	11/7/2006	Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella	Cangene bioPharma, Inc.
1464	Vasoactive intestinal peptide	n/a	3/9/2001	Treatment of Acute Respiratory Distress Syndrome.	mondoBIOTECH
1465	Vasoactive intestinal polypeptide	n/a	6/23/1993	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals
1466	Virulizin	Virulizin	2/1/2001	Treatment of pancreatic cancer.	ZOR Pharmaceuticals, LLC
1467	Water-miscible vitamin A palmitate	Aquasol A Parenteral	3/26/2010	Prevention of bronchopulmonary dysplasia.	Fox Pharma, Inc.
1468	Xenogeneic hepatocytes	Hepatassist Liver Assist System	11/27/1998	Treatment of severe liver failure.	Circe Biomedical, Inc.
1469	Yttrium (90Y) antiferritin polyclonal antibodies	Ferritarg P	9/18/2006	Treatment of Hodgkin's disease.	Alissa Pharma, LLC
1470	Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10	n/a	12/3/2012	Treatment of soft tissue sarcoma	OncoTherapy Science, Inc.
1471	Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembryonic antigen IgG antibody	Cea-Cide	8/3/1999	Treatment of ovarian carcinoma.	Immunomedics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1472	Zalcitabine	n/a	12/9/1986	Treatment of AIDS.	National Cancer Institute, DCT
1473	Zalcitabine	Hivid	6/28/1988	Treatment of AIDS.	Hoffmann-La Roche, Inc.
1474	Zidovudine	Retrovir	7/17/1985	Treatment of AIDS related complex.	Glaxo Wellcome Inc.
1475	Zinc acetate	Galzin	11/6/1985	Treatment of Wilson's disease.	Lemmon Company
1476	Zoledronate	Zometa, Zabel	8/18/2000	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp.
1477	Zosuquidar trihydrochloride	n/a	12/15/2005	Treatment of acute myeloid leukemia	Kanisa Pharmaceuticals, Inc.
1478	[131I]-N-(2-(diethylamino) ethyl-4-(4 fluorebenzamido)-5-(iodo)-2-methoxybenzamide	n/a	9/17/2008	Treatment of metastatic melanoma, stages IIB, IIC, III and IV	Molecular Insight Pharmaceuticals, Inc.
1479	[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride	n/a	11/4/2003	Treatment of Amyotrophic Lateral Sclerosis	Aeolus Pharmaceuticals, Inc.
1480	[5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt	n/a	2/14/2014	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Plexxikon, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1481	[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone	n/a	10/20/2014	Treatment of pancreatic cancer	Synovo GmbH
1482	[AC3-yCD2(V)] and Flucytosine (5-FC XR)	n/a	1/12/2011	Treatment of glioblastoma multiforme	Tocagen, Inc.
1483	[Lu-177]-DOTA-Tyr3-Octreotate	n/a	1/12/2009	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Advanced Accelerator Applications
1484	[Nle4, D-Phe7]-a-melanocyte stimulating hormone	n/a	7/17/2008	Treatment of erythropoietic porphyrias	Clinuvel Inc.
1485	[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	5/14/2014	Treatment of glioblastoma multiforme	Angiochem, Inc.
1486	[met5]-enkephalin	Opioid Growth Factor	1/24/2013	Treatment of pancreatic cancer	TNI BioTech, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1487	[Î±âˆ²N-(2â€™succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[Î¼âˆ²N-(2â€™succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[Î¼âˆ²N-(2â€™succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr	n/a	4/15/2015	Treatment of breast cancer patients with brain metastases	Angiochem, Inc.
1488	a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy	n/a	4/29/2014	Treatment of Stage II to IV invasive cervical carcinoma	Advaxis, Inc.
1489	a-Galactosidase A	Plant-Produced Human A-Galactosidase A	1/21/2003	Treatment of Fabry's disease	iBio, Inc.
1490	aaeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1	n/a	9/12/2013	Treatment of choroideremia due to mutations in the human choroideremia gene (CHM)	Sparks Therapeutics, Inc.
1491	abatacept	Orencia	5/30/2013	Treatment of type 1 diabetes mellitus patients with residual beta cell function	Orban Biotech LLC
1492	abeotaxane inhibitor of microtubules	n/a	4/18/2011	Treatment of pediatric neuroblastoma.	Cortice Biosciences
1493	abeotaxane inhibitor of microtubules	n/a	10/7/2011	Treatment of gliomas	Cortice Biosciences

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1494	acadesine	n/a	3/3/2011	Treatment of chronic lymphocytic leukemia	Avanced In Vitro Cell Technologies, S.L.
1495	acadesine	n/a	5/4/2011	Treatment of multiple myeloma	Advancell-Advanced In Vitro Cell Technologies S.A.
1496	acamprosate	n/a	3/25/2013	Treatment of fragile X syndrome	Confluence Pharmaceuticals, LLC
1497	acetyl-L-carnitine	n/a	7/24/2012	Treatment of Fragile X syndrome	Sigma-Tau Pharmaceuticals, Inc.
1498	acetyl-L-carnitine (ALC)	n/a	3/18/2011	Treatment of Rett syndrome	sigma-tau Pharmaceuticals, Inc.
1499	acetylcysteine	Acetadote	10/19/2001	For the intravenous treatment of moderate to severe acetaminophen overdose	Cumberland Pharmaceuticals, Inc.
1500	acetylcysteine effervescent tablets for oral solution	n/a	2/24/2015	Preventing hepatic injury from acetaminophin overdose	Arbor Pharmaceuticals, LLC
1501	acyclovir	n/a	12/13/2010	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	Fera Pharmaceuticals
1502	adalimumab	Humira	3/21/2005	Treatment of juvenile rheumatoid arthritis	AbbVie Inc.
1503	adalimumab	Humira	10/19/2006	Treatment of pediatric Crohn's disease.	AbbVie Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1504	adalimumab	Humira	5/13/2014	Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis	AbbVie, Inc.
1505	adalimumab	n/a	7/10/2014	Treatment of Behcet's disease	Mucora
1506	adalimumab	Humira	5/13/2015	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	AbbVie, Inc.
1507	adalimumab	Humira	5/11/2011	Treatment of pediatric patients with ulcerative colitis	AbbVie, Inc.
1508	adeno associated viral vector containing human ARSB gene	n/a	3/17/2011	Treatment of mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome)	Fondazione Telethon
1509	adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs	n/a	5/6/2013	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo type A syndrome)	Lysogene
1510	adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene	n/a	3/14/2014	Treatment of hemophilia B	Baxter Healthcare Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1511	adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene	n/a	12/13/2012	treatment of retinitis pigmentosa	Genable Technologies Limited
1512	adeno-associated viral vector containing modified U11 snRNA	n/a	9/15/2010	Treatment of Duchenne muscular dystrophy.	uniQure B.V.
1513	adeno-associated viral vector containing the human NADH Dehydrogenase 4 Gene	n/a	11/20/2013	Treatment of Leber Hereditary Optic Neuropathy	Gen Sight Biologics
1514	adeno-associated viral vector expressing human retinoschisin-1 gene	n/a	5/21/2007	Treatment of X-linked juvenile retinoschisis (XLRS).	Applied Genetic Technologies Corporation
1515	adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene	n/a	11/5/2014	Treatment of choroideremia	NightstaRx Ltd.
1516	adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene	n/a	12/27/2012	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)	Laboratorios del Dr. Esteve, S.A.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1517	adeno-associated viral vector type 2 expressing human recombinant retinal pigment epithelial 65KDa protein gene	n/a	3/18/2015	Treatment of Retinitis Pigmentosa due to autosomal recessive RPE65 gene mutations	Spark Therapeutics, Inc.
1518	adeno-associated virus serotype 9 expressing the human Survival Motor Neuron gene	n/a	9/30/2014	Treatment of spinal muscular atrophy	AveXis, Inc.
1519	adeno-associated virus transgene of follistatin	n/a	11/19/2012	Treatment of Duchennes and Becker's muscular dystrophy	Milo Biotechnology
1520	adeno-associated virus vector serotype 9 expressing human sulfamidase	n/a	6/1/2011	Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A Syndrome).	Laboratorios del Dr. Esteve, S.A.
1521	adenovirus containing a human FAS-c gene	n/a	4/2/2012	Treatment of malignant glioma	Vascular Biogenics Ltd
1522	adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma	n/a	10/1/2014	Treatment of glioma	DNAtrix, Inc.
1523	adult adherent bone marrow-derived multipotent stem cells	Multistem	7/6/2012	Treatment of MPS-1, including Hurler syndrome	Athersys, Inc.
1524	adult hemogenic endothelial cells	n/a	5/27/2015	Treatment of aplastic anemia	HemoGenyx LLC
1525	aerosolized beractant	n/a	3/11/2013	Treatment of respiratory distress syndrome	Beena G. Sood, MD, MS
1526	afamelanotide	n/a	12/11/2009	Treatment of solar urticaria	Clinuvel, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1527	afamelanotide	n/a	5/14/2014	Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)	Clinuvel, Inc.
1528	afatinib	Gilotrif(R)	6/4/2014	Treatment of malignant brain and central nervous system tumors	Boehringer Ingelheim Pharmaceuticals, Inc.
1529	afatinib	Gilotrif	12/3/2012	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Boehringer Ingelheim Pharmaceuticals, Inc.
1530	aldoxorubicin	n/a	9/24/2014	Treatment of small cell lung cancer	CytRx Corporation
1531	aldoxorubicin	n/a	9/24/2014	Treatment of ovarian cancer	CytRx Corporation
1532	aldoxorubicin	n/a	9/24/2014	Treatment of glioblastoma multiforme	CytRx Corporation
1533	alectinib	n/a	1/27/2015	Treatment of ALK-positive non-small cell lung cancer	Genentech, Inc.
1534	alemtuzumab	Campath	10/20/1997	Treatment of chronic lymphocytic leukemia.	Genzyme Corporation
1535	alfimeprase	n/a	9/20/2012	Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention	Niche Therapeutics, LLC
1536	algenpantucel-L	Hyperacute(R)-Pancreatic Cance	10/21/2010	Treatment of pancreatic cancer.	NewLink Genetics Corporation
1537	alicaforsen	n/a	6/24/2008	Treatment of pouchitis.	Atlantic Healthcare Limited

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1538	alisertib	n/a	7/12/2013	Treatment of small cell lung cancer	Millennium Pharmaceuticals, Inc.
1539	alisertib	n/a	5/14/2012	Treatment of peripheral T-cell lymphoma	Millennium Pharmaceuticals, Inc.
1540	all-cis-docosa-4,7,10,13,16,19-hexaenoic acid	Retriacyl	5/21/2014	Treatment of retinitis pigmentosa	Natac Pharma, S.L.
1541	allantoin	Alwextin	11/21/2002	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Scioderm, Inc.
1542	allogeneic cardiosphere-derived cells	n/a	4/21/2015	Treatment of Duchenne Muscular Dystrophy	Capricor, Inc.
1543	allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)	n/a	12/2/2010	Enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neutropenia, thrombocytopenia, lymphopenia, and anemia).	Fate Therapeutics, Inc.
1544	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	2/18/2013	Treatment of Aplastic Anemia	Pluristem Therapeutics, Inc.
1545	allogeneic ex-vivo expanded placental adherent stromal cells	n/a	8/22/2011	Treatment of thromboangiitis obliterans (Buerger's disease)	Pluristem Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1546	allogeneic hematopoietic stem cell	Atir(Tm)	2/2/2010	Prevention (reduction) of transplant related mortality (TRM, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.	Kiadis Pharma Netherlands B.V.
1547	allogeneic mesenchymal precursor cells derived from ex vivo healthy donors harvested from iliac crest.	n/a	9/12/2008	Treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.	Mesoblast, Inc.
1548	allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor	n/a	7/24/2012	Treatment of macular telangiectasia type 2 (MacTel)	Neurotech USA, Inc.
1549	allopregnanolone	n/a	7/12/2013	Treatment of Neimann-Pick disease, type C	La Jolla Pharmaceutical Company, Inc.
1550	allopregnanolone	n/a	4/20/2014	Treatment of status epilepticus	Sage Therapeutics
1551	allosteric activator of the red blood cell-specific form of pyruvate kinase	n/a	3/24/2015	Treatment of pyruvate kinase deficiency	Agios Pharmaceuticals, Inc.
1552	alpha melanotropin	n/a	9/2/2010	Treatment of chronic beryllium disease	mondoBIOTECH Laboratories AG

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1553	alpha-1 proteinase inhibitor (human)	Glassia	7/28/2011	Treatment of patients with recent onset (Kamada, Ltd.
1554	alpha-1 proteinase inhibitor (human)	Glassia	10/23/2014	Treatment of graft versus host disease	Kamada Ltd.
1555	alpha-tocotrienol quinone	n/a	10/21/2010	Treatment of inherited mitochondrial respiratory chain diseases.	Edison pharmaceuticals, Inc.
1556	alpha1 proteinase inhibitor (human)	n/a	1/29/2010	Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.	Grifols Therapeutics, Inc.
1557	alpha1-proteinase inhibitor (human)	n/a	4/6/2012	Treatment of cystic fibrosis	Grifols Therapeutics, Inc.
1558	alpha1-proteinase inhibitor (human)	Prolastin(R)-C	3/3/2015	Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.	Grifols Therapeutics, Inc.
1559	alpha1-proteinase inhibitor (human)	n/a	2/20/2009	Treatment of cystic fibrosis	CSL Behring LLC
1560	alteplase	Activase	1/27/2003	Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage	Daniel F. Hanley, MD
1561	altiratinib	n/a	8/19/2014	Treatment of glioblastoma multiforme.	Deciphera Pharmaceuticals, LLC
1562	amatuximab	n/a	9/28/2012	Treatment of mesothelioma	Morphotek, Inc.
1563	ambrisentan	Letairis	7/16/2004	Treatment of pulmonary arterial hypertension	Gilead Colorado
1564	ambroxol	n/a	6/29/2011	Treatment of Gaucher disease	Belrose Pharma, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1565	amifampridine phosphate	n/a	3/3/2015	Treatment of congenital myasthenic syndromes	Catalyst Pharmaceuticals
1566	amikacin sulfate	n/a	1/5/2015	Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections	PlumeStars s.r.l.
1567	aminolevulinic acid hydrochloride	Levulan	3/20/2007	Treatment of esophageal dysplasia	DUSA Pharmaceuticals, Inc.
1568	aminosidine	Paromomycin	3/29/2005	Treatment of visceral leishmaniasis	The Institute for One World Health
1569	amitriptyline and ketamine	Amiket(TM)	1/19/2010	Treatment of postherpetic neuralgia	Immune Pharmaceuticals, Inc.
1570	ammonium tetrathiomolybdate	n/a	5/5/2008	Treatment of idiopathic pulmonary fibrosis	Pipex Pharmaceuticals, Inc.
1571	amphotericin B	n/a	9/15/2010	Treatment of visceral leishmaniasis.	iCo Therapeutics Inc.
1572	amrubicin	n/a	3/10/2008	Treatment of small cell lung cancer	Celgene Corporation
1573	amylopectin	n/a	3/24/2015	Treatment of glycogen storage disease types Ia and Ib	Michael K. Davis, MD, MBA
1574	an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco)	n/a	12/22/2011	Treatment of hemophilia B	uniQure, B.V.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1575	anakinra	Kineret	8/19/2010	Treatment of cryopyrin-associated periodic syndromes	Swedish Orphan Biovitrum AB (publ)
1576	andexanet alfa	n/a	2/23/2015	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	Portola Pharmaceuticals
1577	angiotensin (1-7)	n/a	8/30/2013	Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor	US Biotest, Inc.
1578	angiotensin (1-7)[A(1-7)]	n/a	7/25/2013	Treatment of Duchenne muscular dystrophy	US Biotest, Inc.
1579	angiotensin 1-7	n/a	1/29/2010	Treatment of sarcoma.	W. Jeffrey Petty, MD

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1580	angiotensin 1-7	n/a	6/17/2010	To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and anemia) in hematopoietic stem cell transplants.	US Biotest, Inc.
1581	antagonist of the complement 5a receptor	n/a	11/17/2014	Treatment of atypical hemolytic uremic syndrome	ChemoCentryx, Inc.
1582	antagonist of the complement 5a receptor	n/a	6/2/2014	Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome.	ChemoCentryx, Inc.
1583	antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9	n/a	12/23/2014	Treatment of Waldenstrom's macroglobulinemia	Idera Pharmaceuticals, Inc.
1584	anthrax immune globulin	n/a	9/3/2009	Treatment of inhalation anthrax disease	Emergent Biosolutions, Inc.
1585	anthrax immune globulin (human)	n/a	7/29/2008	Treatment of inhalational anthrax	Cangene Corp. - Emergent Biosolutions
1586	anti human Nogo-A human monoclonal antibody	n/a	10/20/2008	Treatment of acute spinal cord injury	Novartis Pharmaceuticals Corporation
1587	anti-Beta1 integrin monoclonal antibody	n/a	1/13/2015	Treatment of ovarian cancer	OncoSynergy, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1588	anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein	n/a	9/13/2013	Treatment of graft versus host disease	Xenikos BV
1589	anti-CD30 Fc engineered humanized monoclonal antibody	n/a	12/2/2008	Treatment of Hodgkin lymphoma	Xencor, Inc.
1590	anti-Lewis Y humanized monoclonal antibody	n/a	3/9/2012	Treatment of ovarian cancer	Recepta Biopharma S.A.
1591	anti-T-lymphocyte immune globulin, rabbit	n/a	9/12/2008	Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation	Neovii Biotech NA, Inc.
1592	anti-T-lymphocyte immune globulin, rabbit	Atg-Fresenius(R)	3/26/2010	Prevention of graft versus host disease (GVHD)	Neovii Biotech NA, Inc.
1593	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	1/12/2011	Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age	Tolera Therapeutics, Inc.
1594	anti-TCR murine monoclonal antibody (MAB, type IgM)	n/a	6/7/2010	Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function	Tolera Therapeutics, Inc.
1595	anti-inhibitor coagulant complex	Feiba	4/12/2013	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Baxter Healthcare Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1596	anti-insulin-like type 1 receptor immunoglobulin 1	n/a	11/23/2010	Treatment of pancreatic cancer.	Amgen
1597	anti-interferon-gamma Fab from goats	n/a	11/18/2003	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, Inc.
1598	anti-nogo-A monoclonal antibody	n/a	7/7/2009	Treatment of amyotrophic lateral sclerosis	GlaxoSmithKline
1599	anti-sense oligonucleotide consisting of 2'-(CH ₂) ₂ -O-ribose-phosphate backbone, with a phosphorothioate backbone	n/a	9/23/2013	Treatment of cystic fibrosis	ProQR Therapeutics B.V.
1600	anti-thymocyte globulin [rabbit]	Thymoglobulin	5/25/2010	Prophylaxis of acute organ rejection in patients receiving renal transplants	Genzyme Corporation
1601	anti-tumor necrosis factor (TNF) polyclonal antibody (bovine)	n/a	11/17/2014	Treatment of pediatric ulcerative colitis (0 through 16 years of age)	Avaxia Biologics, Incorporated
1602	antiangiogenic components extracted from marine cartilage	Neovastat (Ae-941)	10/16/2002	Treatment of renal cell carcinoma	AEterna Zentaris, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1603	antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E	n/a	7/21/2014	Treatment of gastric cancer	Millennium Pharmaceuticals, Inc.
1604	antihemophilic factor (recombinant), Fc fusion protein	Eloctate	11/23/2010	Treatment of hemophilia A	Biogen Idec Inc.
1605	antihemophilic factor (recombinant), porcine sequence	Obizur	3/16/2004	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Baxter Healthcare Corporation
1606	antimesothelin-ADC (antibody drug conjugate)	n/a	7/5/2012	Treatment of mesothelioma	Bayer HealthCare Pharmaceuticals, Inc.
1607	antineoplaston A10, antineoplaston AS2-1	n/a	10/30/2008	Treatment of gliomas	Burzynski Research Institute, Inc.
1608	antinuclear antibody conjugated liposomal doxorubicin	n/a	2/3/2015	Treatment of Ewing's sarcoma.	NanoSmart Pharmaceuticals, Inc.
1609	antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA]	Gti-2040	3/12/2003	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1610	antisense oligonucleotide targeted to human transthyretin (TTR) mRNA	n/a	7/24/2012	Treatment of familial amyloid polyneuropathy	Isis Pharmaceuticals, Inc.
1611	antroquinonol	n/a	1/21/2015	Treatment of pancreatic cancer	Golden Biotechnology Corp.
1612	antroquinonol	Hocena(R)	4/30/2015	Treatment of acute myeloid leukemia	Golden Biotechnology Corporation
1613	apolipoprotein E mimetic peptide	n/a	12/3/2012	Treatment of homozygous familial hypercholesterolemia	LipimetiX Development, LLC
1614	apremilast	n/a	1/17/2013	Treatment of Behcet's disease	Celgene Corporation
1615	arimoclomol	n/a	3/29/2005	Treatment of amyotrophic lateral sclerosis	CytRx Corporation
1616	arimoclomol citrate	n/a	1/13/2015	Treatment of Neimann-Pick disease, type C	Orphazyme ApS
1617	aripiprazole	Abilify	1/25/2006	Treatment of Tourette's syndrome	Otsuka Pharmaceutical Development
1618	arsenic	Trisenox	11/2/2001	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Teva Branded Pharmaceutical Products R&D, Inc.
1619	arsenic trioxide	Trisenox	6/13/2003	Treatment of liver cancer	Teva Branded Pharmaceutical Products R&D, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1620	arsenic trioxide	Trisenox	10/18/2001	Treatment of chronic myeloid leukemia	Teva Branded Pharmaceutical Products R*D, Inc.
1621	arsenic trioxide	Trisenox	7/17/2000	Treatment of myelodysplastic syndrome.	Teva Branded Pharmaceutical Products R&D, Inc.
1622	artemether/lumefantrine	Coartem	8/31/2007	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Novartis Pharmaceuticals
1623	arylsulfatase A (rhASA)	n/a	2/27/2008	Treatment of metachromatic leukodystrophy	Shire Human Genetic Therapies, Inc.
1624	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive non-small cell lung cancer	GlaxoSmithKline Biologicals, S.A.
1625	astuprotimut-R	n/a	5/29/2009	Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma	GlaxoSmithKline Biologicals, S.A.
1626	ataluren	n/a	3/10/2008	Treatment of spinal muscular atrophy	PTC Therapeutics, Inc.
1627	ataluren	Translarna	12/10/2014	Treatment of mucopolysaccharidosis type I	PTC Therapeutics, Inc.
1628	ataluren	n/a	1/10/2005	Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrophin gene	PTC Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1629	ataluren	n/a	9/1/2004	For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene	PTC Therapeutics, Inc.
1630	auranofin	Ridaura	4/30/2010	Treatment of amebiasis	Ctr for Discovery & Innovation in Parasitic Diseases
1631	autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc)	n/a	1/15/2015	Treatment of severe combined immune deficiency-X1	Boston Children's Hospital
1632	autologous CD34+ hematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA	n/a	4/19/2012	Treatment of adrenoleukodystrophy	bluebird bio, Inc.
1633	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	2/26/2014	For the treatment of Sickle Cell Disease	bluebird bio Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1634	autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene	n/a	3/18/2013	Treatment of B-thalassemia major and intermedia	bluebird bio, Inc.
1635	autologous CD4+CD25hiFoxP3+regulatory T cells	n/a	11/19/2013	Prevention of graft rejection following solid organ transplantation	iREG Medical AB
1636	autologous Epstein-Barr virus specific T-cells	n/a	3/9/2015	Treatment of Epstein-Barr virus positive non-Hodgkin lymphomas.	Cell Medica, Inc.
1637	autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	n/a	3/14/2014	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corporation
1638	autologous adipose derived mesenchymal stromal cells	n/a	10/22/2014	Treatment of amyotrophic lateral sclerosis	Mayo Clinic
1639	autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 - based lentiviral vector, EFS-ADA	n/a	10/21/2014	Treatment of adenosine deaminase deficient severe combined immunodeficiency	Donald B. Kohn, MD - Professor, UC-UCLA
1640	autologous dendritic cells pulsed with allogeneic tumor cell lysate	n/a	5/6/2014	Treatment of malignant mesothelioma	Amphera BV

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1641	autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2'-deoxycytidine	Alecsat	9/13/2013	Treatment of glioblastoma multiforme	CytoVac A/S
1642	autologous genetically modified human dermal fibroblasts	n/a	6/10/2014	Treatment of dystrophic epidermolysis bullosa.	Fibrocell Technologies, Inc.
1643	autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5	Theralux Photodynamic Therapy	4/3/2008	Treatment of chronic graft versus host disease	Kiadis Pharma Canada, Inc.
1644	autologous neo-uninary conduit	n/a	6/7/2011	Treatment of bladder dysfunction requiring incontinent urinary diversion.	Tengion, Inc.
1645	autologous olfactory neural progenitors	Rhinocytes	12/31/2008	Treatment of amyotrophic lateral sclerosis	RhinoCyte, Inc.
1646	autologous peripheral blood T lymphocytes transduced with retroviral vector containing anti CD19 CD28/CD3 zeta chimeric antigen receptor	n/a	3/27/2014	Treatment of diffuse large B-cell lymphoma.	Kite Pharma, Inc.
1647	autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line	n/a	5/6/2015	Treatment of glioblastoma	Sebastiano Gattoni-Celli, MD

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1648	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	7/11/2002	Treatment of metastatic melanoma	Agenus, Inc.
1649	autologous tumor-derived gp96 heat shock protein-peptide complex	Oncophage	5/10/2002	Treatment of renal cell carcinoma	Agenus, Inc.
1650	autologous umbilical cord blood	n/a	7/24/2012	Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury	Duke University
1651	autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene	n/a	8/26/2009	Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.	Glaxo Group Limited
1652	avicin d	n/a	3/24/2015	Treatment of multiple myeloma	Avicin Therapeutics Ltd.
1653	aviptadil	n/a	2/22/2005	Treatment of pulmonary arterial hypertension	Mondobiotech Laboratories AG
1654	azacitidine	Vidaza	12/3/2001	Treatment of myelodysplastic syndromes	Celgene Corporation
1655	aztreonam	Cayston	3/12/2002	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Gilead Sciences (formerly Corus Pharma)
1656	baclofen	n/a	12/2/2003	Treatment of dystonia	Medtronic Neurological

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1657	baclofen	n/a	12/16/1991	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Infusaid, Inc.
1658	baclofen	Lioresal Intrathecal	11/10/1987	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).	Medtronic, Inc.
1659	bacterium Bacteroides thetaiotaomicron	n/a	9/26/2013	Treatment of active Crohn's disease in the pediatric population	GT Biologics Ltd
1660	bardoxolone	n/a	3/30/2015	Treatment of pulmonary arterial hypertension	Reata Pharmaceuticals, Inc.
1661	basimglurant	n/a	3/9/2012	Treatment of Fragile X Syndrome	Hoffmann-La Roche, Inc.
1662	beclomethasone	n/a	3/4/2009	Treatment of pediatric patients with ulcerative colitis	Aptalis Pharma US, Inc.
1663	beclomethasone 17,21-dipropionate	n/a	11/19/2012	Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster	Soligenix, Inc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1664	beclomethasone 17,21-dipropionate	Orbec(R)	7/24/2009	Treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation	Soligenix, Inc.
1665	beclomethasone 17,21-dipropionate	Bec	8/28/2001	Prevention of gastrointestinal graft-versus-host disease	Soligenix, Inc.
1666	beclomethasone 17,21-dipropionate	n/a	12/18/2007	Treatment of pediatric patients with Crohn disease.	Soligenix, Inc.
1667	bedaquiline; (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol	Sirturo	1/10/2005	Treatment of active tuberculosis	Janssen Research & Development, LLC
1668	belatacept	Nulojix	2/20/2008	Prophylaxis of organ rejection in renal allograft recipients	Bristol-Myers Squibb Company
1669	beloranib	n/a	1/15/2013	Treatment of Prader-Willi syndrome	Zafgen, Inc.
1670	bendamustine for 50 ml admixture	n/a	7/2/2014	Treatment of chronic lymphocytic leukemia	Eagle Pharmaceuticals, INC.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1671	bendamustine for 50ml admixture	n/a	7/2/2014	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Eagle Pharmaceuticals, Inc.
1672	bendamustine hydrochloride	Treanda	11/26/2013	Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)	Cephalon, Inc.
1673	bendamustine hydrochloride with betadex sulfobutyl ether sodium	n/a	9/10/2013	Treatment of chronic lymphocytic leukemia	Supratek Pharma, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1674	benznidazole	n/a	4/14/2014	Treatment of Chagas disease	Chemo Research, S.L.
1675	benzoate	Naben	7/6/2012	Treatment of pediatric schizophrenia	SyneuRx International (Taiwan) Corp.
1676	benzoate/phenylacetate	Ammonul	11/22/1993	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp.
1677	beraprost sodium 314d	n/a	12/22/2011	Treatment of pulmonary arterial hypertension	Lung Rx, Inc.
1678	bevacizumab	Avastin	11/6/2003	Treatment of renal cell carcinoma	Genentech, Inc.
1679	bevacizumab	n/a	10/21/2010	Treatment of hereditary hemorrhagic telangiectasia	Terence M. Davidson, MD
1680	bevacizumab	Avastin	11/2/2010	Treatment of primary peritoneal carcinoma.	Genentech, Inc.
1681	bevacizumab	Avastin	11/23/2010	Treatment of fallopian tube carcinoma	Genentech, Inc.
1682	bevacizumab	Avastin	10/13/2009	Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen	Genentech, Inc.
1683	bevacizumab	Avastin	11/20/2009	In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.	Genentech, Inc.
1684	bevacizumab	Avastin	2/9/2006	Therapeutic treatment of patients with ovarian cancer	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1685	bevacizumab	Avastin	5/26/2006	Treatment of malignant glioma	Genentech, Inc.
1686	bevacizumab	Avastin	10/20/2004	Treatment of pancreatic cancer	Genentech, Inc.
1687	bezafibrate	Bezalip	7/24/2013	For therapeutic treatment of Barth syndrome	Barth Syndrome Foundation, Inc.
1688	bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine	Fang	10/22/2014	Treatment of Ewing's sarcoma	Gradalis, Inc.
1689	bi-shRNA furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine	Fang	2/17/2012	Treatment of stage IIB to IV melanoma	Gradalis, Inc.
1690	bi-shRNA furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine	Fang	4/18/2011	Treatment of ovarian cancer	Gradalis, Inc.
1691	bifidobacterium infantis 35624	n/a	3/24/2008	Treatment of pediatric ulcerative colitis	Alimentary Health Limited
1692	bifidobacterium longum infantis 35624	n/a	1/16/2003	Treatment of pediatric Crohn's disease	Alimentary Health Limited
1693	binimetinib	n/a	11/19/2013	Treatment Stage IIB-IV melanoma.	Novartis Pharmaceuticals Corporation
1694	binimetinib	n/a	7/31/2014	Treatment of ovarian cancer	Array Biopharma, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1695	biocarbonate infusate	Normocarb Hf	8/9/2005	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Dialysis Solutions, Inc.
1696	bisantrene HCl	n/a	2/14/2014	Treatment of acute myeloid leukemia	Update Pharma, Inc.
1697	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction	Merrimack Pharmaceuticals, inc.
1698	bispecific antibody (monoclonal antibody)	n/a	8/8/2013	Treatment of HER2-expressing adenocarcinoma of the esophagus	Merrimack Pharmaceuticals, Inc.
1699	bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13)	n/a	9/14/2011	Treatment of idiopathic pulmonary fibrosis.	Sanofi-Aventis US, Inc.
1700	bivalent anti-human myostatin adnectin-IgG1	n/a	2/11/2015	Treatment of duchenne muscular dystrophy	Bristol-Myers Squibb Co.
1701	bivalirudin	Angiomax	11/2/2005	For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome	The Medicines Company
1702	blinatumomab	n/a	5/16/2008	Treatment of acute lymphocytic leukemia	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1703	blinatumomab	n/a	5/16/2008	Treatment of prolymphocytic leukemia	Amgen, Inc.
1704	blinatumomab	n/a	5/16/2008	Treatment for hairy cell leukemia.	Amgen, Inc.
1705	blinatumomab	n/a	2/6/2006	Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement	Amgen, Inc.
1706	bortezomib	Velcade	2/3/2015	Treatment of acute lymphoblastic leukemia	Millennium Pharmaceuticals, Inc.
1707	bortezomib	Velcade	1/15/2003	Treatment of multiple myeloma	Millennium Pharmaceuticals, Inc.
1708	bortezomib	Velcade	1/4/2011	Treatment of follicular non-Hodgkin lymphoma	Millennium Pharmaceuticals, Inc.
1709	bortezomib	Velcade	5/30/2012	Treatment of mantle cell lymphoma.	Millennium Pharmaceuticals, Inc.
1710	bosutinib	Bosulif	2/24/2009	Treatment of chronic myelogenous leukemia	Wyeth Pharmaceuticals, Inc.
1711	botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)	n/a	6/29/2011	Treatment of botulism.	Cangene Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1712	bovine lactoferrin	n/a	2/23/2015	Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams)	Metrodora Therapeutics, INc.
1713	bovine lactoferrin	n/a	2/19/2015	Prevention of late-onset sepsis in very low birth weight infants	Metrodora Therapeutics, Inc.
1714	brentuximab vedotin	Adcetris	10/23/2008	Treatment of anaplastic large cell lymphoma	Seattle Genetics, Inc.
1715	brentuximab vedotin	Adcetris	4/15/2013	Treatment of patients with peripheral T-cell lymphoma, not otherwise specified	Seattle Genetics, Inc.
1716	brentuximab vedotin	Adcetris	9/13/2013	Treatment of patients with angioimmunoblastic T-cell lymphoma	SeattleGenetics, Inc.
1717	brentuximab vedotin	Adcetris(R)	1/31/2014	Treatment of patients with diffuse large B-cell lymphoma.	Seattle Genetics, Inc.
1718	brentuximab vedotin	Adcetris	11/19/2012	Treatment of mycosis fungoides	Seattle Genetics, Inc.
1719	brentuximab vedotin	Adcetris	1/30/2007	Treatment of Hodgkin's lymphoma	Seattle Genetics, Inc.
1720	brilliant blue G	Brilliant Peel	12/16/2009	For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.	Fluron GmbH - Subsidiary of Geuder AG
1721	bryostatin 1	n/a	3/31/2015	Treatment of Fragile X Syndrome.	Neurotrope BioScience, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1722	bryostatin-1	n/a	12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc.
1723	budesonide	Uceris	5/6/2013	Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.	Santarus, Inc.
1724	budesonide	Nefecon	5/17/2010	To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.	Pharmalink AB
1725	bupivacaine	Transdur	6/18/2008	Relief of persistent pain associated with postherpetic neuralgia	Impax Laboratories, Inc.
1726	buprenorphine in combination with naloxone	Suboxone	10/27/1994	Treatment of opiate addiction in opiate users	Reckitt Benckiser Pharmaceuticals, Inc.
1727	busulfan	Partaject	11/25/2002	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc.
1728	cabozantinib	Cometriq	11/29/2010	Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.	Exelixis, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1729	caffeine and sodium benzoate	n/a	8/22/2012	Treatment of seizure prolongation in patients undergoing electroconvulsive therapy	Luitpold Pharmaceuticals, Inc.
1730	calcium benzoate and risperidone	n/a	12/20/2010	Treatment of pediatric patients with schizophrenia	University of California, Los Angeles
1731	camostat	n/a	5/18/2011	Treatment of chronic pancreatitis	NIXS Corporation
1732	canakinumab	Ilaris	12/5/2013	Treatment of familial mediterranean fever	Novartis Pharmaceuticals Corporation
1733	canakinumab	Ilaris	12/18/2007	Treatment of cryopyrin-associated periodic syndromes	Novartis Pharmaceuticals Corporation
1734	canakinumab	Ilaris	12/5/2013	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Novartis Pharmaceuticals Corporation
1735	canakinumab	Ilaris	9/30/2008	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Novartis Pharmaceuticals Corporation
1736	canakinumab	n/a	9/4/2012	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Novartis Pharmaceuticals Corporation
1737	cannabidiol	n/a	8/20/2014	Treatment of glioblastoma multiforme	Insys Therapeutics, Inc.
1738	cannabidiol	n/a	9/24/2014	Treatment of glioma	Insys Therapeutics, Inc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1739	cannabidiol	n/a	7/1/2014	Treatment of Dravet syndrome	Insys Therapeutics, Inc.
1740	cannabidiol	n/a	11/14/2013	Treatment of Dravet syndrome.	GW Pharma Ltd.
1741	cannabidiol	n/a	4/22/2015	Treatment of neonatal hypoxic ischemic encephalopathy	GW Pharma Ltd.
1742	cannabidiol	n/a	6/23/2014	Treatment of Lennox-Gastaut syndrome	Insys Therapeutics, Inc.
1743	cannabidiol	n/a	11/17/2014	Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age)	Insys Therapeutics, Inc.
1744	cannabidiol;	n/a	2/27/2014	Treatment of Lennox-Gastaut syndrome	GW Pharma Ltd.
1745	cantharidin	n/a	7/24/2012	Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa	Orenova Group, LLC
1746	cantrixil	n/a	4/20/2015	Treatment of ovarian cancer	CanTx, Inc.
1747	caprine hyperimmune serum against HIV lysate	n/a	2/14/2014	Treatment of systemic sclerosis	Daval International Limited
1748	caprine hyperimmune serum against HIV lysate	n/a	10/28/2009	Treatment of amyotrophic lateral sclerosis	Daval International Limited
1749	capsaicin	n/a	10/23/2002	Treatment of erythromelalgia	Acorda Therapeutics, Inc.
1750	capsaicin	Qutenza	5/2/2003	Treatment of painful HIV-associated neuropathy	Acorda Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1751	capsaicin	Qutenza	5/22/2009	Management of neuropathic pain in patients with postherpetic neuralgia	Acorda Therapeutics, Inc.
1752	carbenoxolone	n/a	7/2/2014	Treatment of Huntington's Disease	Oxalys Pharmaceuticals, Inc.
1753	carbetocin	n/a	4/10/2014	Treatment of Prader Willi syndrome	Ferring Pharmaceuticals, Inc.
1754	carbon monoxide	n/a	9/28/2012	Treatment of sickle cell disease	Hillhurst Biopharmaceuticals, Inc.
1755	carboxy pyrrolidine hexanoyl pyrrolidine carboxylate	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline
1756	cardiotrophin-1	n/a	10/16/2014	Prevention of ischemia-reperfusion injury in kidney transplant recipients	Digna Biotech, S.L.
1757	cardiotrophin-1	n/a	6/24/2008	To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.	Digna Biotech, S.L.
1758	cardiotrophin-1	n/a	9/13/2011	Treatment of acute liver failure	Digna Biotech S.L.
1759	carfilzomib	Kyprolis	1/18/2008	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
1760	carglumic acid	Carbaglu	6/17/2014	Treatment of organic acidemias	Orphan Europe SARL

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1761	carglumic acid	Carbaglu	1/20/1998	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe SARL
1762	carisbamate	n/a	3/16/2012	Management of patients with infantile spasms	SK Life Science, Inc.
1763	carlumab	n/a	10/24/2006	Treatment of pancreatic cancer	Centocor, Inc.
1764	catumaxomab	n/a	7/1/2009	Treatment of gastric cancer	Neoviibiotech North America, Inc.
1765	cediranib	n/a	12/13/2010	Treatment of glioblastoma	National Institutes of Health
1766	celiprolol	n/a	1/5/2015	Treatment of Ehlers-Danlos syndrome	Acer Therapeutics, INC.
1767	cell based therapeutic composed of allogeneic donor apoptotic cells	Apocell	3/18/2013	Prevention of graft versus host disease	Enlivex Therapeutics Ltd.
1768	cenersen	Aezea	6/18/2008	Treatment of stage IIB through IV melanoma	Eleos, Inc.
1769	cenersen	Aezea	2/27/2008	Treatment of chronic lymphocytic leukemia	Eleos, Inc.
1770	cenersen	n/a	5/8/2006	Treatment of acute myeloid leukemia	Eleos, Inc.
1771	ceritinib	Zykadia	9/27/2013	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Novartis Pharmaceuticals Corp.
1772	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of tularemia due to Francisella tularensis.	Advanced Life Sciences, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1773	cethromycin	Restanza(Tm)	9/9/2009	Prophylactic treatment of plague due to Yersinia pestis	Advanced Life Sciences, Inc.
1774	cethromycin	n/a	2/28/2007	Prophylactic treatment of patients exposed to inhalation anthrax.	Advanced Life Sciences, Inc.
1775	cetuximab	Erbitux	7/3/2000	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	ImClone Systems Incorporated
1776	chelmab-y or chelamusab-Y	Oncorad Ov103	4/24/1990	Treatment of ovarian cancer.	Cytogen Corporation
1777	chenodeoxycholic acid	n/a	2/12/2007	Treatment of cerebrotendinous xanthomatosis	Sigma-Tau Pharmaceuticals, Inc.
1778	chenodiol	Chenix	9/21/1984	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age	Solvay
1779	chenodiol	Chenadal	3/22/2010	Treatment of cerebrotendinous xanthomatosis	Retrophin, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1780	chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2	n/a	11/25/2014	Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)	BioMarin Pharmaceutical, Inc.
1781	chimeric monoclonal antibody against Claudin 6	n/a	3/18/2013	Treatment of ovarian cancer	Ganymed Pharmaceuticals AG
1782	chimeric monoclonal antibody against claudin-18 splice variant 2	n/a	9/26/2013	Treatment of pancreatic cancer	GANYMED Pharmaceuticals AG
1783	chimeric monoclonal antibody to claudin 18 splice variant 2	n/a	11/20/2012	Treatment of gastric cancer	GANYMED Pharmaceuticals AG
1784	chlorobutanol/propylene glycol/hydrochloric acid	Patul-End	2/18/1997	Treatment of patulous eustachian tube	Ear Foundation
1785	chloropyramine	n/a	10/22/2010	Treatment of pancreatic cancer	CurFAKTor Pharmaceuticals, LLC
1786	chloroquine	n/a	5/20/2015	Treatment of glioblastoma multiforme.	DualTpharma B.,V.
1787	chlorotoxin	n/a	12/2/2008	Treatment of stage IIb, IIc, III & IV melanoma	Morphotek, Inc.
1788	cholest-4-en-3-one, oxime	n/a	2/17/2009	Treatment of spinal muscular atrophy.	Genentech, Inc.
1789	cholic acid	Cholbam	7/18/2003	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Retrophin, Inc.
1790	choline tetrathiomolybdate	n/a	8/25/2011	Treatment of Wilson's disease.	Wilson Therapeutics AB

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1791	chromium picolinate and chromium histidinate	n/a	12/22/2014	Treatment of pediatric polycystic ovary syndrome (0 through 16 years of age)	JDS Therapeutics, LLC
1792	cinacalcet	Sensipar	4/30/2010	Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery	Amgen, Inc.
1793	cinacalcet	Sensipar	5/12/2003	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc.
1794	ciprofloxacin	n/a	6/1/2011	The management of bronchiectasis	Aradigm Corporation
1795	ciprofloxacin DPI	Ciprofloxacin Pulmosphere(R)	2/2/2010	Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients	Bayer HealthCare Pharmaceuticals, Inc.
1796	ciprofloxacin dry powder inhaler	n/a	4/17/2014	Treatment of non-cystic fibrosis bronchiectasis	Bayer HealthCare Pharmaceuticals, Inc.
1797	cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2',4'-trioxaspiro[4.5] decane mesylate	n/a	1/19/2010	Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae	Medicines for Malaria Venture (MMV)
1798	civamide	n/a	2/17/2009	Treatment of postherpetic neuralgia.	Winston Laboratories, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1799	civamide	Zucapsaicin	12/9/2002	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc.
1800	cladribine	n/a	3/19/2015	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chord Therapeutics S.a.r.l.
1801	clarithromycin, rifabutin, clofazimine	n/a	4/26/2011	Treatment of pediatric Crohn's disease.	RedHill Biopharma Ltd.
1802	clenbuterol	Spiropent, Ventipulmin	10/27/2014	Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease	Duke University Medical Center
1803	clobazam	Onfi	12/18/2007	Treatment of Lennox-Gastaut Syndrome	Lundbeck, Inc.
1804	clofarabine	Clolar	2/7/2002	Treatment of acute lymphoblastic leukemia	Genzyme Corporation
1805	clofarabine	Clofarex	3/14/2002	Treatment of acute myelogenous leukemia	Genzyme Corp (Ilex Products, Inc.)
1806	clofazimine	Lamprene	6/25/2014	Treatment of active tuberculosis	Novartis Pharmaceuticals Corp.
1807	coagulation factor IX (recombinant)	Rixubis	10/31/2012	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Baxter Healthcare Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1808	coagulation factor VIIa (recombinant)	Novoseven Rt	6/18/2004	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Novo Nordisk Inc.
1809	coagulation factor XIII A-subunit (recombinant)	Tretten	11/6/2003	Prophylaxis of bleeding associated with congenital factor XIII deficiency	Novo Nordisk, Inc.
1810	cobimetinib	n/a	1/31/2014	Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation	Genentech, Inc.
1811	coccidioidin SD Skin Test Antigen	n/a	12/19/2007	For the diagnosis of Coccidioidomycosis	Allermed Laboratories, Inc.
1812	coenzyme Q10 and d-alpha-tocopherol	n/a	3/14/2011	Treatment of Friedreich's Ataxia.	NBI Pharmaceuticals, Inc.
1813	colchicine	Colcrys	9/25/2007	Treatment of familial Mediterranean fever	AR Holding Company, Inc.
1814	collagenase clostridium histolyticum	Xiaflex	3/12/1996	Treatment of Peyronie's disease.	Auxilium Pharmaceuticals, Inc.
1815	collagenase clostridium histolyticum	Xiaflex	5/23/1996	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Auxilium Pharmaceuticals, Inc.
1816	combretastatin A 1 diphosphate	n/a	11/19/2012	Treatment of acute myelogenous leukemia	OXiGene, Inc.
1817	conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)	Transmid	12/3/2001	Treatment of malignant tumors of the central nervous system	Xenova Biomedix Limited
1818	conjugated bile acids	Cobartin	7/18/2003	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1819	copanlisib	n/a	2/5/2015	Treatment of follicular lymphoma	Bayer HealthCare Pharmaceuticals, Inc.
1820	copper histidine	n/a	5/14/2012	Treatment of Menkes disease	Stephen G. Kaler, M.D.
1821	corifungin	n/a	7/6/2011	Treatment of visceral leishmaniasis	Sandler Center for Drug Discovery
1822	corifungin	n/a	8/22/2011	Treatment of amebic meningoencephalitis.	Ctr for Discovery & Innovation in Parasitic Diseases
1823	creatine	Creapure	2/12/2002	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc.
1824	crenolanib	n/a	3/11/2011	Treatment of soft tissue sarcoma	AROG Pharmaceuticals, LLC
1825	crenolanib	n/a	12/20/2010	Treatment of malignant glioma	AROG Pharmaceuticals, LLC
1826	crenolanib	n/a	10/31/2012	Treatment of acute myelogenous leukemia	AROG Pharmaceuticals, LLC
1827	cridanimod	n/a	1/12/2011	Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.	Kevelt Ltd.
1828	crizotinib	Xalkori	10/31/2012	Treatment of neuroblastoma	Pfizer
1829	crizotinib	Xalkori	9/28/2012	Treatment of anaplastic large cell lymphoma	Pfizer, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1830	crizotinib	Xalkori	9/13/2010	Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer	Pfizer, Inc.
1831	cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	n/a	8/15/2003	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center
1832	cyclic pyranopterin monophosphate (cPMP)	n/a	11/5/2009	Treatment of molybdenum cofactor deficiency type A (MoCD)	Alexion Pharmaceuticals, Inc.
1833	cyclo(-γ-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt	n/a	6/24/2013	Treatment of acromegaly	Aspireo Pharmaceuticals Limited
1834	cyclocreatine	n/a	6/18/2012	Treatment of creatine transporter deficiency	Lumos Pharma
1835	cyclophosphamide	Cyrevia(Tm)	6/17/2011	Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant	Accentia Biopharmaceuticals, Inc.
1836	cyclophosphamide	Cyrevia(Tm)	6/7/2011	Treatment of systemic sclerosis.	Accentia Biopharmaceuticals, Inc.
1837	cyclosporine	n/a	2/17/2009	Treatment of graft-versus-host disease	Sigmoid Pharma Limited

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1838	cyclosporine	n/a	2/17/2009	Prophylaxis of graft-versus-host disease	Sigmoid Pharma Limited
1839	cyclosporine 2% ophthalmic ointment	n/a	8/1/1991	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer	Allergan, Inc.
1840	cyclosporine A	n/a	9/30/2008	Prevention of corneal graft rejection	Santen SAS
1841	cyclosporine A	Nova22007	4/9/2008	Treatment of herpes simplex virus stromal keratitis	Santen SAS
1842	cyclosporine; ciclosporin	Neurostat(R)/Ciclomulsion (R)	11/23/2010	Treatment of moderate to severe traumatic brain injury.	NeuroVive Pharmaceutical AB
1843	cysteamine	n/a	5/9/2008	Treatment of Huntington's disease	Raptor Therapeutics
1844	cysteamine	n/a	9/11/2013	Treatment of pancreatic cancer	Raptor Pharmaceuticals, Inc.
1845	cysteamine	n/a	8/6/2008	Treatment of neuronal ceroid lipofuscinoses (Batten disease)	Raptor Pharmaceuticals, Inc.
1846	cysteamine enteric coated	Procysbi	10/24/2006	Treatment of cystinosis	Raptor Therapeutics, Inc.
1847	cytarabine liposome	Depocyt	1/30/2007	Treatment of gliomas	Bruce Frankel, MD
1848	cytochrome C, flavin mononucleotide and thiamin diphosphate	n/a	6/17/2011	Treatment of mitochondrial disorders	NBI Pharmaceuticals, Inc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1849	cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate	n/a	12/17/2014	Treatment of pancreatic cancer in combination with ifosfamide	Nuvilex, Inc.
1850	d6-tetrabenazine, deutetrabenazine	n/a	11/5/2014	Treatment of Huntington's Disease	Auspex Pharmaceuticals, Inc.
1851	dabrafenib	Tafinlar	1/12/2011	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	Novartis Pharmaceuticals Corp.
1852	dabrafenib	Tafinlar	10/20/2014	Treatment of patients with BRAF mutation positive non-small cell lung cancer	Novartis Pharmaceuticals Corp.
1853	dacetuzumab	n/a	10/6/2005	Treatment of chronic lymphocytic leukemia	Seattle Genetics, Inc.
1854	dacetuzumab	n/a	8/13/2004	Treatment of multiple myeloma.	Seattle Genetics, Inc.
1855	dacomitinib	n/a	3/3/2015	Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.	Pfizer, Inc.
1856	dalbavancin	Dalvance	3/30/2015	Treatment of acute osteomyelitis in children (0 through 16 years of age)	Durata Therapeutics International B.V.
1857	dalfampridine	Ampyra	6/2/1987	Relief of symptoms of multiple sclerosis	Acorda Therapeutics
1858	dantrolene sodium	n/a	9/25/2012	Treatment of heat stroke	Eagle Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1859	dantrolene sodium suspension for injection	Ryanodex	8/16/2013	Treatment of malignant hyperthermia syndrome	Eagle Pharmaceuticals, Inc.
1860	daratumumab	Humax(R)-Cd38	5/6/2013	Treatment of multiple myeloma.	Janssen Research & Development, LLC
1861	dasiprotimut-T	Biovaxid	10/28/2009	Treatment of follicular lymphoma	Biovest International, Inc.
1862	dasiprotimut-T	Biovax Id	6/17/2010	Treatment of mantle cell lymphoma	Biovest International, Inc.
1863	daunorubicin citrate liposome	Daunoxome	4/15/2013	Treatment of acute myeloid leukemia	Galen Limited
1864	davunetide	n/a	12/7/2009	Treatment of progressive supranuclear palsy.	Allon Therapeutics, Inc.
1865	debrase	Debridase	8/20/2003	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd.
1866	decitabine	Dacogen	3/8/1999	Treatment of myelodysplastic syndromes.	Otsuka Pharmaceutical Development
1867	defactinib	n/a	2/12/2015	Treatment of ovarian cancer	Verastem, Inc.
1868	deferasirox	Exjade	2/24/2015	Treatment of chronic iron overload in alpha-thalassemia	Novartis Pharmaceuticals Corporation
1869	deferiprone	n/a	9/1/2011	Treatment of superficial siderosis	ApoPharma, Inc.
1870	deferiprone	n/a	7/31/2008	Treatment of Friedreich's ataxia	ApoPharma, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1871	deferiprone	Ferriprox	12/12/2001	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	ApoPharma, Inc. A Division of
1872	deferoxamine starch conjugate	n/a	1/28/2005	Treatment of acute iron poisoning	Biomedical Frontiers, Inc.
1873	deferoxamine starch conjugate	n/a	12/21/1998	Treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.	Biomedical Frontiers, Inc.
1874	defibrotide	n/a	5/21/2003	For the treatment of hepatic veno-occlusive disease	Gentium SpA
1875	defibrotide	n/a	1/8/2007	For the prevention of hepatic veno-occlusive disease.	Gentium SpA
1876	deflazacort	Calcort	9/16/2010	Treatment of Duchenne muscular dystrophy	University of Rochester Medical Center
1877	deflazacort	n/a	8/16/2013	Treatment of Duchenne muscular dystrophy	Marathon Pharmaceuticals, LLC
1878	dehydrated alcohol	n/a	3/16/2012	Treatment of trigeminal neuralgia	Luitpold Pharmaceuticals, Inc.
1879	dehydrated alcohol	Ablysinol	9/11/2013	Treatment of hypertrophic obstructive cardiomyopathy	Belcher Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1880	delta-1,4,9(11)-pregnatriene-17-alpha,21-dihydroxy-16-alpha-methyl-3,20-dione	n/a	12/2/2011	Treatment of Duchenne muscular dystrophy	ReveraGen Biopharma
1881	demcizumab	n/a	4/30/2014	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
1882	dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2, TRP-2, gp100 and interleukin-13 receptor alpha	n/a	6/7/2010	Treatment of glioblastoma or brain stem glioma	ImmunoCellular Therapeutics Ltd.
1883	dendritic hybrid cell vaccine	Neuroblaxin	9/23/2011	Treatment of neuroblastoma	Orbis Health Solutions, LLC
1884	denileukin diftitox	Ontak	8/21/1996	Treatment of patients with cutaneous T-cell lymphoma	Eisai, Inc.
1885	denileukin diftitox	n/a	7/12/2013	Treatment of cutaneous T-cell lymphoma	Eisai Inc.
1886	denileukin diftitox	Ontak	4/30/2010	Treatment of peripheral T-cell lymphoma	Eisai, Inc.
1887	denileukin diftitox	n/a	6/29/2011	Treatment of peripheral T-cell lymphoma (PTCL)	Eisai, Inc.
1888	denosumab	Xgeva	9/11/2013	Treatment of hypercalcemia in malignancy	Amgen, Inc.
1889	denosumab	Xgeva	12/20/2010	Treatment of patients with giant cell tumor of bone	Amgen, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1890	deutetrabenazine	n/a	1/13/2015	Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age)	Auspex Pharmaceuticals
1891	dexamethasone intravitreal implant	Ozurdex	9/11/1998	Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis	Allergan
1892	dexamethasone phosphate	n/a	12/2/2008	Treatment of corneal graft rejection.	EyeGate Pharmaceuticals, Inc.
1893	dexamethasone sodium phosphate encapsulated in autologous erythrocytes	n/a	7/24/2012	Treatment of ataxia-telangiectasia	EryDel S.p.A.
1894	dexanabinol	n/a	8/11/2004	For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury	Pharmos Corporation
1895	dexpramipexole	n/a	10/11/2007	Treatment of amyotrophic lateral sclerosis	Knopp Biosciences LLC
1896	dexrazoxane	Totect(R)	3/25/2004	Treatment of anthracycline extravasation during chemotherapy	Biocodex

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1897	dexrazoxane hydrochloride	n/a	8/19/2014	Prevention of cardiomyopathy for children and adolescents 0 through 16 years of age treated with anthracyclines	Satiscor, LLC
1898	dextran 1	n/a	3/21/2003	Treatment of cystic fibrosis	BCY LifeSciences Inc.
1899	diacerein	n/a	10/15/2014	Treatment of epidermolysis bullosa	TWI Biotechnology, Inc.
1900	diannexin	n/a	10/28/2009	Prevention of ischemia-reperfusion injury in solid organ transplants	Astellas Pharma Global Development, Inc.
1901	diazepam (intranasal)	n/a	7/31/2012	Management of patients with acute repetitive seizures	Acorda Therapeutics, Inc.
1902	diazepam auto-injector	n/a	5/30/2013	Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity	Meridian Medical Technologies-a Pfizer subsidiary
1903	diazoxide	n/a	12/3/2012	Treatment of Prader Willi Syndrome	Sedogen, LLC
1904	diazoxide choline	n/a	5/13/2014	Treatment of Prader-Willi Syndrome	Essentialis, Inc.
1905	dichlorphenamide	n/a	9/2/2010	Treatment of primary periodic paralyses	Taro Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1906	diethylenetriaminepentaacetate (DPTA)	n/a	4/14/2004	For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.	CIS-US
1907	diferuloylmethane	n/a	6/13/2003	Treatment of cystic fibrosis	Allertein Therapeutics, LLC
1908	difluprednate	Durezol	9/30/2008	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Alcon Pharmaceuticals. Ltd.
1909	digitoxin	n/a	5/27/2005	Treatment of cystic fibrosis	Silver Pharmaceuticals
1910	digitoxin	n/a	11/2/2001	Treatment of ovarian cancer	PrimeCyte, Inc.
1911	digitoxin	n/a	10/18/2001	Treatment of soft tissue sarcomas	PrimeCyte, Inc.
1912	digoxin immune fab (ovine)	n/a	2/3/2012	Treatment of severe preeclampsia and eclampsia	Glenveigh Medical, LLC
1913	dihydroartemisinin and piperazine	Eurartesim	1/8/2007	Treatment of uncomplicated malaria caused by "Plasmodium falciparum," Plasmodium vivax," Plasmodium malariae," or "Plasmodium ovale."	Sigma-Tau Pharmaceuticals, Inc.
1914	dimebon	n/a	5/12/2009	Treatment of Huntington's Disease.	Medivation, Inc.
1915	dimethyl fumarate	n/a	9/11/2013	Treatment of Friedreich's Ataxia	Gino Cortopassi

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1916	dimethyl sulfoxide	n/a	5/9/2008	For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis	Abela Pharmaceuticals, Inc.
1917	dinaciclib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia.	Merck Sharp & Dohme Ltd.
1918	dinutuximab	n/a	12/20/2010	Treatment of neuroblastoma	United Therapeutics Corporation
1919	diphenylcycloenone	n/a	6/13/2003	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr.
1920	docosahexaenoic acid	n/a	4/27/2015	Treatment of sickle cell disease	Sancilio & Company, Inc.
1921	docosahexaenoic acid, DHA	n/a	12/17/2014	Treatment of primary sclerosing cholangitis	Sancilio and Company, Inc.
1922	docosahexanoic acid-paclitaxel	Taxoprexin	3/5/2001	Treatment of hormone-refractory prostate cancer.	Luitpold Pharmaceuticals, Inc.
1923	domperidone	n/a	9/2/2011	Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding	Thomas W. Hale, RPh, PhD

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1924	double stranded RNA which targets the mutated KRAS oncogene	n/a	1/26/2015	Treatment of pancreatic cancer	Silenseed Ltd
1925	dovitinib	n/a	9/26/2013	Treatment of adenoid cystic carcinoma	Novartis Pharmaceuticals Corporation
1926	doxofylline	n/a	2/14/2014	Treatment of bronchiectasis	Alitair Pharmaceuticals, Inc.
1927	doxorubicin	n/a	4/6/2015	Treatment of cutaneous T-cell lymphoma	Louis D. Faló, Jr.
1928	doxorubicin	n/a	8/25/2009	Treatment of hepatocellular carcinoma.	Delcath Systems, Inc.
1929	doxorubicin HCL liposome injection	Doxil	12/29/2004	Treatment of multiple myeloma	Johnson & Johnson Pharmaceutical Research & Dev.
1930	doxorubicin PIHCA nanoparticles	Doxorubicin Transdrug	3/14/2005	Treatment of hepatocellular carcinoma	BioAlliance Pharma
1931	doxorubicin with pluronics F-127 and L-61	n/a	2/20/2008	Treatment of gastric cancer	Supratek Pharma, Inc.
1932	droxidopa	Northera	1/17/2007	Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.	Lundbeck LLC
1933	dry extract from Betulae Cortex (birch bark)	n/a	8/7/2014	Treatment of epidermolysis bullosa	Birken AG

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1934	duvoglustat hydrochloride	n/a	6/18/2007	Treatment of Pompe disease	Amicus Therapeutics, Inc
1935	ecallantide	Kalbitor	2/4/2003	Treatment of angioedema	Dyax Corp.
1936	echinomycin	n/a	5/21/2015	Treatment of acute myeloid leukemia.	OncoImmune, Inc.
1937	echothiophate iodide	n/a	6/2/2014	Treatment of Stargardt's disease	Makindus, Inc.
1938	ecopipam hydrochloride	n/a	7/21/2009	Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.	Psyadon Pharmaceuticals, Inc.
1939	ecopipam hydrochloride	n/a	9/29/2010	Treatment of Tourette's syndrome in children 0-16 years old.	Psyadon Pharmaceuticals, Inc.
1940	eculizumab	Soliris	6/24/2013	Treatment of neuromyelitis optica	Alexion Pharmaceuticals, Inc.
1941	eculizumab	Soliris	8/20/2003	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc.
1942	eculizumab	Soliris	1/10/2014	Prevention of delayed graft function after renal transplantation	Alexion Pharmaceuticals, Inc.
1943	eculizumab	Soliris	4/29/2009	Treatment of atypical hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1944	eculizumab	n/a	3/5/2001	Treatment of idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1945	eculizumab	Soliris	10/18/2011	Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome	Alexion Pharmaceuticals, Inc.
1946	eculizumab	n/a	6/13/2014	Treatment of Myasthenia Gravis.	Alexion Pharmaceuticals, Inc.
1947	edaravone	n/a	3/12/2015	Treatment of amyotrophic lateral sclerosis	Treeway B.V.
1948	efaproxiral	n/a	7/28/2004	Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer	Allos Therapeutics, Inc.
1949	eflornithine	n/a	2/4/2011	Treatment of Familial Adenomatous Polyposis	Cancer Prevention Pharmaceuticals
1950	eflornithine	n/a	11/23/2010	Treatment of neuroblastoma	Cancer Prevention Pharmaceutical, Inc.
1951	eflornithine HCL	n/a	4/7/2015	Treatment of gastric cancer	Cancer Prevention Pharmaceuticals, Inc.
1952	eflornithine plus sulindac	n/a	1/22/2013	Treatment of familial adenomatous polyposis	Cancer Prevention Pharmaceuticals, Inc.
1953	eicosapentaenoic acid	n/a	3/8/2011	Treatment of familial adenomatous polyposis	S.L.A. Pharma Ltd. (UK)
1954	elacytarabine	n/a	6/18/2008	Treatment of acute myeloid leukemia (AML)	Clavis Pharma ASA
1955	elafin	n/a	12/28/2012	Treatment of pulmonary arterial hypertension	Proteo Biotech AG

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1956	eliglustat	Cerdelga	9/17/2008	Treatment of Type I Gaucher disease	Genzyme Corporation
1957	elosulfase alfa	Vimizim	5/15/2009	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	BioMarin Pharmaceutical Inc.
1958	elotuzumab	n/a	9/1/2011	Treatment of multiple myeloma	Bristol-Myers Squibb Company
1959	eltrombopag	Promacta	11/8/2013	Treatment of aplastic anemia	Novartis Pharmaceuticals Corp.
1960	eltrombopag	Promacta	5/5/2008	Treatment of idiopathic thrombocytopenia purpura	Novartis Pharmaceuticals Corp.
1961	emricasan	n/a	11/20/2013	Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease	Conatus Pharmaceuticals Inc.
1962	enalapril maleate (powder for oral solution)	Epaned	1/30/2013	Treatment of hypertension in pediatric patients	Silvergate Pharmaceuticals, Inc.
1963	enchochleate amphotericin B	n/a	1/10/2014	Treatment of visceral leishmaniasis	Aquarius Biotechnologies, Inc.
1964	encorafenib	n/a	11/19/2013	Treatment of Stage IIB-IV melanoma positive for BRAF mutation	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1965	encorafenib + binimetinib	n/a	11/19/2013	Treatment in Stage IIB-IV melanoma positive for the BRAF mutation.	Novartis Pharmaceuticalues Corporation
1966	eniluracil	n/a	12/15/2005	Treatment of hepatocellular carcinoma.	Adherex Technologies, Inc.
1967	ensituximab	n/a	10/21/2010	Treatment of pancreatic cancer.	Neogenix Oncology, Inc.
1968	enzastaurin	n/a	3/4/2009	Treatment of diffuse large B-cell lymphoma	Eli Lilly and Company
1969	epoprostenol	Flolan	3/22/1999	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline
1970	epratuzumab	n/a	9/30/2008	Treatment of acute lymphoblastic leukemia	Immunomedics, Inc.
1971	epratuzumab	Lymphocide	7/13/1998	Treatment of non-Hodgkin's lymphoma	Immunomedics, Inc.
1972	eptifibatide and iloprost	n/a	4/20/2012	Treatment of purpura fulminans	Thrombologic
1973	erdosteine	n/a	12/20/2013	Treatment of bronchiectasis.	Alitair Pharmaceuticals, Inc.
1974	eribulin mesylate	Halaven(R)	5/14/2012	Treatment of advanced soft tissue sarcoma	Eisai, Inc.
1975	estradiol Gel	n/a	10/31/2006	Estrogen replacement therapy in females with Turner syndrome	Ascend Therapeutics US, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1976	etanercept	Enbrel	10/27/1998	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation
1977	etarfolatide	n/a	2/16/2000	For the identification of ovarian carcinomas	Endocyte, Inc.
1978	eteplirsen	n/a	10/23/2007	Treatment of Duchenne Muscular Dystrophy.	Sarepta Therapeutics, Inc.
1979	ethanolamine	Ethamolin	1/17/2014	Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding	QOL Medical, LLC
1980	ethiodized oil injection	Lipiodol	9/26/2013	Management of patients with known hepatocellular carcinoma (HCC)	Guerbet LLC
1981	etirinotecan pegol	n/a	4/18/2011	Treatment of ovarian cancer.	Nektar Therapeutics

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1982	everolimus	Afinitor	6/8/2009	Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangiomyomatosis (LAM)	Novartis Pharmaceuticals Corporation
1983	everolimus	Afinitor	2/14/2008	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
1984	everolimus	Afinitor(R)	6/2/2014	Treatment of diffuse large B-cell lymphoma.	Novartis Pharmaceuticals Corp.
1985	everolimus	Afinitor	7/23/2012	Treatment of hepatocellular carcinoma	Novartis Pharmaceuticals Corporation
1986	ex vivo cultured human mesenchymal stromal cells	n/a	5/8/2014	Prevention of graft rejection following solid organ transplantation	iCell Science AB
1987	ex-vivo cultered adult human mesenchymal stem cells	Prochymal(R)	4/30/2010	Treatment of Type 1 diabetes patients with residual beta cell function	Mesoblast, Inc.
1988	ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells	n/a	12/20/2010	Treatment of Amyotrophic Lateral Sclerosis	TCA Cellular Therapy, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1989	exendin-(9-39)	n/a	6/1/2011	Treatment of congenial hyperinsulinemic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children	The Children's Hospital of Philadelphia
1990	exon 53 specific phosphorothioate oligonucleotide	n/a	1/23/2013	treatment of Duchenne Muscular Dystrophy patients bearing mutations that can be corrected by skipping exon 53	Prosensa Therapeutics B.V.
1991	expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS	n/a	8/20/2009	Treatment of Dystrophic Epidermolysis Bullosa.	Intercytex Ltd.
1992	expanded human allogeneic neural retinal progenitor cells extracted from neural retina	n/a	8/22/2013	Treatment of retinitis pigmentosa	ReNeuron Ltd
1993	extract of sorghum bicolor extract	n/a	11/19/2012	Treatment of sickle cell disease	Invenux, LLC
1994	ezatiostat hydrochloride	Telintra	1/9/2013	Treatment of myelodysplastic syndrome	Telik, Inc.
1995	factor VIII mimetic bispecific antibody	n/a	1/10/2014	Treatment of hemophilia A	Genentech
1996	factor XIII concentrate (human)	Corifact	1/16/1985	Treatment of congenital factor XIII deficiency	CSL Behring LLC
1997	farletuzumab	n/a	6/16/2006	Treatment of ovarian cancer	Morphotek, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
1998	fecal microbiota	n/a	3/10/2014	Treatment of recurrent Clostridium difficile infection (Clostridium difficile gastrointestinal disease)	Rebiotx, Inc.
1999	fenfluramine HCl	Brabafen	12/20/2013	For the Treatment of Dravet Syndrome	Zogenix, Inc.
2000	fenretinide	n/a	9/4/2013	Treatment of cutaneous T-cell lymphoma	CerRx, Inc.
2001	fenretinide	n/a	9/4/2013	Treatment of peripheral T-cell lymphoma	CerRx, Inc.
2002	fenretinide	n/a	2/1/2007	Treatment of Ewing's sarcoma family of tumors.	Cancer Research UK
2003	ferric hexacyanoferrate (II) "Prussian Blue"	n/a	6/26/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG
2004	ferumoxytol	n/a	4/6/2012	For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)	ArsNova Partners, LLC
2005	ferumoxytol	Feraheme	4/29/2011	For use in MR imaging for the mangement of brain tumors	Edward A. Neuwelt, MD

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2006	ferumoxytol	n/a	10/7/2011	For use in magnetic resonance imaging in brain metastases	Oregon Health & Science University
2007	fialuridine	n/a	7/24/1992	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc.
2008	fidaxomicin	Dificid	12/13/2010	Treatment of pediatric Clostridium difficile infection	Optimer Pharmaceuticals, Inc.
2009	filanesib	n/a	5/6/2014	Treatment of multiple myeloma.	Array BioPharma, Inc.
2010	filgrastim	Neupogen	11/20/2013	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Amgen, Inc.
2011	filgrastim	n/a	1/27/2015	Treatment of amyotrophic lateral sclerosis (ALS)	Neurovision Pharma GmbH
2012	filociclovir	n/a	11/29/2010	Treatment of active cytomegalovirus infections	Microbiotix, Inc.
2013	fingolimod	n/a	4/30/2010	Treatment of chronic inflammatory demyelinating polyneuropathy	Novartis Pharmaceutical Corporation
2014	firtecán pegol	n/a	4/18/2011	Treatment of neuroblastoma.	Enzon Pharmaceuticals, Inc.
2015	flubendazole	n/a	10/25/2013	Treatment of onchocerciasis caused by Onchocerca volvulus	Janssen Research & Development, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2016	flubendazole	n/a	1/23/2014	Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.	Janssen Research and Development, LLC
2017	fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)	n/a	4/7/2015	For the diagnosis of glioma	Blue Earth Diagnostics Ltd.
2018	flunarizine hydrochloride	n/a	6/24/2013	Treatment of alternating hemiplegia	Marathon Pharmaceuticals, LLC
2019	fluticasone propionate	n/a	1/19/2011	Treatment of pediatric and adult eosinophilic esophagitis	Forest Laboratories, Inc.
2020	fosfomycin/tobramycin	n/a	11/28/2008	Treatment of pulmonary infections associated with cystic fibrosis	CURx Pharmaceuticals, Inc.
2021	fresolimumab	n/a	10/21/2010	Treatment of primary focal segmental glomerulosclerosis	Genzyme
2022	fusion protein analog with recombinant human growth hormone (rhGH) at once-a-month dosing	n/a	10/16/2013	Treatment of growth hormone deficiency	Versartis, Inc.
2023	gabapentin	Neurontin	7/5/1995	Treatment of amyotrophic lateral sclerosis	Warner-Lambert Company
2024	gabapentin	Gralise	11/8/2010	Management of postherpetic neuralgia	Depomed, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2025	gabapentin enacarbil	Horizant	6/7/2011	Treatment of postherpetic neuralgia	XenoPort, Inc.
2026	ganaxolone	n/a	3/24/2015	Treatment of Protocadherin 19 (PCDH19) female epilepsy.	Marinus Pharmaceuticals, Inc.
2027	ganciclovir	Zirgan	3/22/2007	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Sirion Therapeutics, Inc.
2028	gefitinib	n/a	8/26/2014	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer.	AstraZeneca Pharmaceuticals LP
2029	gemcabene	n/a	2/6/2014	Treatment of homozygous familial hypercholesterolemia	Gemphire Therapeutics, Inc.
2030	gene encoding chimeric CD40 ligand	n/a	2/4/2009	Treatment of chronic lymphocytic leukemia	Memgen, LLC
2031	genetically engineered herpes simplex virus (G207)	n/a	4/29/2002	Treatment of malignant glioma	Aettis, Inc.
2032	gevokizumab	n/a	2/21/2014	Treatment of pyoderma gangrenosum	XOMA (US) LLC
2033	gevokizumab	n/a	7/27/2010	Treatment of Behcet's disease	XOMA (US) LLC
2034	gevokizumab	n/a	8/20/2012	Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis	XOMA (US) LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2035	givinostat	n/a	4/12/2013	Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy	Italfarmaco SpA
2036	glatiramer acetate	Copaxone	11/14/2007	Treatment of amyotrophic lateral sclerosis (ALS).	Teva Neurosciences, Inc.
2037	glioma derived cell lysates and irradiated cells	n/a	1/12/2011	Treatment of glioma.	Epitopoietic Research Corp.
2038	glucagon	n/a	12/5/2012	Prevention of hypoglycemia in the congenital hyperinsulinism population	Biodel, Inc.
2039	glucagon infusion	G-Pump (Tm)	9/25/2014	Prevention of chronic, severe hypoglycemia related to congenital hyperinsulinism	Xeris Pharmaceuticals, Inc.
2040	glucarpidase	Voraxaze	8/19/2003	Treatment of patients at risk of methotrexate toxicity	BTG International Inc.
2041	glufosfamide	n/a	9/18/2006	For treatment of pancreatic cancer.	Eleison Pharmaceuticals LLC
2042	glycafilin	n/a	8/22/2008	Prevention of delayed graft function after solid organ transplantation	ProtAffin Biotechnologie AG
2043	glycerol phenylbutyrate	Ravicti	4/27/2009	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Hyperion Therapeutics, Inc.
2044	glycopyrrolate	Cuvposa	6/9/2006	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Shionogi, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2045	glycopyrrolate 2%	n/a	6/17/2010	Treatment of Frey's syndrome	Wellesley Therapeutics, Inc.
2046	glycosylated recombinant human interleukin-7	n/a	9/27/2012	Treatment of progressive multifocal leukoencephalopathy	Cytheris, Inc.
2047	glycyl-L-2-methylprolyl-L-glutamic Acid	n/a	10/23/2013	Treatment of Fragile X Syndrome	Neuren Pharmaceuticals, Ltd.
2048	glycyl-L-2-methylpropyl-L-glutamic acid	n/a	2/11/2015	Treatment of Rett syndrome	Neuren Pharmaceuticals, Ltd.
2049	golimumab	Simponi	3/16/2012	Treatment of pediatric ulcerative colitis	Janssen Biotech, Inc.
2050	golimumab	Simponi Aria	4/2/2015	Treatment of polyarticular juvenile idiopathic arthritis in pediatric patients (0 through 16 years of age)	Janssen Research & Development, LLC
2051	golnerminogene pradenovec	Tnferade(Tm) Biologic	10/28/2009	Treatment of pancreatic cancer.	GenVec, Inc.
2052	granulocyte macrophage colony stimulating factor	n/a	8/27/2008	Treatment of cystic fibrosis	DrugRecure Aps
2053	granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF	n/a	7/24/2013	Treatment of soft tissue sarcoma	Oncos Therapeutics Ltd
2054	guanfacine	Tenex	8/5/1999	Treatment of fragile X syndrome.	Watson Laboratories, Inc.
2055	gusperimus trihydrochloride	n/a	6/29/2011	Treatment of Wegener's granulomatosis	Nordic Group B.V.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2056	glyceryl tri (4-pheynlybutyrate)	n/a	9/3/2009	For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.	Hyperion Therapeutics, Inc.
2057	hRS7-SN-38 IgG Conjugate	n/a	11/27/2013	Treatment of small cell lung cancer	Immunomedics, INc.
2058	halofuginone hydrobromide	n/a	10/13/2011	Treatment of Duchenne Muscular Dystrophy	Halo Theraeputics, LLC
2059	heat killed Mycobacterium w immunomodulator	Cadi Mw	9/3/2004	Active tuberculosis	Cadila Pharmaceuticals Limited, Inc.
2060	heat killed mycobacterium w immunomodulator	Cadi Mw	11/21/2002	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc.
2061	heat killed mycobacterium w immunomodulator	Cadi-Mw	7/31/2012	Treatment of non-small cell lung cancers that express desmocollin-3	Cadila Pharmaceuticals Limited
2062	heat killed whole cell mycobacterium obuense	n/a	9/23/2014	Treatment of pancreatic cancer	Immodulon Therapeutics Limited
2063	hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist	n/a	8/27/2014	Hematopoietic support in patients with acute lymphoblastic leukemia (ALL)	Novartis Pharmaceuticals Corporation
2064	heparan sulfate mimetic	n/a	5/29/2014	Treatment of pancreatic cancer	Momenta Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2065	heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device	n/a	10/24/2011	Treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(Scale A)	BioArctic Neuroscience AB
2066	hepatitis B immune globulin (human)	Hepagam	3/24/2008	Prevention of hepatitis B recurrence following orthotopic liver transplant	Cangene Corporation
2067	hepatitis B virus neutralizing human monoclonal antibody	Hepabig Gene	5/6/2013	Prevention of hepatitis B recurrence following liver transplantation	Green Cross Corp.
2068	hepcortespenlisimut-L	n/a	12/17/2014	Treatment of hepatocellular carcinoma	Immunitor, Inc.
2069	herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter	n/a	12/23/2014	Treatment of pancreatic cancer	Karcinolys S.A.S.
2070	heterologous human adult liver derived progenitor cells (HHALPC)	n/a	1/13/2012	Treatment of urea cycle disorders	Promethera Biosciences
2071	heterologous human liver derived progenitor cells	n/a	3/9/2012	Treatment of Crigler-Najjar syndrome	Promethera Biosciences
2072	hexasodium phytate	n/a	12/2/2012	Treatment of calciphylaxis	Laboratoris Sanifit, S.L.
2073	homoharringtonine	n/a	2/8/2002	Treatment for chronic myelogenous leukemia	American BioScience, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2074	human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein	n/a	5/11/2011	Treatment of acute liver failure	Alfact Innovation SAS
2075	human IgG1k monoclonal antibody	n/a	10/16/2013	Treatment of systemic sclerosis	MedImmune
2076	human MHC non-restricted cytotoxic T-cell line	n/a	7/6/2012	Treatment of ovarian cancer	Galileo Research srl
2077	human allogeneic bone marrow derived osteoblastic cells	Allob	1/10/2014	Treatment of osteonecrosis	Bone Therapeutics SA
2078	human anti-CD4 monoclonal antibody	Humax-Cd4	8/13/2004	Treatment of mycosis fungoides	Emergent Product Development Seattle, LLC
2079	human anti-cellular adhesion molecule-1 monoclonal antibody	n/a	7/29/2008	Treatment of multiple myeloma	BioInvent International AB
2080	human anti-transforming growth factor-B1,2,3	n/a	7/9/2004	Treatment of idiopathic pulmonary fibrosis	Genzyme Corporation
2081	human coagulation factor VIII	Octanate	12/3/2012	Immune tolerance induction in hemophilia A patients with inhibitors	OCTAPHARMA USA, Inc.
2082	human coagulation factor XI	Hemoleven	11/8/2007	Treatment of severe congenital Factor XI deficiency.	Laboratoire francais du Fractionnement et des Biot
2083	human fibrinogen concentrate, pasteurized	Riastap	3/13/2008	Treatment of fibrinogen deficient patients.	CSL Behring, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2084	human fully IgG1 antibody specific for CD33	n/a	6/19/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
2085	human gammaglobulin	Oralgam	5/25/2001	Treatment for juvenile rheumatoid arthritis	Latona Life Sciences, Inc.
2086	human gammaglobulin	Oralgam	9/16/2002	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.	Latona Life Sciences, Inc.
2087	human gammaglobulin	Oralgam	11/14/2003	Treatment of idiopathic inflammatory myopathies	Latona Life Sciences, Inc.
2088	human glial restricted progenitor cells and their progeny	Q-Cells	9/11/2013	Treatment of amyotrophic lateral sclerosis	Q Therapeutics, Inc.
2089	human haptoglobin	n/a	11/19/2013	Treatment of sickle cell disease	BioProducts Laboratory Limited
2090	human heterologous liver cells	n/a	2/14/2011	Treatment of urea cycle disorders	Cytonet GmbH & Co. KG
2091	human insulin (rDNA)	n/a	4/6/2015	Treatment of short bowel syndrome (SBS).	Nutrinia, Ltd.
2092	human insulin beta chain peptide with incomplete Freund's adjuvant vaccine	n/a	2/11/2013	Treatment of Type 1 diabetes patients with residual beta cell function	Orban Biotech, LLC
2093	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	6/6/2013	Treatment of blastic plasmacytoid dendritic cell neoplasm	Stemline Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2094	human interleukin-3 genetically conjugated to diphtheria toxin protein	n/a	2/18/2011	Treatment of acute myeloid leukemia.	Stemline Therapeutics, Inc.
2095	human laminin-111	n/a	9/23/2011	Treatment of merosin (laminin-alpha2) deficient congenital muscular dystrophy type 1A.	Prothelia, Inc.
2096	human leukocyte antigen-A2 restricted peptides	n/a	1/26/2015	Treatment of glioma.	Stemline Therapeutics, Inc.
2097	human leukocyte-derived cytokine mixture	n/a	7/7/2005	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	IRX Therapeutics, Inc.
2098	human monoclonal IgG2 to human proprotein convertase subtilisin/kexin type 9	n/a	9/12/2013	Treatment of homozygous familial hypercholesterolemia	Amgen Inc.
2099	human monoclonal anti-PA antibody	n/a	10/21/2010	For post-exposure prophylaxis and treatment of inhalation anthrax.	Emergent Product Development Gaithersburg, Inc.
2100	human monoclonal antibody against human interleukin 13 (IL-13)	n/a	10/15/2013	Treatment of eosinophilic esophagitis	Novartis Pharmaceuticals Corporation
2101	human monoclonal antibody directed against active plasma kallikrein	n/a	11/16/2013	Treatment of hereditary angioedema (HAE)	Dyax Corporation
2102	human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa	n/a	1/6/2010	Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa	Kenta Biotech Limited

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2103	human plasminogen	n/a	6/7/2010	Treatment of ligneous conjunctivitis	Kedrion, S.p.A.
2104	human platelet antigen-1a immunoglobulin (anti-HPA-1a)	Tromplate	6/27/2013	Prevention of fetal and neonatal alloimmune thrombocytopenia	Prophylix Pharma AS
2105	human recombinant DNA-derived, IgG1 kappa monoclonal anti-body to connective growth factor	n/a	7/6/2012	Treatment of idiopathic pulmonary fibrosis	FibroGen, Inc.
2106	human recombinant mesencephalic, astrocyte derived neurotrophic factor	n/a	12/22/2014	Treatment of retinitis pigmentosa	Amarantus BioScience Holdings, Inc.
2107	human retinal progenitor cells	n/a	7/23/2012	Treatment of retinitis pigmentosa	jCyte, Inc.
2108	human spinal cord derived neural stem cells	n/a	2/4/2011	Treatment of amyotrophic lateral sclerosis	Neuralstem, Inc.
2109	human trivalent, bi-specific monoclonal antibody that binds and co-inhibits two growth factor receptors; insulin-like growth factor receptor 1 (IGF-1R) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 (ErbB3)	n/a	10/22/2014	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2110	human tumor necrosis factor coupled to the C terminus of CNGRCG peptide	n/a	10/1/2009	Treatment of liver cancer	Molecular Medicine S.p.A. (Molmed)
2111	human umbilical cord blood-derived mesenchymal stem cells	Pneumostem	11/26/2013	Prevention of bronchopulmonary dysplasia	MEDIPOST America, Inc.
2112	humanized Fc engineered monoclonal antibody against CD19	n/a	4/29/2014	Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	MorphoSys AG
2113	humanized Fc engineered monoclonal antibody against CD19	n/a	12/1/2014	Treatment of diffuse large B-cell lymphoma.	MorphoSys AG
2114	humanized IgG1 anti-serum amyloid A monoclonal antibody	n/a	2/17/2012	Treatment of AA amyloidosis and AL amyloidosis	Prothena Therapeutics Limited
2115	humanized IgG1 monoclonal anti-CD20 antibody	n/a	5/26/2011	Treatment of follicular lymphoma	MENTRIK Biotech, LLC
2116	humanized IgG2 antibody	n/a	7/22/2008	Treatment of vaso-occlusive crisis in patients with sickle cell disease.	Selexys Pharmaceuticals Corp.
2117	humanized IgG4 monoclonal antibody	n/a	12/12/2011	Prevention of ischemia/reperfusion injury associated with solid organ transplantation	Opsona Therapeutics
2118	humanized anti-IL-6R receptor neutralizing IgG2 monoclonal antibody	n/a	6/30/2014	Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder	Chugai Pharma USA, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2119	humanized immunoglobulin monoclonal antibody against CD38	n/a	5/22/2014	Treatment of multiple myeloma.	Sanofi-Aventis U.S., LLC
2120	humanized monoclonal antibodies hu1B7 and hu11E6	n/a	9/11/2014	Treatment of Bordetella pertussis	Synthetic Biologics, Inc.
2121	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	8/5/2010	Treatment of idiopathic pulmonary fibrosis	Biogen Idec, Inc.
2122	humanized monoclonal antibody that targets the alpha-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473)	n/a	5/5/2015	Treatment of acute myeloid leukemia	Janssen Research & Development, LLC
2123	humanized monoclonal antibody to tissue factor	n/a	4/26/2011	Treatment of pancreatic cancer.	Morphotek, Inc.
2124	humanized monoclonal antibody against human integrin alphaVbeta6	n/a	6/18/2008	Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.	Stromedix, Inc.
2125	humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains)	n/a	11/17/2011	Treatment of chronic lymphocytic leukemia	Emergent Product Development Seattle, LLC
2126	humanized, afucosylated IgG1 kappa monoclonal antibody	n/a	12/3/2009	Treatment of scleroderma	MedImmune

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2127	hyaluronic acid	n/a	3/19/2002	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	CoTherix
2128	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of cutaneous T-cell lymphoma.	Neolpharma S.A.DE C.V.
2129	hydralazine - magnesium valproate	Transkrip(R)	3/17/2011	Treatment of myelodysplastic syndrome	Neolpharma S.A. de C.V.
2130	hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO)	n/a	3/9/2015	Treatment of amyotrophic lateral sclerosis.	Alsonex Pty Ltd
2131	hydrocortisone modified release capsules	Chronocort	3/18/2015	Treatment of congenital adrenal hyperpasia	Diurnal Limited
2132	hydrocortisone modified release tabs	Duocort	6/18/2008	Treatment of adrenal insufficiency	Shire ViroPharma, Inc.
2133	hydrocortisone oral granules	Infacort(R)	5/13/2015	Treatment of pediatric adrenal insufficiency (0 through 16 years of age).	Diurnal Limited
2134	hydroxycarbamide (hydroxyurea)	Siklos	7/24/2013	Treatment of sickle cell disease in patients under 18 years of age	addmedica Laboratories
2135	hydroxyprogesterone caproate	Makena	1/25/2007	Prevention of preterm birth in singleton pregnancies	KV Pharmaceutical Company
2136	hydroxyurea	Pedroxa	3/16/2015	Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.	Ebelle D'Ebelle Pharmaceuticals LLC
2137	hydroxyurea	n/a	4/15/2005	Treatment of pediatric patients with sickle cell anemia.	UPM Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2138	ibalizumab	n/a	10/20/2014	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	TaiMed Biologics, Inc.
2139	ibritumomab tiuxetan	Zevalin	9/6/1994	Treatment of B-cell non-Hodgkin's lymphoma.	Spectrum Pharmaceuticals, Inc.
2140	ibrutinib	Imbruvica	2/5/2015	Treatment of nodal marginal zone lymphoma	Pharmacyclics, Inc.
2141	ibrutinib	Imbruvica	2/5/2015	Treatment of splenic marginal zone lymphoma	Pharmacyclics, Inc.
2142	ibrutinib	Imbruvica	4/6/2012	Treatment of chronic lymphocytic leukemia (CLL)	Pharmacyclics, Inc.
2143	ibrutinib	Imbruvica	12/3/2012	Treatment of mantle cell lymphoma	Pharmacyclics, Inc.
2144	ibrutinib	n/a	5/16/2013	Treatment of multiple myeloma	Pharmacyclics, Inc.
2145	ibrutinib	n/a	5/30/2013	Treatment of small lymphocytic lymphoma	Pharmacyclics, Inc.
2146	ibrutinib	n/a	10/23/2013	Treatment of diffuse large B-cell lymphoma	Pharmacyclics, Inc.
2147	ibrutinib	Imbruvica	10/15/2013	Treatment of Waldenstrom's macroglobulinemia	Pharmacyclics, Inc.
2148	ibrutinib	n/a	9/8/2014	Treatment of follicular lymphoma	Pharmacyclics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2149	icatibant	Firazyr	11/25/2003	Treatment of angioedema	Shire Orphan Therapies
2150	idebenone	n/a	2/16/2007	Treatment of Duchenne muscular dystrophy	Santhera Pharmaceuticals Limited
2151	idebenone	n/a	10/31/2006	Treatment of Leber's hereditary optic neuropathy.	Santhera Pharmaceuticals Limited
2152	idebenone	n/a	5/22/2009	Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)	Santhera Pharmaceuticals Limited
2153	idebenone	n/a	3/25/2004	Treatment of Friedreich's ataxia	Santhera Pharmaceuticals LLC
2154	idelalisib	n/a	10/15/2013	Treatment of nodal marginal zone lymphoma.	Gilead Sciences, Inc.
2155	idelalisib	n/a	10/15/2013	Treatment of extranodal marginal zone lymphoma	Gilead Sciences, Inc.
2156	idelalisib	Zydelig	9/26/2013	Treatment of follicular lymphoma	Gilead Sciences, Inc.
2157	idelalisib	n/a	9/26/2013	Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia	Gilead Sciences, Inc.
2158	idelalisib	Zydelig	10/15/2013	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Gilead Sciences, Inc

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2159	idelalisib	n/a	10/15/2013	Treatment of splenic marginal zone lymphoma	Gilead Sciences, Inc.
2160	idelalisib	n/a	8/25/2011	Treatment of chronic lymphocytic leukemia	Gilead Sciences, Inc.
2161	idursulfase	Elaprase	11/28/2001	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Shire Human Genetic Therapies, Inc.
2162	idursulfase IT	n/a	9/3/2009	For treatment of neurocognitive symptoms associated with Hunter Syndrome	Shire Human Genetic Therapies
2163	idursulfase beta	n/a	2/11/2013	Treatment of Hunter Syndrome (mucopolysaccharidoses)	Green Cross Corp.
2164	iduvec	n/a	1/21/2011	Treatment of Mucopolysaccharidosis Type I	Zebraic Corporation
2165	iferanserin (S-MPEC)	n/a	12/13/2010	For use in pulmonary arterial hypertension.	Sam Amer & Company, Inc.
2166	iloprost	n/a	4/6/2012	Treatment of pulmonary arterial hypertension	Algorithm Sciences, LLC
2167	imatinib	Gleevec	10/11/2005	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Novartis Pharmaceuticals Corporation
2168	imatinib mesylate	Gleevec	12/19/2005	Treatment of dermatofibrosarcoma protuberans	Novartis Pharmaceuticals Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2169	imatinib mesylate	Gleevec	11/1/2001	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp.
2170	imatinib mesylate	n/a	5/6/2014	Treatment of progressive multifocal leukencephalopathy	Inhibikase Therapeutics, Inc.
2171	imexon	Amplimexon	8/12/2005	Treatment of ovarian cancer.	AmpliMed Corporation
2172	immune globulin (human)	n/a	3/2/2010	Treatment of Guillain-Barre syndrome	Octapharma USA, Inc.
2173	immune globulin infusion (human)	Gammagard Liquid	7/20/2006	Treatment of multifocal motor neuropathy	Baxter Healthcare Corporation
2174	immune globulin intravenous (human)	Gammaplex	4/29/2011	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Bio Products Laboratory
2175	inBreath airway transplant system	n/a	9/4/2014	To restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection	Harvard Apparatus Regenerative Technology, Inc.
2176	infliximab	Remicade	11/14/1995	Treatment of Crohn's disease	Centocor, Inc.
2177	infliximab	Remicade	11/12/2003	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Janssen Biotech Inc.
2178	infliximab	Remicade	10/23/2002	Treatment of juvenile rheumatoid arthritis	Centocor, Inc.
2179	inhibitor of microRNA-451	n/a	2/4/2011	Treatment of polycythemia vera	miRagen Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2180	inolimomab	Leukotac	10/23/2002	Treatment of graft versus host disease	Jazz Pharmaceuticals
2181	inotuzumab ozogamicin	n/a	3/25/2013	Treatment of B-cell acute lymphoblastic leukemia	Pfizer, Inc.
2182	insecticidal toxin derived from Bacillus thuringiensis	n/a	9/5/2008	Treatment of soil transmitted helminth infection strongyloidiasis	University of California, San Diego
2183	interferon gamma	n/a	11/4/2011	Treatment of Friedreich's ataxia	Roberto Testi, MD
2184	interferon gamma-1b	Actimmune	10/1/2014	Treatment of Friedreich's Ataxia	Horizon Pharma Ireland Limited
2185	interferon-alpha secreting autologous micro-organ tissue converting into a biopump	Infradure Biopump	6/14/2012	Treatment of chronic hepatitis D	Medgenics, Inc.
2186	intravenous carbamazepine	n/a	6/27/2013	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Lundbeck, LLC
2187	iobenguane I 131	n/a	7/5/2007	Treatment of neuroendocrine tumors	Jubilant DraxImage, Inc.
2188	iobenguane sulfate I-123	Omaclear	10/21/2005	For the detection, localization, and staging of pheochromocytomas.	Brogan Pharmaceuticals, Inc.
2189	ipilimumab	Yervoy	6/3/2004	Treatment of high risk Stage II, Stage III, and Stage IV melanoma	Bristol-Myers Squibb Pharmaceutical Research Insti

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2190	iron(III)-hexacyanoferrate(II)	Radiogardase	5/1/2003	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG
2191	isavuconazonium sulfate	n/a	5/6/2013	Treatment of invasive aspergillosis	Astellas Pharma Global Development Inc.
2192	isavuconazonium sulfate	n/a	10/25/2013	Treatment of zygomycosis	Astellas Pharma Global Development, Inc.
2193	isavuconazonium sulfate	n/a	10/20/2014	Treatment of invasive candidiasis/candidemia	Astellas Pharma Global Development, Inc.
2194	isocitrate dehydrogenase 2-mutant inhibitor	n/a	6/12/2014	Treatment of acute myelogenous leukemia	Celgene Corporation
2195	isofagomine tartrate	n/a	1/10/2006	Treatment of Gaucher disease	Amicus Therapeutics, Inc.
2196	isotretinoin	n/a	4/10/2014	Treatment of congenital ichthyosis	Patagonia Pharmaceuticals, LLC
2197	ivacaftor	Kalydeco	12/20/2006	Treatment of patients with cystic fibrosis	Vertex Pharmaceuticals, Inc.
2198	ixazomib citrate	n/a	2/18/2011	Treatment of multiple myeloma	Millennium Pharmaceuticals
2199	ketotifen	n/a	2/25/2015	Treatment of mastocytosis	Melbourne Laboratories LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2200	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococci)	n/a	1/15/2002	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc.
2201	lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	n/a	1/15/2002	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc.
2202	lactobacillus brevis CD2	n/a	10/4/2011	Treatment Behcet's disease	VSL Pharmaceuticals, Inc.
2203	laminin-111 (human)	n/a	7/21/2011	Treatment of Duchenne Muscular Dystrophy	Prothelia, Inc.
2204	lanreotide acetate	n/a	9/8/2011	Treatment of symptoms associated with carcinoid syndrome	Ipsen Biopharmaceuticals, Inc.
2205	lanreotide acetate	Somatuline Depot	8/25/2011	Treatment of neuroendocrine tumors	Ipsen Biopharmaceuticals, Inc.
2206	lapatinib	Tykerb	5/29/2009	Treatment of ErbB2 positive gastric cancer	Novartis Pharmaceuticals Corp
2207	lapatinib ditosylate hydrochloride	Tykerb	5/29/2009	Treatment of ErbB2 positive esophageal cancer	Novartis Pharmaceuticals Corp.
2208	laromustine	Onrigin	10/21/2004	Treatment of acute myelogenous leukemia	Vion Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2209	laronidase	Aldurazyme	9/24/1997	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc.
2210	late stage human motor neuron progenitors	Motorgraft(Tm)	11/25/2009	Treatment of spinal muscular atrophy	California Stem Cell, Inc.
2211	lebrikizumab	n/a	3/9/2015	Treatment of idiopathic pulmonary fibrosis	Genentech, Inc.
2212	lenalidomide	Revlimid	3/28/2011	Treatment of diffuse large B-cell lymphoma	Celgene Corporation
2213	lenalidomide	Revlimid	1/17/2007	Treatment of chronic lymphocytic leukemia	Celgene Corporation
2214	lenalidomide	Revlimid	4/27/2009	Treatment of mantle cell lymphoma	Celgene Corporation
2215	lenalidomide	Revlimid(R)	4/29/2015	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.	Celgene Corporation
2216	lenalidomide	Revlimid	9/20/2001	Treatment of multiple myeloma	Celgene Corporation
2217	lenalidomide	Revlimid	9/13/2013	Treatment of follicular lymphoma	Celgene Corporation
2218	lenalidomide	Revlimid	1/29/2004	Treatment of myelodysplastic syndromes	Celgene Corporation
2219	lenvatinib	n/a	3/26/2014	Treatment of stage IIB to Stage IV melanoma	Eisai, Inc.
2220	lenvatinib	Lenvima	12/27/2012	Treatment of follicular, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer	Eisai, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2221	lenvatinib	n/a	3/27/2014	Treatment of hepatocellular carcinoma	Eisai, Inc.
2222	lestaurtinib	n/a	9/3/2009	Treatment of Philadelphia-negative classic myeloproliferative disorders	Teva Branded Pharmaceutical Products R&D, Inc.
2223	letermovir	n/a	12/12/2011	Prevention of human cytomegalovirus viremia and disease in at risk populations	Merck Sharpe & Dhome Corporation
2224	leukocyte interleukin	Multikine	5/4/2007	Neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck	CEL-SCI Corporation
2225	leukotriene A4 hydrolase inhibitor	n/a	1/26/2015	Treatment of cystic fibrosis	Celtaxsys, Inc.
2226	levetiracetam	Keppra	4/30/2010	Treatment of neonatal seizures	University of California
2227	levoleucovorin	Fusilev	12/18/1990	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Spectrum Pharmaceuticals, Inc.
2228	levomefolate calcium	n/a	2/10/2015	Treatment of megaloblastic anemia caused by folate deficiency	Cox Biosciences LLC
2229	levothyroxine sodium	n/a	4/26/2011	The preservation of organ function in brain-dead organ donors.	Fera Pharmaceuticals, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2230	liarozole	n/a	6/18/2004	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
2231	liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide	n/a	4/27/2015	Treatment of acute myeloid leukemia	Bio-Path Holdings, Inc.
2232	liposomal amikacin	Arikace	3/25/2013	Treatment infections caused by non-tuberculous mycobacteria	Insmed Incorporated
2233	liposomal amikacin	Arikace	8/25/2009	Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens	Insmed, Inc.
2234	liposomal busulfan	Busulipo	6/24/2013	For use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation	Pharmalink AB
2235	liposomal ciprofloxacin plus ciprofloxacin	n/a	6/1/2012	For the management of cystic fibrosis	Aradigm Corporation
2236	liposomal cyclosporine	n/a	5/11/2009	Treatment of bronchiolitis obliterans	PARI Pharma GmbH
2237	liposomal cyclosporine for inhalation	n/a	6/24/2008	Prevention of bronchiolitis obliterans.	PARI Pharma GmbH
2238	liposomal encapsulated paclitaxel	n/a	1/21/2015	Treatment of ovarian cancer	Insys Therapeutics, Inc.
2239	liposomal gadodiamide	n/a	11/12/2008	Treatment of glioma.	MedGenesis Therapeutix, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2240	liposomal irinotecan	n/a	7/21/2011	Treatment of pancreatic cancer	Merrimack Pharmaceuticals, Inc.
2241	liposomal p-ethoxy growth receptor bound protein-2 antisense product	n/a	12/5/2003	Treatment of chronic myelogenous leukemia	Bio-Path, Inc.
2242	liposomal topotecan hydrochloride	n/a	10/30/2008	Treatment of gliomas	MedGenesis Therapeutix, Inc.
2243	liposomal α -galactosylceramide	Lip. Alpha Galactosylceramide	9/28/2012	Prevention of graft-versus-host disease	REGiMMUNE Corporation
2244	liposome encapsulated paclitaxel	n/a	12/3/2014	Treatment of gastric cancer	Insys Therapeutics, Inc.
2245	lisinopril oral solution	n/a	1/27/2015	Treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age)	BioRamo, LLC
2246	listeria monocytogenes	n/a	9/5/2013	Treatment of pancreatic cancer	Aduro BioTech, Inc.
2247	lisuride	n/a	1/17/2013	Treatment of pulmonary arterial hypertension	Sinova Pharma GmbH
2248	lithium citrate tetrahydrate (in reverse micelle formulation)	n/a	12/13/2010	Treatment of Huntington's disease.	Medesis Pharma
2249	live attenuated E. Coli expressing Beta catenin shRNA	n/a	12/20/2010	Treatment of Familial Adenomatous Polyposis	Marina Biotech

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2250	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	11/4/2013	Treatment of human papilloma virus-associated head and neck cancer	Advaxis, Inc.
2251	live attenuated bioengineered Listeria monocytogenes immunotherapy	n/a	5/21/2014	Treatment of osteosarcoma.	Advaxis, Inc.
2252	lomitapide	n/a	3/3/2011	Treatment of Familial Chylomicronemia	Aegerion Pharmaceuticals, Inc.
2253	lomitapide	Juxtapid	10/23/2007	Treatment of homozygous familial hypercholesterolemia	Aegerion Pharmaceuticals, Inc.
2254	lonafarnib	n/a	4/18/2011	Treatment of Hutchinson-Gilford progeria syndrome	The Progeria Research Foundation, Inc.
2255	long acting recombinantFactor VIIa-CTP3	n/a	2/27/2014	Treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX	PROLOR Biotech, Ltd
2256	losartan	n/a	12/12/2011	Treatment of Marfan Syndrome	National Marfan Foundation
2257	low molecular weight dextran sulfate	lbsolvmir(R)	7/6/2011	Treatment to mobilze progenitor cells prior to stem cell transplantation	TikoMed AB
2258	low molecular weight dextran sulfate	lbsolvmir	10/20/2009	Prevention of graft rejection during pancreatic islet transplantation	TikoMed AB

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2259	lumacaftor and ivacaftor	n/a	6/30/2014	Treatment of cystic fibrosis	Vertex Pharmaceuticals Inc.
2260	lurbinectedin	n/a	8/20/2012	Treatment of ovarian cancer	Pharma Mar USA Inc.
2261	lutetium (177Lu)-edotreotide	n/a	5/21/2015	Treatment of gastro-entero-pancreatic neuroendocrine tumors	ITG Isotope Technologies Garching GmbH
2262	lyso-thermosensitive liposomal doxorubicin	Thermodox (R)	3/17/2009	Treatment of hepatocellular carcinoma	Celsion Corporation
2263	lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase	n/a	9/10/2008	Treatment of mucopolysaccharidosis Type IVA (Morquio Syndrome)	Vivendy Therapeutics LTD
2264	mPEG-r-crisantaspase	Asparec(Tm)	2/1/2010	Treatment of acute lymphoblastic leukemia.	Jazz Pharmaceuticals, Inc.
2265	mTOR kinase inhibitor (CC-223)	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Celgene Corporation
2266	macitentan	Opsumit	9/3/2009	Treatment of pulmonary arterial hypertension	Actelion Pharmaceuticals Ltd

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2267	manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption)	n/a	9/26/2013	Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be administered	CMC Contrast AB
2268	mannopentaose phosphate sulfate	n/a	4/27/2004	Treatment of high-risk Stage II, Stage III, and Stage IV melanoma	Medigen Biotechnology Corp.
2269	maribavir	n/a	6/7/2011	Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.	Shire ViroPharma, Inc.
2270	maribavir	n/a	2/1/2007	Prevention of cytomegalovirus viremia and disease in the populations at risk.	Shire ViroPharma, Inc.
2271	masitinib	n/a	7/21/2009	Treatment of patients with pancreatic cancer	AB Science
2272	masitinib	n/a	4/20/2005	Treatment of malignant gastrointestinal stromal tumors	AB Science
2273	masitinib mesylate	n/a	3/18/2015	Treatment of amyotrophic lateral sclerosis.	AB Science

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2274	maytansinoid conjugated humanized monoclonal antibody against FOLRI	n/a	7/14/2014	Treatment of ovarian cancer	ImmunoGen, Inc.
2275	mebendazole	Vermox 500 Mg Chewable Tablets	9/3/2014	Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).	Janssen Pharmaceutical Research & Development, LLC
2276	mecasermin	Iplex	12/3/2007	Treatment of myotonic dystrophy	Insmed, Inc.
2277	mecasermin rinfabate	Iplex	5/17/2002	Treatment of growth hormone insensitivity syndrome (GHIS)	Insmed, Inc.
2278	mecasermin rinfabate	Iplex	7/23/2012	Treatment of amyotrophic lateral sclerosis	PCUT BioPartners, Inc.
2279	mecasermin rinfabate	n/a	9/20/2012	Prevention of retinopathy of prematurity in premature infants born at risk for the disease	Premacure AB
2280	meclizethamine	Valchlor	8/17/2004	Treatment of mycosis fungoides	Actelion Pharmaceuticals Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2281	mefloquine HCL	Lariam	4/13/1988	For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Hoffmann-La Roche, Inc.
2282	melarsoprol-hydroxypropylbetadex	n/a	9/13/2013	Treatment of human African trypanosomiasis (sleeping sickness)	Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,
2283	melatonin	n/a	4/12/2013	Treatment of neonatal hypoxic ischemic encephalopathy	Scharper S.p.A.
2284	meloxicam	Mobic	11/22/2002	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc.
2285	melphalan	n/a	11/19/2012	Treatment of retinoblastoma	Icon Bioscience, Inc.
2286	melphalan	n/a	11/19/2012	Treatment of Stage IIB through IV melanoma	OncoTx, LLC
2287	melphalan	n/a	11/24/2008	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Spectrum Pharmaceuticals, INC.
2288	melphalan flufenamide hydrochloride	n/a	3/16/2015	Treatment of plasma cell myeloma, also referred to as multiple myeloma	Oncopeptides AB

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2289	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with cutaneous melanoma.	Delcath Systems, Inc.
2290	melphalan hydrochloride	n/a	5/22/2009	Treatment of neuroendocrine tumors	Delcath Systems, Inc.
2291	melphalan hydrochloride	n/a	11/12/2008	Treatment of patients with ocular (uveal) melanoma.	Delcath Systems, Inc.
2292	melphalan hydrochloride	n/a	9/26/2013	Treatment of patients with hepatocellular carcinoma	Delcath Systems, Inc.
2293	menadione sodium bisulfite	n/a	5/14/2014	Treatment of autosomal dominant polycystic liver disease	IC-MedTech Corporation
2294	menaquinone	Menaquinonegold	9/4/2012	Treatment of calciphylaxis	Nu Science Trading, LLC
2295	menatetrenone	Mk4(R)	2/4/2011	Treatment of myelodysplastic syndrome.	NBI Pharmaceuticals, Inc.
2296	menatetrenone	Mk4	3/17/2011	Treatment of acute myeloid leukemia	NBI Pharmaceuticals, Inc.
2297	menatetrenone	Mk4(R)	11/2/2010	Treatment of acute promyelocytic leukemia.	NBI Pharmaceuticals, Inc.
2298	menatetrenone	Mk4(R)	11/2/2010	Treatment of hepatocellular carcinoma (HCC).	NBI Pharmaceuticals, Inc.
2299	menatetrenone and Vitamin D3	n/a	8/22/2011	Treatment of myelodysplastic syndrome	NBI Pharmaceuticals, Inc.
2300	mepivacaine	n/a	10/18/2006	Treatment of painful HIV-associated neuropathy	Relmada Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2301	mepivacaine	n/a	1/8/2007	Treatment of postherpetic neuralgia	Relmada Therapeutics, Inc.
2302	mepolizumab	n/a	5/28/2004	For first-line treatment in patients with hypereosinophilic syndrome	GlaxoSmithKline LLC
2303	mepolizumab	n/a	7/14/2011	Treatment of Churg-Strauss Syndrome.	GlaxoSmithKline LLC
2304	mercaptopurine oral solution	Purixan	8/20/2012	Treatment of acute lymphoblastic leukemia in pediatric patients	Nova Laboratories Limited
2305	mesalamine	Canasa	1/19/2010	Treatment of pediatric ulcerative colitis	Aptalis Pharma US, Inc.
2306	mesalamine and N-acetylcysteine	n/a	9/10/2009	Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years)	Altheus Therapeutics, Inc.
2307	mesalamine; 5-aminosalicylic acid	Lialda	2/27/2008	Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).	Shire
2308	mesenchymal stromal cells secreting neurotrophic factors	Nurown	2/4/2011	Treatment of Amyotrophic Lateral Sclerosis	BrainStorm Cell Therapeutics Ltd.
2309	met-enkephalin; Met-N	n/a	2/18/2011	Treatment of pancreatic cancer.	NBI Pharmaceuticals, Inc.
2310	metadoxine	n/a	12/16/2013	Treatment of Fragile X Syndrome	Alcobra, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2311	metformin	n/a	5/29/2014	Treatment of pediatric polycystic ovary syndrome	EffRx Pharmaceuticals SA
2312	methotrexate	n/a	8/20/2009	Treatment of acute lymphoblastic leukemia	Orbona Pharma Ltd
2313	methotrexate oral liquid formulation	n/a	3/18/2015	Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.	Chesapeake Therapeutics
2314	methylene blue	n/a	7/24/2012	Treatment of methemoglobinemia	Fera Pharmaceuticals, LLC
2315	methylene blue injection	n/a	8/11/2012	Treatment of congenital and acquired methemoglobinemia	Luitpold Pharmaceuticals, Inc.
2316	methylene blue0.5%	n/a	12/18/2012	Treatment of hereditary and acquired methemoglobinemia	Provepharm SAS
2317	methylparaben suberohydroxamic acid phenyl ester	n/a	4/15/2013	Treatment of cutaneous T-cell lymphoma	TetraLogic Pharmaceuticals
2318	metreleptin	n/a	8/22/2001	Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy	Aegerion Pharmaceuticals, Inc.
2319	metreleptin	Myalept	8/22/2001	Treatment of metabolic disorders secondary to lipodystrophy	Aegerion Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2320	metronidazole	n/a	9/17/2008	Treatment of pouchitis	Formac Pharmaceuticals, NV
2321	metronidazole	n/a	4/26/2011	Treatment of pouchitis.	S.L.A. Pharma Limited (UK)
2322	metyrapone	n/a	9/25/2012	Treatment of Cushing's syndrome	Laboratoire HRA Pharma
2323	metyrosine	Demser	7/25/2008	Treatment of velocardiofacial syndrome associated psychosis.	Cerberus Princeton, LLC
2324	mexiletine	n/a	9/2/2010	Treatment of nondystrophic myotonia	University of Rochester Medical Center
2325	mibefradil	n/a	8/25/2009	Treatment of glioblastoma multiforme.	Cavion, LLC
2326	mibefradil	n/a	10/16/2008	Treatment of pancreatic cancer.	Cavion, LLC
2327	mibefradil	n/a	6/15/2007	Treatment of ovarian cancer	Cavion, LLC
2328	miconazole	n/a	5/22/2014	Treatment of fungal otitis externa (otomycosis)	Hill Dermaceuticals, Inc.
2329	midazolam	n/a	10/20/2009	Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)	Upsher-Smith Laboratories, Inc.
2330	midazolam	n/a	7/24/2012	Treatment of nerve agent-induced seizures	Meridian Medical Technologies, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2331	midazolam	n/a	5/8/2006	Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam	UCB, Inc
2332	mifamuritide	Junovan	6/5/2001	Treatment of osteosarcoma	Millennium Pharmaceuticals, Inc.
2333	mifepristone	Korlym	7/5/2007	Treatment of the clinical manifestations of endogenous Cushing's syndrome	Corcept Therapeutics, Inc.
2334	migalastat hydrochloride	n/a	2/25/2004	Treatment of Fabry Disease	Amicus Therapeutics, Inc.
2335	miglustat	Zavesca	5/29/1998	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd
2336	miglustat	Zavesca (R)	11/12/2008	Treatment of the neurological manifestations of Niemann-Pick disease, type C.	Actelion Pharmaceuticals Ltd
2337	milatuzumab	n/a	6/24/2008	Treatment of chronic lymphocytic leukemia.	Immunomedics, Inc.
2338	milatuzumab	n/a	3/10/2008	Treatment of multiple myeloma	Immunomedics, Inc.
2339	milciclib maleate	n/a	9/20/2012	Treatment of thymic epithelial tumors.	Nerviano Medical Sciences S.r.l.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2340	miltefosine	Miltex/Impavido	3/18/2009	Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma	ExperGen Drug Development GmbH
2341	miltefosine	Impavido	10/10/2006	Treatment of leishmaniasis.	Knight Therapeutics (USA)
2342	mipomersen	Kynamro	5/23/2006	Treatment of homozygous familial hypercholesterolemia	Genzyme Corporation
2343	misoprostol	Gymiso	1/10/2005	Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.	Gynuity Health Projects, LLC
2344	mitomycin	n/a	6/1/2011	Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy	Mobius Therapeutics, LLC
2345	mitomycin	n/a	1/13/2011	Prevention of recurrence of pterygium after its surgical excision.	Mobius Therapeutics, LLC
2346	mitomycin	Mitogel	9/8/2014	Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter)	TheraCoat, Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2347	mitomycin-C	Mitosol	1/8/2008	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	Mobius Therapeutics, LLC
2348	mocetinostat	n/a	8/7/2014	Treatment of diffuse large B-cell lymphoma	Mirati Therapeutics, Inc.
2349	modified human papillomavirus capsid protein conjugated to a near infrared dye	n/a	4/8/2015	Treatment of uveal melanoma	Aura Biosciences, Inc.
2350	modified recombinant human C-type natriuretic peptide (CNP)	n/a	1/17/2013	Treatment of achondroplasia	BioMarin Pharmaceutical, Inc.
2351	modified recombinant human Factor VIIa (rFVIIa) molecule	n/a	5/30/2013	Treatment of bleeding episodes in hemophilia A or B subjects with inhibitors	Bayer HealthCare Pharmaceuticals, Inc.
2352	modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain	n/a	8/20/2012	Treatment of inherited mitochondrial respiratory chain disease	Gencia Corporation
2353	mogamulizumab	n/a	11/2/2010	Treatment of patients with cutaneous T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.
2354	mogamulizumab	n/a	11/2/2010	Treatment of peripheral T-cell lymphoma.	Kyowa Hakko Kirin Pharma, Inc.
2355	mogamulizumab	n/a	7/14/2011	Treatment of adult T-cell leukemia/lymphoma (ATLL).	Kyowa Hakko Kirin Pharma, Inc.
2356	monarsen	n/a	11/14/2003	Treatment of myasthenia gravis	Bioline Rx, Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2357	monoclonal antibody	n/a	1/21/2011	Prevention of congenital cytomegalovirus (CMV)infection following primary CMV infection in pregnant women.	Theraclone Sciences
2358	monoclonal antibody 11-1F4	n/a	12/7/2009	For use as a radioimaging agent in amyloidosis	Alan Solomon, M.D.
2359	monoclonal antibody 11-1F4	n/a	12/11/2009	For use as a therapeutic agent for patients AL amyloidosis.	Alan Solomon, M.D.
2360	monoclonal antibody 3F8	n/a	10/16/2008	Treatment of neuroblastoma	United Therapeutics Corporation
2361	monoclonal antibody Hu3F8	n/a	1/10/2014	Treatment of osteosarcoma	Memorial Sloan-Kettering Cancer Center
2362	monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus	n/a	8/25/2014	Treatment of Ebola virus infection	LeafBio, Inc.
2363	monoclonal antibody directed at hepatitis C virus E2 glycoprotein	n/a	11/4/2013	Prevention of Hepatitis C recurrence in patients receiving liver transplantation	MassBiologics-University of MA Medical School
2364	monoclonal antibody targeting eotaxin-2	n/a	1/6/2015	Treatment of systemic sclerosis	ChemomAb, Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2365	monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C	n/a	7/29/2014	Treatment of pancreatic cancer.	Millennium Pharmaceuticals, Inc.
2366	motexafin gadolinium	Xcytrin	1/27/2003	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc.
2367	mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37	n/a	3/24/2015	Treatment of chronic lymphocytic leukemia (CLL).	Boehringer Ingelheim Pharmaceuticals, Inc.
2368	mouse-human chimeric monoclonal anti-GD2 IgG1 antibody	n/a	9/20/2012	Treatment of neuroblastoma.	APEIRON Biologics AG
2369	moxetumomab pasudotox	n/a	11/15/2007	Treatment of CD22-positive chronic lymphocytic leukemia	MedImmune, LLC
2370	moxetumomab pasudotox	n/a	6/28/2013	Treatment of acute lymphoblastic leukemia	MedImmune, LLC
2371	moxetumomab pasudotox	n/a	11/15/2007	Treatment of hairy cell leukemia	MedImmune, LLC
2372	moxidectin	n/a	9/29/2010	Treatment of onchocerciasis volvulus in children and adults.	Medicines Development Limited

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2373	multi-vitamin infusion without vitamin K	M.V.I.-12	3/8/2004	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Mayne Pharma (USA) Inc.
2374	murine monoclonal antibody against CD26	Begedina	2/18/2011	Treatment of graft versus host disease	Adienne S.A.
2375	mycobacterium vaccae	n/a	8/20/2010	Treatment of tuberculosis	Immodulon Therapeutics Ltd
2376	myo-inositol	n/a	4/7/2005	Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity	Abbott Nutrition
2377	nabumetone	n/a	5/5/2008	Treatment of pediatric juvenile rheumatoid arthritis	Cook Pharma
2378	naloxone	n/a	11/23/2010	Topical treatment of pruritus associated with mycosis fungoides	Elorac, Inc.
2379	naltrexone	n/a	2/23/2015	Treatment of postherpetic neuralgia	Allodynic Therapeutics, LLC
2380	naltrexone	n/a	1/19/2010	Treatment of Crohn's disease in pediatric patients	TNI BioTech, Inc.
2381	naltrexone	n/a	1/13/2015	Treatment of autoimmune hepatitis	TaiwanJ Pharmaceuticals Co., Ltd.
2382	naltrexone/clonidine combination	n/a	4/14/2014	Treatment of postherpetic neuralgia	Allodynic Therapeutics LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2383	naproxcinod	n/a	3/16/2015	Treatment of Duchenne muscular dystrophy.	Nicox SA
2384	natural human lymphoblastoid interferon-alpha	n/a	11/18/2002	Treatment of polycythemia vera	Amarillo Biosciences, Inc.
2385	nelarabine	n/a	9/2/1999	Treatment of chronic lymphocytic leukemia.	Novartis Pharmaceuticals Corp.
2386	nelarabine	Arranon	8/10/2004	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Novartis Pharmaceuticals Corp.
2387	neostigmine	n/a	3/18/2013	Treatment of acute colonic pseudo-obstruction	Luitpold Pharmaceuticals, Inc.
2388	neostigmine methylsulfate	n/a	2/17/2012	Treatment of Myasthenia Gravis	Luitpold Pharmaceuticals, Inc.
2389	neridronate	n/a	3/25/2013	Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)	Grunenthal USA, Inc.
2390	nevirapine	n/a	11/25/2009	Prevention of HIV infection in pediatric patients under the age of 16 years	Auritec Pharmaceuticals
2391	nifurtimox	n/a	12/31/2013	Treatment of Chagas disease	MetronomX Therapeutics, LLC
2392	nifurtimox	Lampit	8/5/2010	Treatment of Chagas disease (American Typanosomiasis) caused by T. cruzi	Bayer HealthCare Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2393	nilotinib	Tasigna	4/27/2006	Treatment of chronic myelogenous leukemia	Novartis Pharmaceutical Corporation
2394	nimodipine	Nymalize	9/16/2011	Treatment of subarachnoid hemorrhage.	Arbor Pharmaceuticals, Inc.
2395	nintedanib	Ofev	6/29/2011	Treatment of patients with idiopathic pulmonary fibrosis.	Boehringer Ingelheim Pharmaceuticals, Inc.
2396	niprisan	Hemoxin	8/15/2003	Treatment of sickle cell disease	Xechem International, Inc.
2397	niraparib	n/a	4/30/2010	Treatment of ovarian cancer	TESARO, Inc.
2398	nitazoxanide	Alinia	2/14/2002	Treatment of intestinal giardiasis	Romark Laboratories, L.C.
2399	nitazoxanide	Cryptaz	10/23/2001	Treatment for intestinal amebiasis	Romark Laboratories, L.C.
2400	nitric oxide	Inomax (R)	9/5/2008	Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises)	INO Therapeutics
2401	nitric oxide	Inomax	12/28/2011	Treatment of pulmonary arterial hypertension	Bellerophon Therapeutics
2402	nitric oxide	n/a	9/23/2014	Treatment of cystic fibrosis	Advanced Inhalation Therapies Ltd.
2403	nitric oxide	n/a	6/18/2012	Treatment of persistent pulmonary hypertension in newborns	GeNO, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2404	nivolumab	n/a	8/7/2014	Treatment of Hodgkin lymphoma	Bristol-Myers Squibb Co.
2405	nivolumab	n/a	1/23/2013	Treatment of Stage IIb to IV melanoma	Bristol-Myers Squibb Co.
2406	non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I	n/a	12/15/2014	Treatment of hypoparathyroidism	Chugai Pharma USA, LLC
2407	non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene	At001	12/3/2014	Treatment of x-linked myotubular myopathy	Audentes Therapeutics, Inc.
2408	non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein	n/a	10/20/2014	Treatment of retinitis pigmentosa	RetroSense Therapeutics, LLC
2409	obeticholic acid	n/a	4/9/2008	Treatment of primary biliary cirrhosis	Intercept Pharmaceuticals, Inc.
2410	obinutuzumab	Gazyva(R)	4/15/2015	Treatment of follicular lymphoma	Genentech, Inc.
2411	obinutuzumab	n/a	2/17/2012	Treatment of diffuse large B cell lymphoma	Genentech, Inc.
2412	obinutuzumab	Gazyva	2/17/2012	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2413	oblimersen	Genasense	8/28/2001	Treatment of acute myelocytic leukemia	Genta Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2414	oblimersen	Genasense	7/31/2000	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc.
2415	oblimersen	Genasense	8/28/2001	Treatment of multiple myeloma	Genta, Inc.
2416	oblimersen	Genasense	8/28/2001	Treatment of chronic lymphocytic leukemia	Genta, Inc,
2417	octreotide	Sandostatin Lar	8/5/2010	Treatment of neuroendocrine tumors	Novartis Pharmaceuticals Corporation
2418	octreotide (oral)	Octreolin(Tm)	6/17/2010	For the oral treatment of acromegaly	Chiasma, Inc.
2419	octreotide acetate subcutaneous implant	n/a	12/7/2009	Treatment of acromegaly	Endo Pharmaceuticals Solutions, Inc.
2420	ofatumumab	Arzerra	3/10/2009	Treatment of chronic lymphocytic leukemia	Novartis Pharmaceuticals Corp.
2421	ogluferanide disodium	n/a	9/24/2001	Treatment of ovarian cancer	Implicit Bioscience Pty Ltd
2422	olaparib	Lynparza	10/16/2013	Treatment of ovarian cancer	AstraZeneca Pharmaceuticals LP
2423	olaptesed pegol	n/a	8/19/2014	Treatment of glioblastoma in conjunction with radiotherapy.	Noxxon Pharma AG
2424	olaratumab	n/a	10/9/2014	Treatment of soft tissue sarcoma	Eli Lilly and Company
2425	oleylphosphocholine	n/a	10/25/2013	Treatment of leishmaniasis	Dafra Pharma International nv

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2426	oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH)	n/a	2/27/2014	Treatment of amyotrophic lateral sclerosis	Genervon Biopharmaceuticals, LLC
2427	olipudase alfa	n/a	8/3/2000	Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease)	Genzyme Corporation
2428	omacetaine mepesuccinate	n/a	1/12/2009	Treatment of myelodysplastic syndromes	IVAX International GmbH
2429	omacetaxine mepesuccinate	Synribo	3/10/2006	Treatment of chronic myelogenous leukemia	IVAX International GmbH
2430	ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenyl}-L-serinamide hydrochloride	n/a	3/3/2011	Treatment of soft tissue sarcoma	Sanofi-Aventis U.S., Inc.
2431	omeprazole-lansoprazole with buffer	n/a	2/10/2015	Treatment of esophageal ulcers	Effexus Pharmaceuticals, LLC
2432	omigapil	n/a	6/24/2008	Treatment of congenital muscular dystrophy.	Santhera Pharmaceuticals Limited
2433	oncophage	n/a	4/14/2009	Treatment of glioma	Agenus, Inc.
2434	opioid growth factor	n/a	4/16/2013	Treatment of liver and intrahepatic bile duct cancer	Primocure Pharma, Inc.
2435	opium tincture	n/a	12/2/2011	Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment	Valeant Pharmaceuticals International, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2436	oprozomib	n/a	10/28/2014	Treatment of multiple myeloma	Onyx Therapeutics, Inc.
2437	oprozomib	n/a	8/25/2014	Treatment of Waldenstrom's macroglobulinemia	Onyx Therapeutics, Inc.
2438	optically pure phenylalanine derivative	n/a	8/20/2012	Treatment of narcolepsy	Jazz Pharmaceuticals International III Limited
2439	oral unfractionated heparin	n/a	1/29/2004	Treatment of sickle cell disease	TRF Technologies, Inc.
2440	osilodrostat	n/a	9/13/2013	Treatment of Cushing's disease	Novartis Pharmaceuticals corporation
2441	otelixizumab	n/a	2/6/2006	Treatment of new-onset type I diabetes mellitus	GlaxoSmithKline
2442	oxaloacetate	n/a	7/24/2012	Treatment of gliomas	Terra Biological LLC
2443	oxfendazole	n/a	7/14/2014	Treatment of cysticercosis (including neurocysticercosis)	Robert H. Gilman, MD, DTMH and
2444	oxybate	Xyrem	11/7/1994	Treatment of narcolepsy.	Jazz Pharmaceuticals
2445	oxytocin	n/a	11/24/2014	Treatment of Prader-Willi syndrome	Pr Maithe Tauber
2446	p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt	n/a	3/7/2001	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2447	p38 mitogen-activated kinase inhibitor	n/a	5/27/2014	Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations	Array BioPharma, Inc.
2448	paclitaxel	n/a	5/1/2009	Treatment of pancreatic cancer	MediGene AG
2449	paclitaxel aqueous gel	Oncogel (Tm)	12/23/2008	Treatment of brain cancer.	BTG International, Inc
2450	paclitaxel aqueous gel	Oncogel(Tm)	2/1/2008	Treatment of esophageal cancer	BTG International, Inc.
2451	paclitaxel nanoparticles	n/a	1/3/2013	Treatment of pancreatic cancer	CIRJ Co., Ltd.
2452	paclitaxel poliglumex	Opaxio	9/20/2012	Treatment of glioblastoma multiforme	CTI BioPharma Corporation
2453	paclitaxel protein-bound particles	Abraxane	9/3/2009	Treatment of pancreatic cancer.	Abraxis BioScience, LLC
2454	paclitaxel, micellar	Paclical	4/3/2009	Treatment of ovarian cancer	Oasmia Pharmaceutical AB
2455	pacritinib	n/a	3/13/2008	Treatment of myeloproliferative disorders with the JAK2 V617F mutation	CTI BioPharma Corporation
2456	pafuramidine maleate	n/a	11/17/2006	Treatment of pneumocystis jiroveci pneumonia	Immtech Pharmaceuticals, Inc.
2457	palovarotene	n/a	7/21/2014	Treatment of fibrodysplasia ossificans progressiva	Clementia Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2458	panobinostat	Farydak	8/20/2012	Treatment of multiple myeloma	Novartis Pharmaceuticals Corporation
2459	pantothenate phosphate	n/a	5/4/2015	Treatment of pantothenate kinase associated neurodegeneration (PKAN).	Retrophin, Inc.
2460	paquinimod	n/a	1/17/2014	Treatment of systemic sclerosis	Active Biotech AB
2461	parathyroid hormone	Natpara	8/31/2007	Treatment of hypoparathyroidism	NPS Pharmaceuticals, Inc.
2462	paromomycin	n/a	2/11/2015	Treatment of cutaneous leishmaniasis (Old World and New World)	The Surgeon General, Dept. of the Army
2463	paromomycin sulfate/gentamicin sulfate	n/a	1/18/2008	Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World)	Office of the Surgeon General
2464	pasireotide	n/a	8/25/2009	Treatment of acromegaly	Novartis Pharmaceuticals Corporation
2465	pasireotide	Signifor	7/24/2009	Treatment of Cushing's disease	Novartis Pharmaceuticals Corporation
2466	pazopanib	n/a	5/6/2013	Treatment of ovarian cancer.	Novartis Pharmaceuticals Corp.
2467	pazopanib	Votrient	10/20/2009	Treatment of soft tissue sarcomas	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2468	pegargiminase	n/a	7/21/2014	Treatment of mesothelioma.	Polaris Group
2469	peginterferon alfa-2b	Sylatron	4/9/2008	Treatment of malignant melanoma stages IIb through IV.	Schering-Plough Corporation
2470	pegloticase	Krystexxa	2/21/2001	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Crealta Pharmaceuticals LLC
2471	pegsitacase	Uricase-Peg 20	12/3/2009	Treatment of Lesch-Nyhan syndrome.	EnzymeRx, LLC
2472	pegylated arginine deiminase	Hepacid	3/26/1999	Treatment of hepatocellular carcinoma	Polaris Pharmaceuticals, Inc.
2473	pegylated carboxyhemoglobin	n/a	10/21/2010	Treatment of acute painful sickling crises in patients with sickle cell disease	Sangart, Inc.
2474	pegylated carboxyhemoglobin bovine	Sanguinate	1/15/2015	Treatment of the comorbidities associated with Sickle Cell Disease	Prolong Pharmaceuticals, LLC
2475	pegylated granulocyte colony stimulating factor	n/a	4/30/2014	Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident	PharmaEssentia
2476	pegylated human recombinant arginase I	n/a	3/16/2015	Treatment of arginase I deficiency (hyperargininemia).	AERase, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2477	pegylated proline interferon alpha-2b	n/a	4/11/2014	Treatment of essential thrombocythemia	PharmaEssentia, Corporation
2478	pegylated proline interferon alpha-2b	n/a	4/10/2014	Treatment of myelofibrosis	PharmaEssentia, Corporation
2479	pegylated proline-interferon alpha-2b; PEG-P-IFNa-2b	n/a	4/2/2012	Treatment of polycythemia vera	PharmaEssentia Corporation
2480	pelareorep	Reolysin	2/24/2015	Treatment of fallopian tube cancer	Oncolytics Biotech, Inc.
2481	pelareorep	Reolysin(R)	2/10/2015	Treatment of ovarian cancer	Oncolytics Biotech, Inc.
2482	pelareorep	Reolysin(R)	2/24/2015	Treatment of primary peritoneal cancer	Oncolytics Biotech, Inc.
2483	pelareorep	Reolysin(R)	2/11/2015	Treatment of pancreatic cancer	Oncolytics Biotech, Inc.
2484	pelareorep	Reolysin	5/4/2015	Treatment of gastric cancer	Oncolytics Biotech, Inc.
2485	pelareorep	Reolysin	4/15/2015	Treatment of malignant glioma	Oncolytics Biotech, Inc.
2486	pembrolizumab	Keytruda	11/19/2012	Treatment of Stage IIB through IV malignant melanoma	Merck, Sharp & Dohme Corp.
2487	pemetrexed disodium	Alimta	8/28/2001	Treatment of malignant pleural mesothelioma	Eli Lilly and Company
2488	pentagastrin	n/a	5/29/2009	To aid in the diagnosis of medullary thyroid carcinoma	Medical Defense Technologies, LLC
2489	pentamidine	n/a	8/12/2013	Treatment of liver and intrahepatic bile duct cancer	Verlyx Pharma, Inc.
2490	pentapeptide with sequence Ac-VSRRR-NH2	n/a	1/13/2015	Treatment of intracerebral hemorrhage	CereNOva, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2491	pentetate trisodium	Diethylenetriaminepentaacetate	4/12/2004	Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.	Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG
2492	pentosan polysulfate sodium	n/a	9/16/2011	Treatment of sickle cell disease.	Vanguard Therapeutics, Inc.
2493	pentosan polysulfate sodium	Lysosan (Tm)	1/5/2015	Treatment of mucopolysaccharidosis (MPS) type VI	Plexcera Therapeutics, LLC
2494	pentosan polysulfate sodium	n/a	11/21/2008	Treatment of sickle cell disease.	TRF Pharma, Inc.
2495	pentoxifylline	n/a	6/14/2012	Treatment of Behcet's disease	Keck Graduate Institute of Applied Life Sciences
2496	peptide YY	n/a	4/18/2011	Treatment of hepatocellular carcinoma.	mondoBIOTECH Laboratories AG
2497	peptide-based vaccine targeting telomerase reverse transcriptase	n/a	2/20/2009	Treatment of telomerase reverse transcriptase (TERT) positive non-small cell lung cancer in HLA-A*0201 positive patients	VAXON-Biotech

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2498	peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)	n/a	9/3/2009	Treatment of Duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 51-55).	Sarepta Therapeutics, Inc.
2499	peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis	n/a	2/4/2011	Treatment of myasthenia gravis	CuraVac Europe SPRL
2500	perampanel	Fycompa	12/7/2012	Treatment of Lennox-Gastaut Syndrome	Eisai, Inc.
2501	peretinoin	n/a	9/23/2011	Treatment of hepatocellular carcinoma.	Kowa Pharmaceutical Europe Co. Ltd.
2502	perhexiline maleate	n/a	6/14/2012	Treatment of moderate to severe symptomatic (NYHA class III or IV) hypertrophic cardiomyopathy	Heart Metabolics, Limited.
2503	perifosine	n/a	7/9/2010	Treatment of neuroblastoma	Aeterna Zentaris GmbH
2504	perillyl alcohol	n/a	4/18/2011	Treatment of glioma	NeOnc Technologies, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2505	pertuzumab	n/a	6/8/2009	Treatment of ovarian cancer	Genentech, Inc.
2506	pertuzumab	n/a	7/12/2013	Treatment of gastric cancer	Genentech, Inc.
2507	pexastimogene devacirepvec	n/a	5/6/2013	Treatment of hepatocellular carcinoma	SillaJen Biotherapeutics, Inc.
2508	phenobarbital sodium injection	n/a	10/23/2013	Treatment of hypoxic-ischemic encephalopathy to prevent seizures in neonates	Fera Pharmaceuticals, LLC
2509	phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethylethyl) monohydrochloride	n/a	3/16/2015	Treatment of Huntington's disease.	Ipsen Biopharmaceuticals, Inc.
2510	phenylephrine	n/a	2/14/2002	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma
2511	phenylephrine	n/a	1/31/2012	Treatment of Tetralogy of Fallot	Luitpold Pharmaceuticals, Inc.
2512	phosphorothioate antisense oligonucleotide against EWS-Flt-1	n/a	9/22/2008	Treatment of Ewing's sarcoma	The Cure Our Children Foundation
2513	phoxilium	n/a	2/14/2014	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Gambro Renal Products, Inc.
2514	picibanil	n/a	5/15/2009	Treatment of patients with lymphatic malformations	Royds Pharmaceuticals, Inc.
2515	picibanil	n/a	3/17/2011	Treatment of lymphatic malformations	Richard Smith, M.D.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2516	pirfenidone	n/a	7/31/2014	Treatment of idiopathic pulmonary fibrosis	Genoa Pharmaceuticals, Inc.
2517	pirfenidone	n/a	11/19/2013	Treatment of systemic sclerosis (including the associated interstitial lung disease)	Genentech, Inc.
2518	pirfenidone	Esbriet	3/5/2004	Treatment of idiopathic pulmonary fibrosis	Genentech
2519	plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent	n/a	6/30/2014	Treatment of cystic fibrosis	Imperial Innovations Limited
2520	plasmin (human)	n/a	3/30/2009	Treatment of acute peripheral arterial occlusion	Grifols Therapeutics, Inc.
2521	plasminogen (human)	n/a	3/5/2013	Treatment of hypoplasminogenemia, or type I plasminogen deficiency	ProMetic Biotherapeutics, Inc.
2522	pleconaril	n/a	12/22/2014	Treatment of symptomatic entoviral infection in the neonate	AntiVirus Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2523	plerixafor	Mozobil (R)	7/10/2003	For use to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Genzyme Corporation
2524	polidocanol	n/a	2/19/2015	Treatment of congenital venous malformations	Provensis Ltd
2525	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc.
2526	polifeprosan 20 with carmustine	Gliadel	12/13/1989	Treatment of malignant glioma	Guilford Pharmaceuticals, Inc.
2527	poloxamer 188	n/a	11/8/2013	Treatment of Acute Limb Ischemia	Mast Therapeutics, Inc
2528	poloxamer 188 (purified)	n/a	6/27/1989	Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease)	Mast Therapeutics Inc.
2529	poloxamer-188 NF	n/a	1/19/2010	Treatment of Duchenne muscular dystrophy	Phrixus Pharmaceuticals, Inc.
2530	poly(lactide-co-glycolide) carboxylated microparticle	n/a	10/25/2013	Treatment of acute encephalitis syndrome	Cour Pharmaceutical Development Company, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2531	poly-CD-PEG-camptothecin	n/a	5/21/2015	Treatment of ovarian cancer.	Cerulean Pharma, Inc.
2532	polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase	n/a	3/17/2015	Treatment of homocystinuria	Orphan Technologies Limited
2533	polyinosinic-polycytidilic acid	Poly-Iclc	3/3/2003	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir
2534	polyinosinic-polycytidilic acid	Poly-Iclc	8/2/2002	As an adjuvant to smallpox vaccination	Oncovir
2535	polyinosinic-polycytidilic acid (Poly-ICLC)	Hiltonol	11/19/2002	Treatment for orthopox virus infections	Oncovir
2536	polymer surgical mesh delivering paclitaxel	n/a	7/15/2014	For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.	AcuityBio, Inc.
2537	polyphenon E	n/a	7/17/2008	Treatment of chronic lymphocytic leukemia	Mitsui Norin Co., Ltd
2538	pomalidomide	n/a	9/21/2010	Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2539	pomalidomide	Pomalyst	1/15/2003	Treatment of multiple myeloma	Celgene Corporation
2540	ponatinib	Iclusig	11/20/2009	Treatment of chronic myeloid leukemia	ARIAD Pharmaceuticals Inc.
2541	ponatinib	Iclusig	11/20/2009	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	ARIAD Pharmaceuticals Inc.
2542	ponatinib	Iclusig(R)	3/12/2015	Treatment of gastrointestinal stromal tumors (GIST).	ARIAD Pharmaceuticals, Inc.
2543	porcine GM1 ganglioside	n/a	12/3/2012	Treatment of acute spinal cord injury	TRB Chemedica International S.A.
2544	porfimer	Photofrin	10/19/2001	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc.
2545	potassium sodium aluminosilicate	n/a	1/8/2007	For treatment of poisoning by or exposure to cesium.	Framework Therapeutics, LLC
2546	pracinostat	n/a	2/27/2014	Treatment of acute myeloid leukemia	MEI Pharma Inc.
2547	pralatrexate	n/a	5/3/2010	Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder	Allos Therapeutics, Inc.
2548	pralatrexate	Folotylin	7/20/2006	Treatment of T-cell lymphoma	Allos Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2549	pralatrexate	n/a	10/20/2008	Treatment of follicular lymphoma	Allos Therapeutics, Inc.
2550	pralatrexate	n/a	10/20/2008	Treatment of diffuse large B-cell lymphoma	Allos Therapeutics, Inc.
2551	pralmorelin hydrochloride	n/a	10/18/2012	As a diagnostic agent for the detection of growth hormone deficiency	Sella Pharmaceuticals, Inc.
2552	pramipexole	Mirapex	1/31/2008	Treatment of Tourette's syndrome in pediatric patients	Boehringer-Ingelheim Pharmaceuticals, Inc.
2553	prasugrel hydrochloride	Effient	5/26/2015	Treatment of sickle cell disease	Eli Lilly
2554	pritumumab	n/a	10/28/2014	Treatment of glioma	Nascent Biotech, Inc.
2555	profimer sodium	Photofrin(R)	12/2/2011	Treatment of malignant mesothelioma	Concordia Laboratories, Inc.
2556	progesterone	n/a	12/22/1994	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc.
2557	prolactin receptor antagonist	Prolanta	4/15/2013	Treatment of ovarian cancer	Oncolix, Inc.
2558	propranolol	Hemangeol	9/5/2008	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Pierre Fabre Dermatologie
2559	propranolol hydrochloride and etodolac	n/a	2/24/2015	Treatment of hepatocellular carcinoma	Vicus Therapeutics, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2560	prothrombin complex concentrate (human)	Kcentra	12/27/2012	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	CSL Behring
2561	purified bovine type collagen	n/a	4/27/2009	Treatment of idiopathic pulmonary fibrosis	ImmuneWorks, Inc.
2562	pyridoxine; vitamin B6	n/a	3/3/2011	Treatment of pyridoxine dependent seizures.	NBI Pharmaceuticals, Inc.
2563	pyrimethamine	n/a	8/16/2011	Treatment of GM-2 gangliosidosis (Tay-Sachs disease and Sandhoff disease).	ExSAR Corporation
2564	pyrvinium	n/a	1/5/2015	Treatment of familial adenomatous polyposis	StemSynergy Therapeutics, Inc.
2565	quinacrine	n/a	9/28/2012	Treatment of hepatocellular carcinoma	Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur
2566	quinine Sulfate	n/a	6/3/2004	Treatment of malaria	AR Holding Company, Inc.
2567	quinine sulfate	n/a	12/2/2008	Treatment of malaria excluding Plasmodium falciparum	Zydus Pharmaceuticals, Inc.
2568	rAAV2-CB-hRPE65	n/a	2/11/2005	Treatment of type II Leber's Congenital Amaurosis	Applied Genetic Technologies Corp.
2569	rSP-C lung surfactant	Venticute	4/3/2000	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2570	rSP-C surfactant	Venticute	9/18/2006	For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment	Altana Pharma
2571	rVIIa-FP	n/a	12/22/2011	Treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX	CSL Behring
2572	radiolabeled somastatin analog	Galiomedix(Tm)	12/31/2013	Diagnostic for the management of neuroendocrine tumors	RadioMedix, Inc.
2573	raloxifene	Evista	7/14/2005	Reduction of the risk of breast cancer in postmenopausal women	Eli Lilly and Company
2574	raloxifene hydrochloride	Evista	8/20/2010	Treatment of hereditary hemorrhagic telangiectasia	Consejo Superior de Investigaciones Cientificas
2575	ramucirumab	Cyramza	2/16/2012	Treatment of gastric cancer	Eli Lilly and Company
2576	ramucirumab	n/a	11/4/2011	Treatment of hepatocellular carcinoma	ImClone Systems LLC
2577	ranagengliotucel-L	Glionix(Tm)	5/29/2009	Treatment of astrocytic tumors	NovaRx Corporation
2578	ranprinase	Onconase	1/25/2007	Treatment of malignant mesothelioma	Alfacell Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2579	rasburicase	Elitek	10/11/2000	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research
2580	raxibacumab	Abthraxtm	11/12/2003	Treatment of anthrax	Human Genome Sciences, Inc.
2581	recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase	n/a	4/29/2014	Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A)	Abeona Therapeutics
2582	recombinant DNA plasmid	n/a	1/31/2014	Treatment of stage IIb, IIc, III and IV melanoma.	Scancell Ltd.
2583	recombinant IgA protease of bacterium Heamophilus influenzae	n/a	4/18/2011	Treatment of immunoglobulin A nephropathy (IgAN, Berger's disease).	Shire Human Genetics Therapies
2584	recombinant activated Factor X variant	n/a	3/3/2015	Treatment of intracerebral hemorrhage	Pfizer, Inc.
2585	recombinant adeno-associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits	n/a	3/25/2013	For the treatment of Sandhoff disease	Nat'l Tay-Sachs & Allied Diseases Association
2586	recombinant adeno-associated virus alpha 1-antitrypsin vector	Raav-Aat	1/27/2003	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp.
2587	recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP)	n/a	8/25/2009	Treatment of Huntington's disease.	Neurologix, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2588	recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3)	n/a	2/4/2011	Treatment of achromatopsia caused by mutations in the CNGB3 gene.	Applied Genetic Technologies Corporation
2589	recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits	n/a	3/25/2013	Treatment of Tay-Sachs disease	Na't Tay-Sachs & Allied Diseases Association
2590	recombinant chimeric monoclonal antibody to anthrax	Anthim	6/9/2006	Treatment of exposure to B. anthracis spores	Elusys Therapeutics, Inc.
2591	recombinant derivative of C3 transferase	Cethrin	11/18/2005	Treatment of acute spinal cord injury	Vertex Pharmaceuticals, Inc.
2592	recombinant elafin	n/a	3/18/2013	Prevention of inflammatory complications of transthoracic esophagectomy	Proteo Biotech AG
2593	recombinant fusion protein consisting of a modified form of extracellular domain of human Activin receptor IIB	n/a	3/18/2013	Treatment of myelodysplastic syndrome	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2594	recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB (ActRIIB) linked to a human IgG1 Fc domain	n/a	3/11/2013	Treatment of B-thalassemia	Celgene Corporation
2595	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	n/a	4/27/2012	Treatment of patients with congenital factor IX deficiency (hemophilia B).	CSL Behring LLC
2596	recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)	n/a	5/6/2013	Treatment of congenital factor VII deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor VII deficiency	CSL Behring
2597	recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin	Proxinium	1/28/2005	Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck	Viventia Biotech, Inc.
2598	recombinant glycosylated independent lysosomal targeting (GILT) tagged human acid alpha glucosidase	n/a	8/20/2010	Treatment of Pompe disease.	BioMarin Pharmaceutical, Inc.
2599	recombinant human GM-CSF, molgramostim	n/a	10/31/2012	Treatment of pulmonary alveolar proteinosis	Serendex ApS

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2600	recombinant human IgG1 monoclonal antibody	n/a	12/14/2009	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Ultragenyx Pharmaceutical, Inc.
2601	recombinant human Naglu-insulin-like growth factor II	n/a	3/5/2013	Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B)	Shire Human Genetic Therapies, Inc.
2602	recombinant human Pentraxin-2	n/a	8/26/2014	Treatment of myelofibrosis	Promedior, Inc.
2603	recombinant human Pentraxin-2; recombinant human Serum Amyloid P	n/a	2/17/2012	Treatment of idiopathic pulmonary fibrosis.	Promedior, Inc.
2604	recombinant human acid ceramidase	Plexcerase(Tm)	12/24/2013	Treatment of Faber disease	Plexcera Therapeutics, LLC
2605	recombinant human alkaline phosphatase	n/a	5/13/2015	Treatment of hypophosphatasia.	AM-Pharma BV
2606	recombinant human alpha 1-antitrypsin (rAAT)	n/a	11/20/2001	Treatment of cystic fibrosis	AiroMedica LLC
2607	recombinant human alpha-1 antitrypsin	n/a	3/6/1998	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited
2608	recombinant human alpha-1 antitrypsin (rAAT)	n/a	8/28/2001	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	AiroMedica LLC
2609	recombinant human alpha-N-acetylglucosaminidase	n/a	4/15/2013	Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome)	Synageva BioPharma Corp.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2610	recombinant human alpha-glucosidase conjugated with synthetic bis-mannose-6-phosphate-Man6 glycan	n/a	11/19/2013	Treatment of Pompe Disease	Genzyme, a Sanofi Company
2611	recombinant human anti-GDF-8 monoclonal antibody	n/a	7/24/2012	Treatment of Duchenne Muscular Dystrophy.	Pfizer, Inc.
2612	recombinant human antithrombin	Atryn	12/7/2007	Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures	GTC Biotherapeutics, Inc.
2613	recombinant human beta-glucuronidase	n/a	2/16/2012	Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)	Ultragenyx Pharmaceutical, Inc.
2614	recombinant human collagen alpha-1 (VII) chain homotrimer (rC7)	n/a	3/17/2014	Treatment of dystrophic epidermolysis bullosa	Shire Human Genetic Therapies, Inc.
2615	recombinant human deoxyribonuclease I	n/a	8/19/2014	Treatment of graft-vs-host disease	SciVac Ltd
2616	recombinant human deoxyribonuclease I (DNase I)	n/a	8/18/2014	Prevention of graft-vs-host disease	SciVac Ltd.
2617	recombinant human endostatin protein	n/a	2/21/2002	Treatment of metastatic melanoma	EntreMed, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2618	recombinant human erythropoietin (rHuEPO)	n/a	5/26/2011	Treatment of mutiple myeloma	XTL Biopharmaceuticals, Ltd
2619	recombinant human fucosyltransferase VI [FTVI] + GDP-fucose	n/a	1/27/2015	To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation	TargaZyme, Inc.
2620	recombinant human galactocerebrosidase (rhGALC);	Galaczym	12/12/2011	Treatment of globoid cell leukodystrophy (Krabbe Disease)	ACE BioSciences A/S
2621	recombinant human growth hormone in an ocular delivery system	n/a	12/3/2012	Treatment of persistent corneal epithelial defects	Jade Therapeutics LLC
2622	recombinant human histidyl tRNA synthetase	n/a	4/22/2015	Treatment of facioscapulohumeral muscular dystrophy	aTyr Pharma, Inc.
2623	recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3	Oncohist	10/20/2008	Treatment of acute myeloid leukemia	Xenetic Biosciences Plc
2624	recombinant human lecithin:cholesterol acyltransferase (rhLCAT)	n/a	9/2/2010	Treatment of LCAT deficiency syndromes	AlphaCore Pharma, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2625	recombinant human minibody against complement component	Mubodina(R)	6/7/2011	Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.	Adienne S.A
2626	recombinant human minibody against complement component C5	Mubodina	2/4/2009	Treatment of primary membranoproliferative glomerulonephritis	Adienne S.A.
2627	recombinant human minibody against complement component C5 fused with RGD-motif	n/a	2/4/2009	Prevention of ischemia/reperfusion injury associated with solid organ transplantation.	Adienne S.A.
2628	recombinant human monoclonal IgM antibody targeting glucose regulated protein 78	n/a	10/25/2013	Treatment of multiple myeloma	Patrys Ltd.
2629	recombinant human monoclonal antibody against activin receptors type II	n/a	6/18/2012	Treatment of inclusion body myositis	Novartis Pharmaceuticals Corp.
2630	recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor	n/a	8/19/2014	Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath	Novartis Pharmaceuticals Corp
2631	recombinant human monoclonal antibody to hsp90	Mycograb	9/16/2002	Treatment of invasive candidiasis	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2632	recombinant human nerve growth factor	n/a	8/8/2013	Treatment of retinitis pigmentosa	Dompe s.p.a.
2633	recombinant human nerve growth factor	n/a	6/23/2014	Treatment of neurotrophic keratitis	Dompe s.p.a.
2634	recombinant human neutrophil inhibitor (hNE)	n/a	12/9/2003	Treatment of cystic fibrosis	Dyax Corporation
2635	recombinant human platelet derived growth factor-BB	n/a	8/6/2010	Treatment of osteochondritis dissecans	Biomimetic Therapeutics, Inc.
2636	recombinant human porphobilinogen deaminase	Porphozyme	9/9/2002	Treatment of acute intermittent porphyria attacks	Zymenex A/S
2637	recombinant human porphobilinogen deaminase, erythropoietic form	n/a	7/11/2002	Treatment of acute intermittent porphyria preventing attacks	ZymenexA/S
2638	recombinant human proinsulin (Including rhPI-Methionine)	n/a	12/10/2008	Treatment of retinitis pigmentosa	ProRetina Therapeutics, S.L.
2639	recombinant human surfactant protein D	n/a	6/23/2014	Prevention of bronchopulmonary dysplasia	Airway Therapeutics LLC
2640	recombinant human tripeptidyl-peptidase 1 (rhTPP1)	n/a	4/1/2013	Treatment of neuronal ceroid lipofuscinosis type 2	BioMarin Pharmaceutical, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2641	recombinant human type I pancreatic elastase	n/a	4/3/2009	Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis	Proteon Therapeutics, Inc.
2642	recombinant human type VII collagen	n/a	6/18/2008	Treatment of hereditary dystrophic epidermolysis bullosa (DEB)	David T. Woodley, MD and Mei Chen, MD
2643	recombinant human vascular endothelial growth factor	n/a	6/7/2010	Treatment of amyotrophic lateral sclerosis	NeuroNova AB
2644	recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR)	n/a	4/12/2013	Treatment of sickle cell disease	NKT Therapeutics, Inc.
2645	recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody	n/a	2/11/2015	Treatment of eosinophilic esophagitis	Receptos, Inc.
2646	recombinant humanized anti-tau antibody	n/a	1/22/2015	Treatment of progressive supranuclear palsy	C2N Diagnostics, LLC
2647	recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages	n/a	5/14/2014	Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor	Genentech, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2648	recombinant kallikrein inhibitor	n/a	11/23/2010	Treatment of Netherton Syndrome.	Dermadis SA
2649	recombinant lens epithelium derived growth factor 1-326	n/a	5/19/2014	Treatment of retinitis pigmentosa	Ocugen, Inc.
2650	recombinant monoclonal antibody to human serum amyloid P component	n/a	2/10/2015	Treatment of AL amyloidosis	Glaxo Group Limited, England d/b/a GlaxoSmithKline
2651	recombinant nematode anticoagulant protein c2 (rNAPc2)	n/a	12/8/2014	Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola)	ARCA Biopharma, Inc.
2652	recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S	n/a	11/17/2014	Treatment of patients with carbon monoxide poisoning	University of Pittsburgh
2653	recombinant ovine interferon tau	Tauferon	1/25/2005	Treatment of pediatric multiple sclerosis	PEPGEN Corporation
2654	recombinant thymidine phosphorylase encapsulated with autologous erythrocytes	n/a	12/13/2010	Treatment of mitochondrial neurogastrointestinal encephalomyopathy due to thymidine phosphorylase deficiency.	St. George's University of London
2655	recombinant von Willebrand factor (rhVWF)	n/a	11/23/2010	Treatment of von Willebrand disease.	Baxter Healthcare Corporation
2656	reduced oxidized N-acetyl heparin	n/a	3/19/2015	Treatment of multiple myeloma	Sigma-Tau Research Switzerland S.A.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2657	refanalinal	n/a	5/25/2010	To improve renal function and prevent delayed graft function following renal transplantation	Angion Biomedica Corporation
2658	regorafenib	Stivarga	1/12/2011	Treatment gastrointestinal stromal tumors	Bayer HealthCare Pharmaceuticals, Inc.
2659	reparixin	n/a	9/25/2012	Prevention of graft loss in pancreatic islet transplantation	Dompe S.p.A.
2660	reparixin	n/a	1/27/2003	Prevention of delayed graft function in solid organ transplant	Dompe S.p.A.
2661	replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA	n/a	5/3/2013	Treatment of symptoms of Grade 2 and Grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.	John A. Chiorini, PhD
2662	repository corticotropin injection	H.P. Acthar Gel	6/28/2013	Treatment of amyotrophic lateral sclerosis	Questor Pharmaceuticals, Inc.
2663	repository corticotropin or adrenocorticotrophic hormone	H.P. Acthar Gel	5/21/2003	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc.
2664	resiniferatoxin	n/a	5/13/2003	Treatment of intractable pain at end-stage disease	Sorrento Therapeutics, Inc.
2665	reslizumab	Cinquil	1/12/2011	Treatment of hypereosinophilic syndrome	Teva Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2666	reslizumab	n/a	12/19/2007	Treatment of children with eosinophilic esophagitis	TEVA
2667	resminostat	n/a	9/16/2011	Treatment of Hodgkin's lymphoma.	4SC AG
2668	resminostat	n/a	6/29/2011	Treatment of hepatocellular carcinoma	4SC AG
2669	retroviral gamma-c cDNA containing vector	n/a	4/29/2002	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc.
2670	revusiran	n/a	5/18/2015	Treatment of transthyretin amyloidosis	Alnylam Pharmaceuticals, Inc.
2671	rh-microplasmin, ocriplasmin	Jetrea	3/16/2004	Adjunct to surgery in cases of pediatric vitrectomy	ThromboGenics Inc.
2672	rhIGF-I/rhIGFBP-3	Somatokine	12/9/2003	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmed, Inc.
2673	ribavirin	Rebetol	4/4/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation
2674	ribavirin	Virazole	4/12/1991	Treatment of hemorrhagic fever with renal syndrome	Valeant Pharmaceuticals International

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2675	ribavirin elaidate	n/a	9/2/2011	Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer	Translational Therapeutics, Inc.
2676	riboflavin ophthalmic solution & ultraviolet A	n/a	9/2/2011	Treatment of keratoconus	Avedro, Inc.
2677	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	n/a	12/2/2011	Treatment of corneal ectasia following refractive surgery	Avedro, Inc.
2678	ricin vaccine	Rivax(R)	1/7/2011	Prevention of ricin intoxication.	Soligenix, Inc.
2679	rifaximin	Normix	2/10/1998	Treatment of hepatic encephalopathy	Salix Pharmaceuticals, Inc.
2680	rigosertib	n/a	3/18/2011	Treatment of pancreatic cancer.	Onconova Therapeutics, Inc
2681	rigosertib	n/a	3/16/2012	Treatment of ovarian cancer	Onconova Therapeutics, Inc.
2682	rigosertib	n/a	9/3/2009	Treatment of myelodysplastic syndromes	Onconova Therapeutics, Inc.
2683	rilonacept	Arcalyst	1/9/2013	Treatment of familial Mediterranean fever	Philip J Hashkes, MD, MSc.
2684	rilotumumab	n/a	6/18/2012	Treatment of gastric cancer including gastroesophageal junction adenocarcinoma	Amgen, Inc.
2685	rindopepimut	n/a	11/19/2007	Treatment of EGFRvIII-expressing glioblastoma multiforme	CellDex Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2686	riociguat	Adempas	7/24/2014	Treatment of systemic sclerosis	Bayer HealthCare Pharmaceuticals
2687	riociguat	Adempas	9/19/2013	Treatment of pulmonary arterial hypertension.	Bayer HealthCare Pharmaceuticals, Inc.
2688	riociguat	Adempas	9/19/2013	Treatment of chronic thromboembolic pulmonary hypertension	Bayer HealthCare Pharmaceuticals, Inc.
2689	rituximab	Rituxan	2/14/2006	Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)	Genentech, Inc.
2690	rituximab	Rituxan	6/13/1994	Treatment of non-Hodgkin's B-cell lymphoma	Genentech, Inc.
2691	rituximab	Rituxan	3/12/2002	Treatment of immune thrombocytopenic purpura	Genentech, Inc.
2692	rituximab	Rituxan	1/29/2004	Treatment of chronic lymphocytic leukemia	Genentech, Inc.
2693	rituximab	Rituxan(R); Mabthera(R)	2/23/2015	Treatment of pemphigus vulgaris.	Genentech, Inc.
2694	rofecoxib	Vioxx	3/16/2004	Treatment of juvenile rheumatoid arthritis	MERCK & Co., Inc.
2695	romidepsin	Istodax	9/30/2004	Treatment of non-Hodgkin T-cell lymphomas	Celgene Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2696	romiplostim	n/a	10/31/2007	Treatment of thrombocytopenia associated with myelodysplasia syndrome	Amgen Inc.
2697	romiplostim	Nplate	3/27/2003	Treatment of immune thrombocytopenic purpura	Amgen, Inc.
2698	rosuvastatin	Crestor	2/14/2014	For the treatment of pediatric homozygous familial hypercholesterolemia	AstraZeneca Pharmaceuticals LP
2699	rozrolimupab	n/a	9/13/2010	Treatment of primary immune thrombocytopenia.	Symphogen A/S
2700	rsATP7A cDNA	n/a	1/10/2014	Treatment of Menkes disease	Stephen G. Kaler, MD
2701	rt-PA	Activase	10/20/2014	Treatment of plastic bronchitis	Kathleen A Stringer, PharmD, FCCP - Professor
2702	rubitecan	n/a	7/17/2002	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc.
2703	rucaparib	n/a	7/31/2012	Treatment of ovarian cancer	Clovis Oncology, Inc.
2704	rufinamide	Banzel	10/8/2004	Treatment of Lennox-Gastaut Syndrome.	Eisai, Inc.
2705	ruxolitinib	Jakafi	8/16/2013	Treatment of pancreatic cancer	Incyte Corporation
2706	ruxolitinib	Jakafi	3/26/2010	Treatment of polycythemia vera	Incyte Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2707	ruxolitinib phosphate	Jakafi	3/22/2010	Treatment of essential thrombocythemia	Incyte Corporation
2708	ruxolitinib phosphate	Jakafi	9/5/2008	Treatment of myelofibrosis	Incyte Corporation
2709	salicylic acid 6%	n/a	2/17/2012	Treatment of rare congenital ichthyoses.	Orenova Group, LLC
2710	salirasib	n/a	12/18/2006	Treatment of pancreatic cancer.	Kadmon Corporation, LLC
2711	salmeterol xinafoate/fluticasone propionate	n/a	10/29/2009	Treatment of symptomatic exophthalmos associated with thyroid related eye disease	Lithera, Inc.
2712	saposin C	n/a	2/3/2015	Treatment of glioblastoma multiforme	Bexion Pharmaceuticals, LLC
2713	sapropterin	Kuvan	1/29/2004	Treatment of hyperphenylalaninemia	Biomarin Pharmaceutical Inc.
2714	sarcosine	n/a	10/12/2011	Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age)	Guochuan Emil Tsai, MD, PhD
2715	sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs	n/a	4/15/2013	Treatment of pachyonychia congenita	TransDerm, Inc.
2716	sebelipase alfa	n/a	7/1/2010	Treatment of lysosomal acid lipase deficiency	Synageva BioPharma Corp.
2717	selective antagonist of the chemokine receptor type 4	n/a	9/5/2013	Treatment of acute myeloid leukemia	BioLineRx, Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2718	selective deacylglycerol acyltransferase 1 inhibitor	n/a	3/28/2011	Treatment of hypertriglyceridemia in te setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronema Syndrome	Novartis Pharmaceuticals Corporation
2719	selective inhibitor of fungal lanosterol demethylase	n/a	8/19/2014	Treatment of cryptococcal meningitis	Viamet Pharmaceuticals, Inc.
2720	selexipag	n/a	4/30/2010	Treatment of pulmonary arterial hypertension	Actelion Ltd
2721	self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid	n/a	9/27/2013	Treatment of Giant Axonal Neuropathy	Hannah's Hope Fund
2722	selinexor	n/a	1/5/2015	Treatment of multiple myeloma	Karyopharm Therapeutics, Inc.
2723	selisistat	n/a	12/7/2009	Treatment of Huntington's disease	Siena Biotech SpA
2724	selumetinib	n/a	4/15/2015	Treatment of uveal melanoma.	AstraZeneca Pharmaceuticals LP
2725	sevuparin	n/a	3/17/2015	Treatment of sickle cell disease	Dilaforette AB
2726	sialic acid	n/a	9/23/2011	Treatment of hereditary inclusion body myopathy.	Ultragenyx Pharmaceutical, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2727	sildenafil	Revatio	7/28/2011	Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension	Pfizer, Inc.
2728	silibinin-C-2',3-dihydrogensuccinate, disodium salt	Legalon(R) Sil	9/11/2014	Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure	Rottapharm S.p.A.
2729	siltuximab	Sylvant	5/26/2006	Treatment of Castleman's disease	Janssen Biotech, Inc.
2730	simtuzumab	n/a	1/5/2015	Treatment of primary sclerosing cholangitis	Gilead Sciences, Inc.
2731	single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21	n/a	7/17/2014	Treatment of Alport syndrome	Regulus Therapeutics, Inc.
2732	siponimod	n/a	7/10/2014	Treatment of dermatomyositis	Novartis Pharmaceuticals Corporation
2733	sirolimus	n/a	11/17/2011	Treatment of lymphangioleiomyomatosis	Cote Orphan Consulting, LLC
2734	sirolimus	n/a	6/25/2014	Treatment of lymphangioleiomyomatosis	LAM Therapeutics, Inc.
2735	sirolimus	Rapamune	10/31/2012	Treatment of lymphangioleiomyomatosis	Pfizer, Inc.
2736	sirolimus	n/a	3/18/2013	Treatment of pachyonychia congenita	TransDerm, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2737	sirolimus	n/a	11/4/2011	Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).	Santen Inc.
2738	sirolimus in an implantable collagen matrix	Coll-R, Sirogen	5/10/2012	Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis	Vascular Therapies, LLC
2739	sitimagene ceradenovec	Cerepro	7/31/2001	Use with gancyclovir in the treatment of malignant glioma	Finvector Vision Therapies Ltd
2740	skin tissue	Stratagraft	5/21/2012	Treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting	Stratatech Corporation
2741	small molecule inhibitor of histone methyltransferase DOT1L	n/a	8/8/2013	Treatment of acute lymphoblastic leukemia (ALL)	Epizyme Inc.
2742	small molecule inhibitor of phosphodiesterase 10	n/a	9/26/2013	Treatment of Huntington's disease	Omeros Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2743	small molecule normalizing the p53 function	n/a	6/12/2014	Treatment of ovarian cancer	Critical Outcome Technologies, Inc.
2744	smilagenin	Cogane	7/21/2011	Treatment of amyotrophic lateral sclerosis	Junaxo, Inc.
2745	sobetirome	n/a	4/29/2011	Treatment of X-linked adrenoleukodystrophy	NeuroVia, Inc.
2746	sodium 2, 2 dimethylbutyrate	n/a	7/25/2008	Treatment of sickle cell disease.	HemaQuest Pharmaceuticals, Inc.
2747	sodium 4-phenylbutyrate	n/a	10/18/2011	Treatment of spinal muscular atrophy	GMP-Orphan SAS
2748	sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate	n/a	4/3/2009	Treatment of ovarian cancer	Millennium Pharmaceuticals, Inc.
2749	sodium ascorbate and menadione sodium bisulfite	Apatone(R)	4/15/2013	Treatment of autosomal dominant polycystic liver disease	IC-Medtech Corporation
2750	sodium ascorbate and menadione sodium bisulfite	Apatone	4/9/2015	Treatment of noninfected painful total joint without mechanical complication	IC-MedTech Corporation
2751	sodium ascorbate and menadione sodium bisulfite	Apatone	4/15/2013	Treatment of autosomal dominant polycystic kidney disease	IC-MedTech Corporation
2752	sodium benzoate and clozapine	n/a	12/22/2011	Treatment of treatment-resistant schizophrenia	Guochuan Emil Tsai, MD, PhD

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2753	sodium chlorite	n/a	8/22/2011	For slowing the progression of amyotrophic lateral sclerosis.	Neuraltus Pharmaceuticals, Inc.
2754	sodium dichloroacetate	n/a	7/3/2003	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group
2755	sodium dichloroacetate	n/a	11/29/2010	For pulmonary arterial hypertension.	Peter W. Stackpoole, PhD, MD
2756	sodium fusidate	n/a	10/23/2013	Treatment of patients with prosthetic joint infections	Cempra Pharmaceuticals, Inc.
2757	sodium nitrite	n/a	9/3/2009	Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation	Hope Pharmaceuticals
2758	sodium nitrite	n/a	7/8/2008	Treatment of pulmonary arterial hypertension	Airess Pharmaceuticals, Inc.
2759	sodium nitrite	n/a	1/9/2012	Treatment of chlorine gas poisoning	Hope Pharmaceuticals
2760	sodium nitrite and sodium thiosulfate	Nithiodote	4/9/2008	Treatment of known or suspected cyanide poisoning	Hope Pharmaceuticals
2761	sodium phenylbutyrate	n/a	1/19/2010	Treatment of urea cycle disorder.	Navinta LLC
2762	sodium phenylbutyrate	Pheburane	6/6/2013	Treatment of urea cycle disorders	Lucane Pharma SA
2763	sodium phenylbutyrate	n/a	8/19/2014	Treatment of maple syrup urine disease	Acer Therapeutics, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2764	sodium phenylbutyrate	Buphenyl	11/22/1993	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and argininosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp.
2765	sodium phenylbutyrate	n/a	7/2/1992	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.	Medicis Pharmaceutical Corp.
2766	sodium stibogluconate	n/a	10/28/2009	Treatment of cutaneous leishmaniasis	Surgeon General of the US Army
2767	sodium sulfate, potassium sulfate, and magnesium sulfate	Suprep	10/31/2012	For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents	Braintree Laboratories, Inc.
2768	sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride	Suclear	9/4/2013	For use in cleansing of the colon in preparation for colonoscopy in children and adolescents	Braintree Laboratories, Inc.
2769	sodium thiosulfate	n/a	3/3/2011	Treatment of sulfur mustard poisoning	Hope Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2770	sodium thiosulfate	n/a	12/2/2010	Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.	Hope Pharmaceuticals
2771	sodium thiosulfate	n/a	10/28/2014	Treatment of dermatomyositis	Hope Pharmaceuticals
2772	sodium thiosulfate	n/a	11/19/2012	Treatment of calciphylaxis	Edinburg BioQuarter
2773	sodium thiosulfate	n/a	10/13/2011	Prevention of platinum-induced ototoxicity in pediatric patients	Hope Pharmaceuticals
2774	sodium thiosulfate	n/a	11/9/2011	Treatment of uremic and non-uremic calciphylaxis	Hope Pharmaceuticals
2775	solvent/detergent treated non-blood-group specific human coagulation active plasma	Uniplas	12/12/2005	Treatment of thrombotic thrombocytopenic purpura	Octapharma USA, Inc.
2776	somatorelin	Somatrel	8/8/1989	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc.
2777	somatropin [rDNA]	Genotropin	12/27/2000	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company
2778	sonidegib	n/a	3/23/2015	Treatment of medulloblastoma	Novartis Pharmaceuticals Corp.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2779	sorafenib	Nexavar	12/12/2011	Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer	Bayer HealthCare Pharmaceuticals, Inc.
2780	sotalol (IV)	So-Aqueous	7/25/2008	For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.	Academic Pharmaceuticals
2781	sotalol hydrochloride	n/a	2/10/2014	Treatment of life-threatening ventricular arrhythmias in pediatric patients	Arbor Pharmaceuticals, LLC
2782	sotatercept	n/a	12/5/2013	Treatment of beta-thalassemia intermedia and major	Celgene Corporation
2783	sotatercept	n/a	4/28/2014	Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.	Celgene Corporation
2784	sparsentan	n/a	1/5/2015	Treatment of Focal Segmental Glomerulosclerosis	Retrophin, LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2785	spherical carbon adsorbent	n/a	12/19/2007	Treatment of chronic pouchitis	Ocera Therapeutics, Inc.
2786	spironolactone	Aldactone	5/22/2014	Use in pediatric patients with primary hyperaldosteronism	CMP Pharma, Inc.
2787	squalamine lactate	n/a	5/11/2001	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation
2788	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of acute lymphoblastic leukemia.	Gambia Cell Ltd.
2789	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of Hodgkin lymphoma.	Gambia Cell Ltd.
2790	stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells	Nicord(R)	11/13/2014	Treatment of myelodysplastic syndrome.	Gamida Cell Ltd.
2791	stiripentol	Diacomit	10/30/2008	Treatment of Dravet syndrome	Biocodex
2792	sulfamidase	n/a	5/22/2008	For treatment of Sanfilippo Syndrome (MPS IIIA)	Shire Human Genetic Therapies, Inc.
2793	sulfonated monophosphorylated mannose oligosaccharide	n/a	2/17/2012	Treatment of hepatocellular carcinoma	Medigen Biotechnology Corporation

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2794	sulthiame	n/a	7/25/2013	Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy	Marathon Pharmaceuticals, LLC
2795	superoxide dismutase, gliadin	Etr019	4/30/2010	Treatment of amyotrophic lateral sclerosis	Verius Limited
2796	synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene	n/a	4/22/2015	Treatment of primary hyperoxaluria type 1	Dicerna Pharmaceuticals, Inc.
2797	synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA	n/a	8/16/2013	Treatment of hemophilia A	Alnylam Pharmaceuticals
2798	synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA	n/a	8/12/2013	Treatment of hemophilia B	Alnylam Pharmaceuticals
2799	synthetic double-stranded siRNA oligonucleotide against p53 mRNA	n/a	12/23/2009	Prophylaxis of delayed graft function in renal transplant patients	Quark Pharmaceuticals, Inc.
2800	synthetic double-stranded siRNA oligonucleotide against transthyretin (TTR) mRNA	n/a	6/14/2012	Treatment of familial amyloidotic polyneuropathy	Alnylam Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2801	synthetic oligomer of 16 nucleotides	n/a	1/15/2015	Treatment of myotonic dystrophy Type I	Isis Pharmaceuticals, Inc.
2802	synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH	n/a	10/12/2011	Treatment of necrotizing soft tissue infections (NSTI)	Atox Bio, Inc.
2803	synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys	n/a	1/15/2013	Treatment of high altitude pulmonary edema	Apeptico Forschung und Entwicklung GmbH
2804	synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue	n/a	3/16/2012	Treatment of preterm neonatal respiratory distress syndrome	Chiesi USA, Inc.
2805	tabalumab	n/a	11/19/2012	Treatment of multiple myeloma	Eli Lilly and Company
2806	taberminogene vadenovec	Trinam	10/24/2000	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Finvector Vision Therapies, Ltd.
2807	tacrolimus	n/a	5/4/2015	Treatment of pulmonary arterial hypertension	Stanford University School of Medicine
2808	tacrolimus	n/a	7/6/2012	Treatment of hemorrhagic cystitis	Lipella Pharmaceuticals Inc.
2809	tacrolimus	n/a	3/16/2015	Treatment of pulmonary arterial hypertension.	Selten Pharma, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2810	tadalafil	Cialis(R); Adcirca(R)	5/4/2015	Treatment of Duchenne Muscular Dystrophy (DMD)	Eli Lilly and Company
2811	tadalafil	Adcirca	12/18/2006	Treatment of pulmonary arterial hypertension	Eli Lilly and Company
2812	tafamidis	n/a	5/23/2006	Treatment of familial amyloid polyneuropathy	Pfizer, Inc.
2813	tafamidis meglumine	n/a	2/17/2012	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Pfizer, Inc.
2814	tafenoquine	n/a	1/15/2013	Treatment of malaria	Glaxo Group Limited, England
2815	talactoferrin alfa	n/a	8/20/2003	For the prevention of graft-versus-host disease	Agennix, Inc.
2816	talactoferrin alfa	n/a	8/20/2003	For the treatment of graft versus host disease	Agennix, Inc.
2817	talazolate	n/a	3/16/2012	Treatment of congenital ichthyosis	Stiefel Laboratories, Inc.
2818	talimogene laherparepvec	n/a	3/14/2011	Treatment of stage IIb-stage IV melanoma	BioVex, Inc. (subsidiary of Amgen)
2819	tarextumab	n/a	1/26/2015	Treatment of small cell lung cancer	OncoMed Pharmaceuticals, Inc.
2820	tarextumab	n/a	1/26/2015	Treatment of pancreatic cancer	OncoMed Pharmaceuticals, Inc.
2821	tasimelteon	n/a	4/30/2010	Treatment of sleep-wake disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion	Vanda Pharmaceuticals, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2822	tasimelteon	Hetlioz	1/19/2010	Non-24-hour sleepwake disorder in blind individuals without light perception	Vanda Pharmaceuticals, Inc.
2823	taurine	n/a	3/22/2010	Treatment of cystathionine beta-synthase deficient homocystinuria	Johan L. Van Hove, MD, PhD
2824	technetium Tc 99m tilmanocept	Lymphoseek	9/17/2014	Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck	Navidea Biopharmaceuticals
2825	tecovirimat	n/a	9/29/2010	Treatment of orthopoxvirus infections.	SIGA Technologies, Inc.
2826	tecovirimat	n/a	12/27/2006	Treatment of smallpox.	SIGA Technologies, Inc.
2827	tecovirimat	n/a	12/18/2006	post exposure prophylaxis against smallpox	SIGA Technologies, Inc.
2828	teduglutide [rDNA origin]	Gattex	6/29/2000	Treatment of short bowel syndrome.	NPS Pharmaceuticals, Inc.
2829	telatinib	n/a	5/17/2010	Treatment of gastric cancer	ACT Biotech Inc.
2830	temocillin sodium	Negaban	4/21/2004	Treatment of pulmonary infections caused by Burkholderia cepacia	Belpharma S.A.
2831	temozolomide	Temodar	10/5/1998	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute
2832	tenofovir	Viread	3/17/2009	Treatment of pediatric HIV infection.	Gilead Sciences, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2833	teprotumumab	n/a	5/6/2013	Treatment of active (dynamic) phase Grave's orbitopathy	River Vision, Inc.
2834	terguride	Mysalfon, Teluron	5/17/2013	Treatment of systemic sclerosis	Serodapharm UG
2835	teriparatide	Forteo	4/18/2014	Treatment of hypoparathyroidism	Entera Bio, Ltd.
2836	terlipressin	n/a	10/29/2004	Treatment of Hepatorenal Syndrome	Ikaria (INO Therapeutics)
2837	tesetaxel	n/a	12/22/2008	Treatment of gastric cancer	Genta Inc.
2838	tesetaxel	n/a	11/21/2008	Treatment of stages IIB, IIC, III, and stage IV melanoma	Genta, Inc.
2839	testosterone undecanoate (oral)	n/a	2/13/2013	Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age)	SOV Therapeutics, Inc.
2840	tetra substituted prophyrin derivative containing manganese (III)	n/a	1/17/2014	For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.	Aeolus Pharmaceuticals, Inc.
2841	tetra-substituted porphyrin derivative containing manganese (III)	n/a	3/16/2015	Treatment of idiopathic pulmonary fibrosis	Aeolus Pharmaceuticals
2842	tetrabenazine	n/a	7/1/2009	Treatment of Tourette's Syndrome in school-age children, ages 5-16	Valeant International (Barbados) SRL

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2843	tetracosactide hexaacetate (beta 1-24-corticotrophin)	Synacthen Depot, S. Retard	10/31/2012	Treatment of infantile spasms	Cerium Pharmaceuticals, Inc.
2844	theranost 68Ga-RGD	n/a	12/8/2014	Diagnostic for clinical management of patients with neuroblastoma	Advanced Imaging Projects, LLC
2845	thymopentin	n/a	2/4/2011	Treatment of sarcoidosis.	mondoBIOTECH Laboratories, AG
2846	thymosin beta 4	n/a	12/31/2013	Treatment of patients with neurotrophic keratopathy	RegeneRx Biopharmaceuticals, Inc.
2847	tigecycline	n/a	10/23/2013	Treatment of acute myeloid leukemia.	Trillium Therapeutics, Inc.
2848	tin ethyl etiopurpurin	n/a	11/4/2003	Prevention of access graft disease in hemodialysis patients	Miravant Medical Technologies
2849	tinidazole	Tindamax	4/18/2002	Treatment of giardiasis	Presutti Laboratories, Inc.
2850	tipelukast	n/a	10/20/2014	Treatment of idiopathic pulmonary fibrosis	MediciNova, Inc.
2851	tiptorelin pamoate	n/a	8/20/2012	Treatment of central precocious puberty	Debiopharm
2852	tirapazamine	n/a	10/23/2002	Treatment of head and neck cancer	Sanofi-Aventis US, Inc.
2853	tisagenlecleucel-T	n/a	2/3/2015	Treatment of diffuse large B-cell lymphoma	Novartis Pharmaceuticals Corporation
2854	tivantinib	n/a	10/16/2013	Treatment of hepatocellular carcinoma	Daiichi Sankyo Pharma Development

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2855	tocilizumab	Actemra	7/31/2012	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Genentech, Inc.
2856	tocilizumab	Actemra	4/17/2013	Treatment of systemic sclerosis	Genentech, Inc.
2857	tolerogen	n/a	2/5/2015	Treatment of myasthenia gravis	Toleranzia AB
2858	tolvaptan	Samsca	4/6/2012	Treatment of autosomal dominant polycystic kidney disease	Otsuka Pharmaceuticals Co., Ltd.
2859	topiramate injection	n/a	7/24/2013	Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate	CURx Pharmaceuticals, Inc.
2860	trabectedin	Yondelis	9/30/2004	Treatment of soft tissue sarcoma	Janssen Research & Development, LLC
2861	trabectedin	Yondelis	3/29/2005	Treatment of patients with ovarian cancer	Janssen Research & Development, LLC
2862	trabedersen	n/a	7/21/2009	Treatment of pancreatic cancer.	Isarna Therapeutics GmbH

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2863	trabedersen	Oncomun	6/5/2002	Treatment of malignant glioma	Isarna Therapeutics GmbH
2864	trabedersen	n/a	8/22/2011	Treatment of Stage IIB through Stage IV malignant melanoma.	Isarna Therapeutics GmbH
2865	tralokinumab	n/a	7/24/2012	Treatment of idiopathic pulmonary fibrosis	MedImmune Ltd.
2866	trametinib	Mekinist	12/20/2010	Treatment of Stage IIb through Stage IV melanoma	Novartis Pharmaceuticals Corp.
2867	trametinib and dabrafenib	Mekinist And Tafinlar	9/20/2012	Treatment of Stage IIb through IV melanoma.	Novartis Pharmaceuticals Corp.
2868	tranilast	Rizaben	12/23/2010	Prevention of scarring following glaucoma filtration surgery	Altacor Ltd
2869	trans sodium crocetin	n/a	7/21/2011	Treatment of glioblastoma in conjunction with radiotherapy	Diffusion Pharmaceuticals, LLC
2870	trans sodium crocetin	n/a	12/3/2012	Treatment of brain metastasis	Diffusion Pharmaceuticals, LLC
2871	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	3/11/2013	Treatment of glioma	Eli Lilly and Company
2872	transforming growth factor-beta receptor 1 kinase inhibitor	n/a	4/1/2013	Treatment of hepatocellular carcinoma	Eli Lilly and Company

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2873	trastuzumab	Herceptin	10/13/2009	Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction	Genentech, Inc.
2874	trastuzumab	Herceptin	12/14/1999	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc.
2875	trastuzumab emtansine	Kadcyla ƒĒ'Ā+Ā€™ ƒĀċĀċĀ€Šâ~Ā ...Āĭ ƒĒ'ĀċĀ,~Āĭ ƒĀċĀ,Ā®	10/25/2013	For the treatment of gastric cancer including gastroesophageal junction cancer.	Genethech, Inc.
2876	trebananib	n/a	8/30/2013	Treatment of ovarian cancer	Amgen, Inc.
2877	trehalose	Cabaletta	10/25/2013	Treatment of oculopharyngeal muscular dystrophy	BIOBLAST PHARMA LTD.
2878	trehalose	n/a	11/17/2014	Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease)	BioBlast Pharma Ltd
2879	tremelimumab	n/a	3/18/2015	Treatment of malignant mesothelioma	MedImmune, LLC
2880	tremelimumab	n/a	9/18/2006	Treatment of stage IIb to stage IV metastatic melanoma	MedImmune

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2881	treosulfan	n/a	4/8/2015	Conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases in adults and pediatric patients.	Medac GmbH
2882	treprostinil	Remodulin	6/4/1997	Treatment of pulmonary arterial hypertension.	United Therapeutics Corp.
2883	treprostinil (inhalational)	Tyvaso	6/17/2010	Treatment of pulmonary arterial hypertension	LungRx, Inc.
2884	tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate	n/a	11/23/2001	Treatment for hepatocellular carcinoma	Cell Works Inc.
2885	tricitabine	n/a	2/1/2008	Treatment of multiple myeloma	VioQuest Pharmaceuticals, Inc.
2886	trientine hydrochloride	Syprine(R)	11/2/2010	Treatment of manganism.	Cerberus Princeton, LLC
2887	trifarotene	n/a	6/6/2014	Treatment of congenital ichthyosis	Galderma R&D, LLC
2888	triheptanoin	n/a	10/21/2014	Treatment of glucose transporter type-1 deficiency syndrome	Ultragenyx Pharmaceutical, Inc.
2889	triheptanoin	n/a	4/15/2015	Treatment of fatty acid oxidation disorders	Ultragenyx Pharmaceutical, Inc.
2890	triterpenoid saponin	n/a	7/23/2014	Treatment of mantle cell lymphoma	Avicin Therapeutics, Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2891	tryptophan hydroxylase (TPH) inhibitor	n/a	3/9/2012	Management of symptoms of carcinoid syndrome associated with carcinoid tumor	Lexicon Pharmaceuticals, Inc.
2892	tyrosine kinase inhibitor	n/a	9/14/2005	Treatment of mastocytosis	AB Science
2893	ubiquinol	Ubi-Q-NoI, Li-Q-NoI	4/12/2004	Treatment of Huntington's Disease	Gel-Tec, Division of Tishcon Corp
2894	ublituximab	n/a	8/6/2010	Treatment of chronic lymphocytic leukemia	TG Therapeutics, Inc.
2895	ublituximab	n/a	9/5/2013	Treatment of Nodal marginal zone lymphoma	TG Therapeutics, Inc.
2896	ublituximab	n/a	9/5/2013	Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)	TG Therapeutics, Inc.
2897	ulocuplumab	n/a	1/12/2015	Treatment of acute myeloid leukemia	Bristol-Myers Squibb Company
2898	unoprostone isopropyl	Rescula	9/16/2010	Treatment of retinitis pigmentosa	R-Tech Ueno, Ltd.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2899	urea	n/a	11/7/2011	Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosiform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Netherton syndrome, neutral lipid storage disease, Sjorgren-Larsson syndrome, trichothiodystrophy, X-linked ichthyosis).	Orenova Group, LLC
2900	uridine triacetate	n/a	8/9/2013	Treatment of hereditary orotic aciduria	Wellstat Therapeutics, Inc.
2901	uridine triacetate	n/a	5/1/2009	An antidote in the treatment of 5-fluorouracil poisoning	Wellstat Therapeutics Corp.
2902	uridine triacetate	n/a	9/3/2009	Treatment of mitchondrial disease	Wellstat Therapeutics Corporation
2903	ursodiol	Ursofalk Suspension	10/23/2007	Treatment of cystic fibrosis liver disease	Asklepion Pharmaceuticals, LLC
2904	ustekinumab	Stelara	11/29/2010	Treatment of type 1 diabetes mellitus patients with residual beta-cell function.	Johnson & Johnson Pharmaceutical & Development LLC

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2905	valine-valine-ganciclovir	n/a	5/21/2007	Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.	Verenta Pharmaceuticals, Inc.
2906	vancomycin	n/a	12/27/2012	Treatment of endophthalmitis	Fera Pharmaceuticals, LLC
2907	vancomycin hydrochloride (inhalational)	n/a	9/20/2012	Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis	Savara Pharmaceuticals, Inc.
2908	vandetanib	Caprelsa(R)	10/21/2005	Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma	AstraZeneca Pharmaceutical LP
2909	vapreotide	Octastatin	3/6/2000	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A.
2910	vapreotide	Sanvar	1/10/2000	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiovision, Inc.
2911	vapreotide	Octastatin	1/10/2000	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A.
2912	vapreotide	Sanvar	11/4/2003	Treatment of acromegaly	H3 Pharma, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2913	vascular endothelial growth factor 165b	n/a	6/24/2008	Treatment of advanced melanoma stages IIb through IV.	PhiloGene, Inc.
2914	vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein	n/a	5/13/2014	Treatment of pulmonary arterial hypertension, WHO Group 1	PhaseBio Pharmaceuticals, Inc.
2915	vatiquinone	Vincerinone	1/31/2014	Treatment of Friedreich's ataxia	Edison Pharmaceuticals, Inc.
2916	vatiquinone	Vincerinone	6/4/2014	Treatment of Leigh Syndrome	Edison Pharmaceuticals, Inc.
2917	vatiquinone	Vincerinone	11/17/2014	Treatment of Rett syndrome	Edison Pharmaceuticals, Inc.
2918	velaglucerase-alfa	Vpriv	6/8/2009	Treatment of Gaucher disease	Shire Human Genetics Therapies, Inc.
2919	veliparib	n/a	12/17/2014	Treatment of brain metastases when used in combination with DNA-damaging agents	AbbVie Inc.
2920	veliparib	n/a	5/9/2008	Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents	AbbVie, Inc.
2921	veliparib	n/a	11/20/2009	Treatment of hepatocellular carcinoma in combination with DNA-damaging agents	AbbVie, Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2922	veliparib	n/a	9/3/2009	Treatment of epithelial ovarian cancer in combination with DNA-damaging agents	AbbVie, Inc.
2923	veltuzumab	n/a	11/17/2014	Treatment of pemphigus	Immunomedics, Inc.
2924	veltuzumab	n/a	8/28/2008	Treatment of chronic lymphocytic leukemia	Immunomedics, Inc.
2925	vemurafenib	Zelboraf	11/26/2013	Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation	Genentech, Inc.
2926	vemurafenib	Zelboraf(R)	9/8/2014	Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600E mutation	Genentech, Inc.
2927	vemurafenib	Zelboraf (R)	8/26/2014	Treatment of hairy cell leukemia (HCL).	Genentech, Inc.
2928	vemurafenib	Zelboraf	12/20/2010	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Hoffmann-La Roche, Inc.
2929	verteporfin	Visudyne(R)	3/9/2012	Treatment of chronic or recurrent central serous chorioretinopathy	Valeant Pharmaceuticals North America LLC
2930	vibriolysin	Vibrilase	6/16/2006	Debridement of severe, deep dermal burns in hospitalized patients	BioMarin Pharmaceutical Inc.

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2931	vigabatrin	Sabril	6/12/2000	Treatment of infantile spasms.	H. Lundbeck A/S
2932	vinCRISTine sulfate LIPOSOME injection	Marqibo	1/8/2007	Treatment of acute lymphoblastic leukemia	Talon Therapeutics, Inc.
2933	vincristine sulfate liposomes	Marqibo	6/24/2008	Treatment of metastatic uveal melanoma.	Talon Therapeutics
2934	vintafolide	n/a	12/16/2013	Treatment of ovarian cancer	Endocyte, Inc.
2935	volasertib	n/a	4/14/2014	Treatment of acute myeloid leukemia	Boehringer Ingelheim Pharmaceuticals, Inc.
2936	von Willebrand Factor Human Concentrate	Wilfactin	5/29/2014	Treatment of Von Willebrand Disease	rEVO Biologics, Inc.
2937	vorinostat	Zolinza	3/16/2004	Treatment of T-cell non-Hodgkin's lymphoma	Merck & Co., Inc.
2938	vosaroxin	n/a	10/28/2009	Treatment of acute myeloid leukemia	Sunesis Pharmaceuticals, Inc.
2939	xenon gas	n/a	12/3/2014	Treatment of hypoxic ischemic encephalopathy	Neuroprotexon
2940	xenon gas	n/a	5/18/2015	To improve neurological outcome in hospitalized cardiac arrest patients.	Neuroprotexon
2941	zidovudine	Retrovir	7/17/1985	Treatment of AIDS	Glaxo Wellcome Inc.
2942	zoledronate D,L-lysine monohydrate (ZLM)	n/a	4/15/2015	Treatment of complex regional pain syndrome (CRPS)	Thar Pharmaceuticals

Orphan Drug Designations and Approvals List as of 06-01-2015
Governs July 1, 2015 - September 30, 2015

Row Num	Generic Name	Trade Name	Designation Date	Designation	Contact Company/Sponsor
2943	zoledronic acid	Zometa, Reclast, Aclasta	5/6/2013	Treatment of complex regional pain syndrome (CRPS).	Axsome Therapeutics, Inc.
2944	{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide	n/a	4/10/2014	Treatment of ovarian cancer	VentiRx Pharmaceuticals, Inc.
2945		Dysport(R)	12/5/1991	Treatment of essential blepharospasm.	Ipsen Biopharmaceuticals, Inc.
2946		Minnelide	3/30/2015	Treatment of gastric cancer.	Minneamrita Therapeutics, LLC
2947		Nicord	4/28/2014	For the treatment of acute myeloid leukemia	Gamida Cell Ltd
2948		Biothrax	4/11/2014	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Emergent Product Development Gaithersburg, Inc.